PHARMAC
Pharmaceutical Management Agency

Funding decisions relating to hospital pharmaceuticals

May 2013

The following list details the pharmaceuticals that have been considered for inclusion in Part II of Section H f the Pharmaceutical Schedule from 1 July 2013. We expect that there will be some changes made between now and July, however this list represents the decisions that have been made to date, with the contents of all therapeutic groups (chapters) having now been determined.

Note that restrictions only apply to formulations that are marked as ***restricted*** - some chemicals (e.g. adenosine, iloprost) have restrictions only applying to particular formulations.

Formulations underlined in red have been considered, but have not been included in Section H at this point.

Abacavir sulphate

Oral liq 20 mg per ml - ***restricted***

Tab 300 mg - ***restricted***

Must meet community Special Authority criteria

Abacavir sulphate with lamivudine

Tab 600 mg with lamivudine 300 mg - ***restricted***

Must meet community Special Authority criteria

Abatacept

Inj 250 mg

Abciximab

Inj 2 mg per ml, 5 ml vial - ***restricted***

RESTRICTED
Either:
1 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or
2 For use in patients undergoing intra-cranial intervention.

Acamprosate

Tab 333 mg

Acarbose

Tab 50 mg

Tab 100 mg

Acebutolol

Cap 200 mg

Acetazolamide

Tab 250 mg

Inj 500 mg

Acetic acid

Soln 3%

Soln 5%

Liq

Acetic acid with hydroxyquinoline, glycerol and ricinoleic acid

Jelly 0.94% with hydroxyquinoline sulphate 0.025%, glycerol 5% and ricinoleic acid 0.75% with applicator

Acetic acid with propylene glycol

Ear drops 2.3% with propylene glycol 2.8%

Acetone

Liquid

Acetylcholine chloride

Inj 20 mg vial with diluent

Acetylcysteine

Eye drops 5%

Eye drops 10%

Tab eff 600 mg

Tab eff 200 mg

Inj 200 mg per ml, 10 ml ampoule

Inj 200 mg per ml, 30 ml vial

Note: proprietary eye drops are excluded, but compounded (from injection) eye drops are allowed.

Aciclovir

Tab dispersible 200 mg

Tab dispersible 400 mg

Tab dispersible 800 mg

Inj 250 mg vial

Eye oint 3%

Cream 5%

Acipimox

Cap 250 mg

Acitretin

Cap 10 mg

Cap 25 mg

Adalimumab

Inj 40 mg per 0.8 ml pen - ***restricted***

Inj 40 mg per 0.8 ml syringe - ***restricted***

RESTRICTED

Initiation – rheumatoid arthritis – rheumatologist

Re-assessment required after 6 months

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from etanercept; or

1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or

2 All of the following:

2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and

2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and

2.5 Any of the following:

2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or

2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or

2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

2.6 Either:

2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or

2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.7 Either:

2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or

2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and

Continuation – rheumatoid arthritis – rheumatologist

Re-assessment required after 6 months

All of the following:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2 Either:

2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

3 Either:

3.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or

3.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.

Initiation – ankylosing spondylitis – rheumatologist

Re-assessment required after 6 months

Either:
1 Both:
1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
1.2 Either:
1.2.1 The patient has experienced intolerable side effects from etanercept; or
1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis.
2 All of the following:
2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and
2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
2.5 Either:
2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the following average normal values corrected for age and gender (see Notes); and
2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.
Average normal chest expansion corrected for age and gender:
18-24 years - Male: 7.0 cm; Female: 5.5 cm
25-34 years - Male: 7.5 cm; Female: 5.5 cm
35-44 years - Male: 6.5 cm; Female: 4.5 cm
45-54 years - Male: 6.0 cm; Female: 5.0 cm
55-64 years - Male: 5.5 cm; Female: 4.0 cm
65-74 years - Male: 4.0 cm; Female: 4.0 cm
75+ years - Male: 3.0 cm; Female: 2.5 cm

Continuation – ankylosing spondylitis – rheumatologist
Re-assessment required after 6 months
All of the following:
1 Following 12 weeks of adalimumab treatment, BASDAI has improved by 4 or more points from pre-adalimumab baseline on a 10 point scale, or by 50%, whichever is less; and
2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – psoriatic arthritis – rheumatologist
Re-assessment required after 6 months
Either:
1 Both:
1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and
1.2 Either:
1.2.1 The patient has experienced intolerable side effects from etanercept; or
1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or
2 All of the following:
2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and

2.4 Either:
2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
2.5 Any of the following:
2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation – psoriatic arthritis – rheumatologist
Re-assessment required after 6 months
All of the following:
1 Either:
1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – Crohn's disease – gastroenterologist
Re-assessment required after 3 months
All of the following:
1 Patient has severe active Crohn's disease; and
2 Any of the following:
2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
4 Surgery (or further surgery) is considered to be clinically inappropriate.

Continuation – Crohn's disease – gastroenterologist
Re-assessment required after 3 months
Both:
1 Either:
1.1 Either:
1.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
1.1.2 CDAI score is 150 or less; or
1.2 Both:
1.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
1.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Initiation – plaque psoriasis, prior TNF use – dermatologist
Re-assessment required after 4 months
Both:
1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
2 Either:
2.1 The patient has experienced intolerable side effects from etanercept; or
2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for

etanercept for severe chronic plaque psoriasis.

Initiation – plaque psoriasis, treatment-naïve – dermatologist
Re-assessment required after 4 months
All of the following:
1 Either:
1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
4 The most recent PASI assessment is no more than 1 month old at the time of initiation.
Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation – plaque psoriasis – dermatologist
Re-assessment required after 6 months
All of the following:
1 Either:
1.1 Both:
1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
1.1.2 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
1.2 Both:
1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
1.2.2 Either:
1.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
1.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value; and
2 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Adapalene

Crm 0.1%

Gel 0.1%

Adapalene with benzoyl peroxide

Gel 0.1% with benzoyl peroxide 2.5%

Adefovir dipivoxil

Tab 10 mg - ***restricted***

Must meet community Special Authority criteria

Adenosine

Inj 10 mg per ml, 2 ml

Inj 3 mg per ml, 10 ml vial - ***restricted***

Inj 3 mg per ml, 2 ml vial

RESTRICTED
For use in cardiac catheterisation, electrophysiology and MRI

Adrenaline

Inj 1 in 1,000, 1 ml ampoule

Inj 1 in 1,000, 30 ml vial

Inj 1 in 10,000, 10 ml ampoule

Inj 1 in 10,000, 10 ml syringe

Inj 1 in 1,000, 0.3 ml auto-injector

Inj 1 in 2,000, 0.3 ml auto-injector

Ajmaline

Inj 5 mg per ml, 10 ml ampoule - ***restricted***

RESTRICTED – cardiologist

Albendazole

Tab 200 mg - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Alendronate sodium

Tab 40 mg - ***restricted***

Tab 70 mg - ***restricted***

Must meet community Special Authority criteria

Alendronate sodium with cholecalciferol

Tab 70 mg with cholecalciferol 5,600 iu - ***restricted***

Must meet community Special Authority criteria

Alfacalcidiol

Inj 2 mg

Alfacalcidol

Cap 0.25 mcg

Cap 1 mcg

Oral drops 2 mcg per ml

Alfentanil hydrochloride

Inj 0.5 mg per ml, 2 ml ampoule

Allopurinol

Tab 100 mg

Tab 300 mg

Almond oil

Liquid

Alpha tocopheryl acetate

Cap 100 u - ***restricted***

Cap 500 u - ***restricted***

Oral liq 156 u per ml - ***restricted***

RESTRICTED
Cystic fibrosis
Both:
1 Cystic fibrosis patient; and
2 Either:
2.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck); or
2.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for the patient; or
Osteoradionecrosis
For the treatment of osteoradionecrosis
Other indications
All of the following:
1 Infant or child with liver disease or short gut syndrome; and
2 Requires vitamin supplementation; and
3 Either:
3.1 Patient has tried and failed the other available funded fat soluble vitamin A,D,E,K supplements (Vitabdeck); or
3.2 The other available funded fat soluble vitamin A,D,E,K supplement (Vitabdeck) is contraindicated or clinically inappropriate for patient.

Alprazolam

Tab 250 mcg

Tab 500 mcg

Tab 1 mg

Alprostadil hydrochloride

Inj 500 mcg per ml, 1 ml ampoule

Alprostatil

Inj 10 mcg

Inj 20 mcg

Alteplase

Inj 10 mg vial

Inj 50 mg vial

Alum

Powder BP

Aluminium hydroxide

Tab 600 mg

Aluminium hydroxide with magnesium hydroxide and simeticone

Oral liq 200 mg with magnesium hydroxide 200 mg and simeticone 20 mg per 5 ml

Tab 200 mg with magnesium hydroxide 200 mg and simeticone 20 mg

Oral liq 400 mg with magnesium hydroxide 400 mg and simeticone 30 mg per 5 ml

Amantadine hydrochloride

Cap 100 mg

Ambrisentan

Tab 10 mg - ***restricted***

Tab 5 mg - ***restricted***

RESTRICTED
Either:
1. For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
2. In-hospital stabilisation in emergency situations.

Amikacin

Inj 250 mg per ml, 2 ml vial - ***restricted***

Inj 5 mg per ml, 5 ml syringe - ***restricted***

Inj 5 mg per ml, 10 ml syringe - ***restricted***

Inj 15 mg per ml, 5 ml syringe - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist or respiratory physician

Amiloride hydrochloride

Oral liq 1 mg per ml

Tab 5 mg

Amiloride hydrochloride with furosemide

Tab 5 mg with furosemide 40 mg

Amiloride hydrochloride with hydrochlorothiazide

Tab 5 mg with hydrochlorothiazide 50 mg

Amino acid formula

Powder 16 g protein, 51.4 g carbohydrate and 21 g fat per 100 g, 400 g can {Neocate Advance} - ***restricte***

Powder 14 g protein, 50 g carbohydrate and 22.1 g fat per 100 g, 400 g can {Neocate Advance} - ***restricte***

Powder 1.95 g protein, 8.1 g carbohydrate and 3.5 g fat per 100 ml, 400 g can {Neocate} - ***restricted***

Powder 13.5 g protein, 52 g carbohydrate and 24.5 g fat per 100 g, 400 g can {Neocate Gold} - ***restricted***

Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, 400 g can {Elecare LCP} - ***restricted***

Powder 2.2 g protein, 7.8 g carbohydrate and 3.4 g fat per 100 ml, 400 g can {Elecare} - ***restricted***

Powder 6 g protein, 31.5 g carbohydrate and 5.88 g fat per 48.5 g sachet {Vivonex Paediatric} - ***restricted***

Powder 13 g protein, 52.5 g carbohydrate and 24.5 g fat per 100 g, 400 g can {Neocate LCP} - ***restricted***

RESTRICTED

Initiation

Any of the following:

1 Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or

2 History of anaphylaxis to cows' milk protein formula or dairy products; or

3 Eosinophilic oesophagitis.

Continuation

Both:

1 An assessment as to whether the infant can be transitioned to a cows' milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and

2 The outcome of the assessment is that the infant continues to require an amino acid infant formula.

Amino acid formula (without isoleucine, leucine and valine)

Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 fibre per 100 ml, 125 ml bottle {MSUD Anamix Junio LQ} - ***restricted***

Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can {MSUD Anamix Infant} - ***restricted***

Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can {MSUD Maxamaid} - ***restricted***

Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can {MSUD Maxamum} - ***restricted***

RESTRICTED

Either:

1 For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria isovaleric acidaemia, propionic acidaemia, methylmalonic acidaemia, tyrosinaemia or urea cycle disorders; or

2 Patient has adrenoleukodystrophy; or

3 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Amino acid formula (without isoleucine, methionine, threonine and valine)

Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 fibre per 100 g, 400 g can {MMA/PA Anamix Infant} - ***restricted***

Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can {XMTVI Maxamaid} - ***restricted***

Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can {XMTVI Maxamum} - ***restricted***

RESTRICTED

Either:

1 For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria isovaleric acidaemia, propionic acidaemia, methylmalonic acidaemia, tyrosinaemia or urea cycle disorders; or

2 Patient has adrenoleukodystrophy; or

3 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Amino acid formula (without leucine)

Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can {IVA Anamix Infant} - ***restricted***

Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can {XLEU Maxamaid} - ***restricted***

Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can {XLEU Maxamum} - ***restricted***

RESTRICTED
Either:
1 For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria isovaleric acidaemia, propionic acidaemia, methylmalonic acidaemia, tyrosinaemia or urea cycle disorders; or
2 Patient has adrenoleukodystrophy; or
3 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Amino acid formula (without lysine and low tryptophan)

Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can {GA1 Anamix Infant} - ***restricted***

Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can {XLYS Low TRY Maxamaid} - ***restricted***

RESTRICTED
Either:
1 For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria isovaleric acidaemia, propionic acidaemia, methylmalonic acidaemia, tyrosinaemia or urea cycle disorders; or
2 Patient has adrenoleukodystrophy; or
3 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Amino acid formula (without methionine)

Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle {HCU Anamix Junic LQ} - ***restricted***

Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can {HCU Anamix Infant} - ***restricted***

Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can {XMET Maxamaid} - ***restricted***

Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can {XMET Maxamum} - ***restricted***

RESTRICTED
Either:
1 For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria isovaleric acidaemia, propionic acidaemia, methylmalonic acidaemia, tyrosinaemia or urea cycle disorders; or
2 Patient has adrenoleukodystrophy; or
3 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Amino acid formula (without phenylalanine and tyrosine)

Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 fibre per 100 ml, 125 ml bottle {TYR Anamix Junior LQ} - ***restricted***

Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 fibre per 100 g, 400 g can {TYR Anamix Infant} - ***restricted***

Powder 29 g protein, 38 g carbohydrate and 13.5 g fat per 100 g, 29 g sachet {TYR Anamix Junior} - ***restricted***

Powder 25 g protein and 51 g carbohydrate per 100 g, 400 g can {XPHEN, TYR Maxamaid} - ***restricted***

RESTRICTED
Either:
1 For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria isovaleric acidaemia, propionic acidaemia, methylmalonic acidaemia, tyrosinaemia or urea cycle disorders; or
2 Patient has adrenoleukodystrophy; or
3 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Amino acid formula (without phenylalanine)

Tab 833 mg {Phlexy-10} - ***restricted***

Liquid 6.7 g protein, 5.1 g carbohydrate and 2 g fat per 100 ml, 250 ml carton {Easiphen} - ***restricted***

Liquid 8 g protein, 7 g carbohydrate, 3.8 g fat and 0.25 g fibre per 100 ml, 125 ml bottle {PKU Anamix Junio LQ} - ***restricted***

Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 62.5 ml bottle {PKU Lophlex LQ 10} - ***restricted***

Liquid 16 g protein, 7 g carbohydrate and 0.27 g fibre per 100 ml, 125 ml bottle {PKU Lophlex LQ 20} - ***restricted***

Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 62.5 ml bottle {PKU Lophlex LQ 10} - ***restricted***

Liquid 16 g protein, 7 g carbohydrate and 0.4 g fibre per 100 ml, 125 ml bottle {PKU Lophlex LQ 20} - ***restricted***

Powder 8.33 g protein and 8.8 g carbohydrate per 20 g sachet {Phlexy-10} - ***restricted***

Powder 13.1 g protein, 49.5 g carbohydrate, 23 g fat and 5.3 g fibre per 100 g, 400 g can {PKU Anamix Infant} - ***restricted***

Powder 25 g protein and 51 g carbohydrate per 100 g, 500 g can {XP Maxamaid} - ***restricted***

Powder 39 g protein and 34 g carbohydrate per 100 g, 500 g can {XP Maxamum} - ***restricted***

RESTRICTED
Either:
1 For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria isovaleric acidaemia, propionic acidaemia, methylmalonic acidaemia, tyrosinaemia or urea cycle disorders; or
2 Patient has adrenoleukodystrophy; or
3 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Amino acid formula (without phenylalanine) with minerals

Powder 172 mmol sodium 212 mmol potassium 205 mmol calcium and 192 mmol phosphorus per 100 g {Metabolic Mineral Mixture}

Amino acid oral feed

Powder 11.5 g protein, 61.7 g carbohydrate and 0.8 g fat per 80.4 g sachet {Vivonex TEN} - ***restricted***

RESTRICTED
Any of the following:
1 Malabsorption; or
2 Short bowel syndrome; or
3 Enterocutaneous fistulas; or
4 Eosinophilic enteritis (including oesophagitis); or
5 Inflammatory bowel disease; or
6 Acute pancreatitis where standard feeds are not tolerated; or
7 Patients with multiple food allergies requiring enteral feeding.

Amino acid oral feed 0.8 kcal/ml

Liquid 2.5 g protein, 11 g carbohydrate and 3.5 g fat per 100 ml, 250 ml carton {Elemental 028 Extra} - ***restricted***

RESTRICTED
Any of the following:
1 Malabsorption; or
2 Short bowel syndrome; or
3 Enterocutaneous fistulas; or
4 Eosinophilic enteritis (including oesophagitis); or
5 Inflammatory bowel disease; or
6 Acute pancreatitis where standard feeds are not tolerated; or
7 Patients with multiple food allergies requiring enteral feeding.

Amino acid supplement

Powder 25 g protein and 65 g carbohydrate per 100 g, 200 g can {Dialamine} - ***restricted***

Powder 79 g protein per 100 g, 200 g can {Essential Amino Acid Mix} - ***restricted***

RESTRICTED
Either:
1 For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria isovaleric acidaemia, propionic acidaemia, methylmalonic acidaemia, tyrosinaemia or urea cycle disorders; or
2 Patient has adrenoleukodystrophy; or
3 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Aminophylline

Inj 25 mg per ml, 10 ml ampoule

Tab modified-release 350 mg

Amiodarone hydrochloride

Inj 50 mg per ml, 3 ml ampoule

Tab 100 mg

Tab 200 mg

Amisulpride

Tab 100 mg

Tab 200 mg

Tab 400 mg

Oral liq 100 mg per ml

Amitriptyline

Tab 10 mg

Tab 25 mg

Tab 50 mg

Amlodipine

Tab 10 mg

Tab 2.5 mg

Tab 5 mg

Amorolfine

Nail soln 5% - ***restricted***

RESTRICTED
For continuation only

Amoxycillin

Cap 250 mg

Cap 500 mg

Grans for oral liq 25 mg per ml

Grans for oral liq 50 mg per ml

Inj 250 mg vial

Inj 500 mg vial

Inj 1 g vial

Drops 125 mg per ml, 1.25 ml

Amoxycillin with clavulanic acid

Tab 500 mg with clavulanic acid 125 mg

Grans for oral liq 25 mg with clavulanic acid 6.25 mg per ml

Grans for oral liq 50 mg with clavulanic acid 12.5 mg per ml

Inj 500 mg with clavulanic acid 100 mg vial

Inj 1000 mg with clavulanic acid 200 mg vial

Amphotericin B

Lozenge 10 mg

Inj 50 mg vial - ***restricted***

Inj (liposomal) 50 mg vial - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist, haematologist, oncologist, transplant specialist or respiratory physician
Either:
1 Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
2 Both:
2.1 Possible invasive fungal infection; and
2.2 A multidisciplinary team (including an Infectious Disease physician or a Clinical Microbiologist) considers the treatment to be appropriate.

Amsacrine

Inj 50 mg per ml, 1.5 ml ampoule

Amyl nitrite

Liq 98% in 3 ml capsule

Amylobarbitone sodium

Inj 500 mg

Anagrelide hydrochloride

Cap 0.5 mg

Anakinra

Inj 150 mg per ml, 0.67 ml

Anastrozole

Tab 1 mg

Ancestim

Inj 1.875 mg

Anise oil

Liquid

Antithymocyte globulin (equine)

Inj 50 mg per ml, 5 ml ampoule

Antithymocyte globulin (rabbit)

Inj 25 mg vial

Apomorphine hydrochloride

Inj 10 mg per ml, 1 ml ampoule

Inj 10 mg per ml, 2 ml ampoule

Apraclonidine

Eye drops 0.5%

Aprepitant

Cap 2 x 80 mg and 1 x 125 mg - ***restricted***

Must meet community Special Authority criteria

Aqueous cream

Crm

Arachis oil [Peanut oil]

Liq

Argatroban

Inj 100 mg per ml, 2.5 ml vial

Arginine

Powder

Inj 600 mg per ml, 25 ml vial

Inj 50 mg per ml, 500 ml bottle

Inj 100 mg per ml, 300 ml bottle

Argipressin

Inj 20 u per ml, 1 ml ampoule

Aripiprazole

Tab 10 mg - ***restricted***

Tab 15 mg - ***restricted***

Tab 20 mg - ***restricted***

Tab 30 mg - ***restricted***

Must meet community Special Authority criteria

Arnica

Crm 10%

Arsenic trioxide

Inj 1 mg per ml, 10 ml vial

Artemether with lumafantrine

Tab 20 mg with lumefantrine 120 mg - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Artesunate

Inj 60 mg vial - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Articaine hydrochloride with adrenaline

Inj 4% with adrenaline 1:100,000, 2.2 ml dental cartridge

Ascorbic acid

Tab 100 mg

Tab chewable 250 mg

Powder

Tab chewable 500 mg

Tab chewable 1 g

Inj 500 mg per 5 ml

Aspirin

Tab dispersible 300 mg

Tab EC 300 mg

Powder

Tab 100 mg

Suppos 300 mg

Tab 75 mg

Tab 150 mg

Atazanavir sulphate

Cap 150 mg - ***restricted***

Cap 200 mg - ***restricted***

Must meet community Special Authority criteria

Atenolol

Oral liq 25 mg per ml

Oral liq 5 mg per ml

Tab 100 mg

Tab 50 mg

Atomoxetine

Cap 10 mg - ***restricted***

Cap 18 mg - ***restricted***

Cap 25 mg - ***restricted***

Cap 40 mg - ***restricted***

Cap 60 mg - ***restricted***

Cap 80 mg - ***restricted***

Cap 100 mg - ***restricted***

Must meet community Special Authority criteria

Atorvastatin

Tab 10 mg

Tab 20 mg

Tab 40 mg

Tab 80 mg

Atosiban

Inj 37.5 mg in 5 ml

Atovaquone with proguanil hydrochloride

Tab 250 mg with proguanil hydrochloride 100 mg - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Atracurium besylate

Inj 10 mg per ml, 2.5 ml ampoule

Inj 10 mg per ml, 5 ml ampoule

Atropine sulphate

Inj 1000 mcg, 10 ml syringe

Inj 500 mcg, 5 ml syringe

Inj 600 mcg per ml, 1 ml ampoule

Eye drops 0.5%

Eye drops 1%

Eye drops 1%, single dose

Auranofin

Tab 3 mg

Azathioprine

Tab 50 mg

Inj 50 mg vial

Azithromycin

Tab 250 mg - ***restricted***

Tab 500 mg - ***restricted***

Oral liq 40 mg per ml - ***restricted***

RESTRICTED
Any of the following:
1 Patient has received a lung transplant and requires treatment or prophylaxis for bronchiolitis obliterans syndrome; or
2 Patient has cystic fibrosis and has chronic infection with Pseudomonas aeruginosa or Pseudomonas related gram negative organisms; or
3 For any other condition, with a maximum of five days' treatment.

Aztreonam

Inj 1 g vial - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Bacillus calmette-guerin (BCG)

Inj 2-8 x 10^8 CFU vial - ***restricted***

RESTRICTED
For use in bladder cancer

Bacillus calmette-guerin vaccine

Inj 2-8 million CFU per ml vial with diluent - ***restricted***

RESTRICTED
For infants at increased risk of tuberculosis
Note: increased risk is defined as:

1. living in a house or family with a person with current or past history of TB; or
2. have one or more household members or carers who within the last 5 years lived in a country with a rate of TB > or equal to 40 per 100,000 for 6 months or longer; or
3. during their first 5 years will be living 3 months or longer in a country with a rate of TB > or equal to 40 per 100,000.

A list of countries with high rates of TB are available at www.moh.govt.nz/immunisation or www.bcgatlas.org/index.php.

Baclofen

Inj 0.05 mg per ml, 1 ml ampoule

Inj 2 mg per ml, 5 ml ampoule

Oral liq 1 mg per ml

Tab 10 mg

Barium sulphate

Oral liq 1 mg per ml

Oral liq 13 mg per ml

Oral liq 21 mg per ml

Oral liq 22 mg per g, 250 ml

Oral liq 22 mg per g, 450 ml

Oral liq 130 mg per ml

Oral liq 400 mg per ml

Oral liq 1250 mg per ml

Liq 1000 mg per ml

Eosophogeal cream 30 mg per g

Eosophogeal cream 600 mg per g

Eosophogeal paste 400 mg per ml

Enema 1250 mg per ml

Powder for oral liq 22.1 g

Powder for oral liq 100 g

Powder for oral liq 148 g

Powder for oral liq 300 g

Powder for oral liq 340 g

Powder for oral liq 10,000 g

Powder for enema 397 g

Basiliximab

Inj 20 mg vial - ***restricted***

RESTRICTED
For use in solid organ transplants

Beclomethasone dipropionate

Nasal spray 50 mcg per dose

Nasal spray 100 mcg per dose

Aerosol inhaler 50 mcg per dose

Aerosol inhaler 100 mcg per dose

Aerosol inhaler 250 mcg per dose

Bee venom

Inj 120 mcg vial with diluent - ***restricted***

Inj 550 mcg vial with diluent - ***restricted***

RESTRICTED
Both:
1 RAST or skin test positive; and
2 Patient has had severe generalised reaction to the sensitising agent.

Bendroflumethazide (bendrofluazide)

Tab 2.5 mg

Tab 5 mg

Benzalkonium chloride with triclosan and paraffin

Soln 6% with triclosan 2% and paraffin liquid 52.5%

Benzalkonium with panthenol

Crm 0.05% with panethenol 5%

Benzathine benzylpenicillin

Inj 900 mg (1.2 million units) in 2.3 ml syringe

Benzbromarone

Tab 100 mg - ***restricted***

RESTRICTED
Both:
1 Any of:
- 1.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and appropriate doses of probenecid; or
- 1.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite appropriate doses of probenecid; or
- 1.3 Both:
  - 1.3.1 The patient has renal impairment and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); and
  - 1.3.2 The patient has a rate of creatinine clearance greater than or equal to 20 ml/min; or
- 1.4 All of the following:
  - 1.4.1 The patient is taking azathioprine and requires urate-lowering therapy; and
  - 1.4.2 Allopurinol is contraindicated; and
  - 1.4.3 Appropriate doses of probenecid are ineffective or probenecid cannot be used due to reduced renal function; and

2 The patient is receiving monthly liver function tests.

Notes: Benzbromarone has been associated with potentially fatal hepatotoxicity. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

Benzoin

Tincture compound BP

Benzoyl peroxide

Soln 5%

Gel 2.5%

Gel 5%

Gel 10 %

Benztropine mesylate

Inj 1 mg per ml, 2 ml ampoule

Tab 2 mg

Benzydamine hydrochloride

Soln 0.15%

Spray 0.15%

Benzydamine hydrochloride with cetylpyridinium chloride

Lozenge 3 mg with cetylpyridinium chloride

Benzylpenicillin sodium [Penicillin G]

Inj 600 mg (1 million units) vial

Beractant

Soln 200 mg per 8 ml vial

Betahistine dihydrochloride

Tab 16 mg

Betaine

Powder - ***restricted***

RESTRICTED – metabolic disorders physician or metabolic disorders dietitian

Betamethasone

Tab 500 mcg

Inj 4 mg per ml, 1 ml ampoule

Betamethasone dipropionate

Crm 0.05%

Oint 0.05%

Betamethasone dipropionate with calcipotriol

Gel 500 mcg with calcipotriol 50 mcg per g

Oint 500 mcg with calcipotriol 50 mcg per g

Betamethasone sodium phosphate with betamethasone acetate

Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml ampoule

Betamethasone valerate

Crm 0.1%

Lotn 0.1%

Oint 0.1%

Scalp app 0.1%

Betamethasone valerate with clioquinol

Crm 0.1% with clioquiniol 3% - ***restricted***

Oint 0.1% with clioquiniol 3% - ***restricted***

RESTRICTED
Either:
1 For the treatment of intertrigo; or
2 For continuation use

Betamethasone valerate with fusidic acid

Crm 0.1% with fusidic acid 2%

Betaxolol

Eye drops 0.25%

Eye drops 0.5%

Bevacizumab

Inj 25 mg per ml, 4 ml vial - ***restricted***

Inj 25 mg per ml, 16 ml vial - ***restricted***

RESTRICTED
Either:
1 Ocular neovascularisation; or
2 Exudative ocular angiopathy.

Bezafibrate

Tab 200 mg

Tab long-acting 400 mg

Bicalutamide

Tab 50 mg - ***restricted***

RESTRICTED
For the treatment of advanced prostate cancer

Bifonazole

Crm 1%

Bimatoprost

Eye drops 0.03%

Bisacodyl

Tab 5 mg

Suppos 5 mg

Suppos 10 mg

Bismuth

Tab 120 mg

Bismuth subgallate

Powder

Bismuth subnitrate and iodoform paraffin

Paste

Bisoprolol

Tab 10 mg

Tab 2.5 mg

Tab 5 mg

Bivalirudin

Inj 250 mg vial - ***restricted***

RESTRICTED
Any of the following:
1 For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance; or
2 For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention; or
3 For use in patients undergoing intra-cranial intervention.

Bleomycin sulphate

Inj 15,000 iu (10 mg) vial

Bonney's blue dye

Soln

Boric acid

Powder

Bortezomib

Inj 1 mg vial - ***restricted***

Inj 3.5 mg vial - ***restricted***

Must meet PCT Special Authority criteria

Bosentan

Tab 125 mg - ***restricted***

Tab 62.5 mg - ***restricted***

RESTRICTED
Either:
1. For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
2. In-hospital stabilisation in emergency situations.

Botulism antitoxin

Inj 250 ml vial

Breast milk fortifier

Powder 0.2 g protein, 0.7 g carbohydrate and 0.02 g fat per 1 g sachet {FM 85}

Powder 0.5 g protein, 1.2 g carbohydrate and 0.08 g fat per 2 g sachet {S26 Human Milk Fortifier}

Powder 0.4 g protein and 1.5 g carbohydrate per 2.1 g sachet {Nutricia Breast Milk Fortifier}

Brimonidine tartrate

Eye drops 0.2%

Eye drops 0.15%

Brimonidine tartrate with timolol

Eye drops 0.2% with timolol 0.5%

Brinzolamide

Eye drops 1%

Bromhexine hydrochloride

Tab 8 mg

Oral liq 4 mg per 5 ml

Oral liq 8 mg per 5 ml

Bromocriptine

Tab 2.5 mg

Cap 5 mg

Tab 10 mg

Budesonide

Cap 3 mg - ***restricted***

Nasal spray 50 mcg per dose

Nasal spray 100 mcg per dose

Powder for inhalation 100 mcg per dose

Powder for inhalation 200 mcg per dose

Powder for inhalation 400 mcg per dose

Nebuliser soln 250 mcg per ml, 2 ml ampoule

Nebuliser soln 500 mcg per ml, 2 ml ampoule

RESTRICTED
Crohn's disease
Both:
1. Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and
2. Any of the following:
    2.1. Diabetes; or
    2.2. Cushingoid habitus; or
    2.3. Osteoporosis where there is significant risk of fracture; or
    2.4. Severe acne following treatment with conventional corticosteroid therapy; or
    2.5. History of severe psychiatric problems associated with corticosteroid treatment; or
    2.6. History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
    2.7. Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Collagenous and lymphocytic colitis (microscopic colitis)
Patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies
Gut Graft versus Host disease
Patient has a gut Graft versus Host disease following allogenic bone marrow transplantation

Budesonide with eformoterol

Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg - ***restricted***

Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg - ***restricted***

Powder for inhalation 100 mcg with eformoterol fumarate 6 mcg - ***restricted***

Powder for inhalation 200 mcg with eformoterol fumarate 6 mcg - ***restricted***

Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg - ***restricted***

Must meet community Special Authority criteria

Bumetanide

Inj 500 mcg per ml, 4 ml vial

Tab 1 mg

Bupivacaine hydrochloride

Inj 1.25 mg per ml, 100 ml bag

Inj 1.25 mg per ml, 200 ml bag

Inj 2.5 mg per ml, 20 ml ampoule

Inj 2.5 mg per ml, 100 ml bag

Inj 2.5 mg per ml, 200 ml bag

Inj 5 mg per ml, 4 ml ampoule

Inj 5 mg per ml, 10 ml ampoule

Inj 3.75 mg per ml, 20 ml

Bupivacaine hydrochloride with adrenaline

Inj 2.5 mg per ml with adrenaline 1:400,000, 20 ml vial

Inj 5 mg per ml with adrenaline 1:200,000, 20 ml vial

Inj 5 mg per ml with adrenaline 1:200:000, 2.2 ml dental cartridge

Inj 2.5 mg per ml with adrenaline 1:400,000, 10 ml vial

Inj 5 mg per ml with adrenaline 1:200,000, 10 ml vial

Bupivacaine hydrochloride with fentanyl

Inf 0.625 mg with fentanyl 2 mcg per ml, 100 ml bag

Inj 1.25 mg with fentanyl 2 mcg per ml, 15 ml syringe

Inj 1.25 mg with fentanyl 2 mcg per ml, 20 ml syringe

Inj 1.25 mg with fentanyl 2 mcg per ml, 50 ml syringe

Inf 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag

Inf 1.25 mg with fentanyl 2 mcg per ml, 100 ml syringe

Inf 1.25 mg with fentanyl 2 mcg per ml, 200 ml bag

Inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag

Bupivacaine hydrochloride with glucose

Inj 0.5% with glucose 8%, 4 ml ampoule

Buprenorphine

Patch 5 mcg per hour

Patch 10 mcg per hour

Patch 20 mcg per hour

Inj 0.3 mg per ml, 1 ml ampoule

Buprenorphine with naloxone

Tab 2 mg with naloxone 0.5 mg - ***restricted***

Tab 8 mg with naloxone 2 mg - ***restricted***

RESTRICTED
Detoxification
All of the following:
1 Patient is opioid dependent; and
2 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
3 Prescriber works in an opioid treatment service approved by the Ministry of Health.
Maintenance treatment
All of the following:
1 Patient is opioid dependent; and
2 Patient will not be receiving methadone; and
3 Patient is currently enrolled in an opioid substitution treatment program in a service approved by the Ministry of Health; and
4 Prescriber works in an opioid treatment service approved by the Ministry of Health.

Bupropion hydrochloride

Tab modified-release 150 mg

Buserelin

Inj 1 mg per ml, 5.5 ml vial

Buspirone hydrochloride

Tab 5 mg - ***restricted***

Tab 10 mg - ***restricted***

RESTRICTED
Both:
1 For use only as an anxiolytic; and
2 Other agents are contraindicated or have failed.

Busulfan

Tab 2 mg

Inj 6 mg per ml, 10 ml ampoule

Cabergoline

Tab 0.5 mg

Caffeine

Tab 100 mg

Caffeine citrate

Inj 20 mg per ml (caffeine 10 mg per ml), 2.5 ml ampoule

Oral liq 20 mg per ml (caffeine 10 mg per ml)

Calamine

Crm, aqueous, BP

Lotn, BP

Calcipotriol

Crm 50 mcg per g

Oint 50 mcg per g

Soln 50 mcg per ml

Calcitonin

Inj 100 iu per ml, 1 ml ampoule

Calcitriol

Cap 0.25 mcg

Cap 0.5 mcg

Oral liq 1 mcg per ml

Inj 1 mcg per ml, 1 ml ampoule

Inj 1 mcg

Calcium carbonate

Tab 420 mg

Oral liq 250 mg per ml (100 mg elemental per ml) - ***restricted***

Tab 1.25 g (500 mg elemental)

Tab 1.5 g (600 mg elemental)

Tab eff 1.75 g (1 g elemental)

RESTRICTED
Only for use in children under 12 years of age for use as a phosphate binding agent

Calcium chloride

Inj 100 mg per ml, 10 ml vial

Calcium chloride with magnesium chloride, potassium chloride, sodium acetate, sodium chloride and sodium citrate

Eye drops 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39% mg, sodium chloride 0.64% mg and sodium citrate 0.17%

Irrigation soln 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39% mg, sodium chloride 0.64% mg and sodium citrate 0.17%, 250 ml

Irrigation soln 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39% mg, sodium chloride 0.64% mg and sodium citrate 0.17%, 500 ml

Note: balanced salt solution

Calcium folinate

Inj 1 mg per ml, 50 ml

Tab 15 mg

Inj 3 mg per ml, 1 ml ampoule

Inj 10 mg per ml, 5 ml ampoule

Inj 10 mg per ml, 10 ml vial

Inj 10 mg per ml, 30 ml vial

Inj 10 mg per ml, 100 ml vial

Calcium gluconate

Gel 2.5%

Inj 10%, 10 ml ampoule

Calcium polystyrene sulphonate

Powder

Candesartan cilexetil

Tab 16 mg - ***restricted***

Tab 32 mg - ***restricted***

Tab 4 mg - ***restricted***

Tab 8 mg - ***restricted***

RESTRICTED
ACE inhibitor intolerance
Either:
1. Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor); or
2. Patient has a history of angioedema.
Unsatisfactory response to ACE inhibitor
Patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor.

Capecitabine

Tab 150 mg

Tab 500 mg

Capreomycin

Inj 1 g

Capsaicin

Crm 0.025% - ***restricted***

Crm 0.075% - ***restricted***

RESTRICTED
(Cream 0.025%)
Patient has osteoarthritis that is not responsive to paracetamol and oral non-steroidal anti-inflammatories are contraindicated.
(Cream 0.075%)
For post-herpetic neuralgia or diabetic peripheral neuropathy

Captopril

Oral liq 5 mg per ml - ***restricted***

Tab 12.5 mg

Tab 25 mg

Tab 50 mg

RESTRICTED
Either:
1. For use in children under 12 years of age; or
2. For use in tube-fed patients.

Carbachol

Inj 150 µg in 1.5 ml vial

Carbamazepine

Oral liq 20 mg per ml

Tab 200 mg

Tab 400 mg

Tab long-acting 200 mg

Tab long-acting 400 mg

Carbimazole

Tab 5 mg

Carbohydrate and fat supplement

Powder 72.7 g carbohydrate and 22.3 g fat per 100 g, 400 g can {Super Soluble Duocal} - ***restricted***

RESTRICTED
Both:
1 Infant or child aged four years or under; and
2 Any of the following:
- 2.1 Cystic fibrosis; or
- 2.2 Cancer in children; or
- 2.3 Faltering growth; or
- 2.4 Bronchopulmonary dysplasia; or
- 2.5 Premature and post premature infants.

Carbohydrate supplement

Powder 96 g carbohydrate per 100 g, 400 g can {Polycal} - ***restricted***

Powder 95 g carbohydrate per 100 g, 368 g can {Moducal} - ***restricted***

RESTRICTED
Use as an additive
Any of the following:
1 Cystic fibrosis; or
2 Chronic kidney disease; or
3 Cancer in children; or
4 Cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
5 Faltering growth in an infant/child; or
6 Bronchopulmonary dysplasia; or
7 Premature and post premature infant; or
8 Inborn errors of metabolism.
Use as a module
For use as a component in a modular formula

Carbomer

Ophthalmic gel 0.2%

Ophthalmic gel 0.3%, single dose

Carboplatin

Inj 10 mg per ml, 5 ml vial

Inj 10 mg per ml, 15 ml vial

Inj 10 mg per ml, 45 ml vial

Inj 10 mg per ml, 100 ml vial

Carboprost trometamol

Inj 250 mcg per ml, 1 ml ampoule

Carboxymethylcellulose

Oral spray

Soln 1.5%

Carboxymethylcellulose with propylene glycol

Gel

Carmellose sodium

Eye drops 0.5%

Eye drops 0.5%, single dose

Eye drops 1%

Eye drops 1%, single dose

Carmustine

Implant 7.7 mg

Inj 100 mg vial

Carob bean gum with maize starch and maltodextrin

Powder {Karicare Aptamil Food Thickener}

Carvedilol

Tab 12.5 mg

Tab 25 mg

Tab 6.25 mg

Caspofungin

Inj 50 mg vial - ***restricted***

Inj 70 mg vial - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist, haematologist, oncologist, transplant specialist or respiratory physician
Either:
1 Proven or probable invasive fungal infection, to be prescribed under an established protocol; or
2 Both:
2.1 Possible invasive fungal infection; and
2.2 A multidisciplinary team (including an Infectious Disease physician or a Clinical Microbiologist) considers the treatment to be appropriate.

Cefaclor

Cap 250 mg

Grans for oral liq 25 mg per ml

Cefalexin

Cap 500 mg

Grans for oral liq 25 mg per ml

Grans for oral liq 50 mg per ml

Cefamandole nafate

Inj 500 mg

Inj 1 g

Cefazolin

Inj 500 mg vial

Inj 1 g vial

Cefepime

Inj 1 g vial - ***restricted***

Inj 2 g vial - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Cefotaxime

Inj 500 mg vial

Inj 1 g vial

Inj 2 g

Cefoxitin

Inj 1 g vial

Cefpirome

Inj 1 g

Cefpodoxime proxetil

Tab 100 mg

Cefradine

Cap 250 mg

Cap 500 mg

Inj 500 mg

Inj 1 g

Ceftazadime

Inj 500 mg vial - ***restricted***

Inj 1 g vial - ***restricted***

Inj 2 g vial - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist or respiratory physician

Ceftriaxone

Inj 500 mg vial

Inj 1 g vial

Inj 2 g vial

Cefuroxime

Tab 250 mg

Inj 750 mg vial

Inj 1.5 g vial

Cefuroxime sodium

Inj 250 mg

Celecoxib

Cap 100 mg

Cap 200 mg

Note: Peri-operative use of celecoxib is still under consideration.

Celiprolol

Tab 200 mg

Cetirizine hydrochloride

Oral liq 1 mg per ml

Tab 10 mg

Cetomacrogol

Crm BP

Cetomacrogol with glycerol

Crm 90% with glycerol 10%

Cetomacrogol with paraffin and cetyl alcohol

Crm cetomacrogol with soft white paraffin, paraffin liquid and cetyl alcohol

Cetrimide

Shampoo 20%

Soln 40%

Cetylpyridinium chloride

Lozenge

Mouthwash 0.05%

Cetylpyridinium chloride with benzocaine

Mouthwash 7.5 mg with benzocaine 60 mg per 15 ml

Charcoal

Tab 300 mg

Oral liq 200 mg per ml

Chloral hydrate

Oral liq 100 mg per ml

Oral liq 200 mg per ml

Chlorambucil

Tab 2 mg

Chloramphenicol

Inj 1 g vial - ***restricted***

Ear drops 0.5%

Eye drops 0.5%

Eye drops 0.5%, single dose

Eye oint 1%

RESTRICTED – infectious disease physician or clinical microbiologist

Chlordiazepoxide hydrochloride

Tab 10 mg

Chlorhexidine

Crm 1%

Lotn 1%

Soln 4%

Soln 5%

Irrigation soln 0.1%, 30 ml ampoule

Irrigation soln 0.02%, 100 ml bottle

Irrigation soln 0.02%, 500 ml

Irrigation soln 0.05%, 100 ml bottle

Irrigation soln 0.05%, 500 ml bottle

Irrigation soln 0.1%, 100 ml bottle

Irrigation soln 0.5%, 500 ml bottle

Chlorhexidine gluconate

Mouthwash 0.2%

Chlorhexidine with cetrimide

Foaming soln 0.5% with cetrimide 0.5%

Crm 1% with cetrimide 0.5%

Irrigation soln 0.015% with cetrimide 0.15%, 30 ml ampoule

Irrigation soln 0.015% with cetrimide 0.15%, 100 ml bottle

Irrigation soln 0.015% with cetrimide 0.15%, 500 ml bottle

Irrigation soln 0.015% with cetrimide 0.15%, 1000 ml bottle

Irrigation soln 0.05% with cetrimide 0.5%, 100 ml bottle

Irrigation soln 0.05% with cetrimide 0.5%, 500 ml bottle

Irrigation soln 0.1% with cetrimide 1%, 100 ml bottle

Irrigation soln 0.1% with cetrimide 1%, 500 ml bottle

Chlorhexidine with ethanol

Soln 0.5% with ethanol 70%

Soln 2% with ethanol 70%

Chloroform

Chloroform BP

Chloroquine phosphate

Tab 250 mg - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist, dermatologist or rheumatologist

Chlorothiazide

Oral liq 50 mg per ml

Chlorpheniramine maleate

Inj 10 mg per ml, 1 ml ampoule

Oral liq 0.4 mg per ml

Chlorpromazine hydrochloride

Tab 10 mg

Tab 25 mg

Tab 100 mg

Oral liq 10 mg per ml

Inj 25 mg per ml, 2 ml ampoule

Chlorpropamide

Tab 250 mg

Chlortalidone (chlorthalidone)

Tab 25 mg

Cholecalciferol

Tab 1.25 mg (50,000 iu)

Cholestyramine

Powder for oral liquid 4 g

Choline salicylate with cetalkonium chloride

Adhesive gel 8.7% with cetalkonium chloride 0.01%

Note: Bonjela

Choriogonadotropin alfa

Inj 250 mcg in 0.5 ml syringe

Ciclopirox olamine

Nail soln 8%

Soln 1% - ***restricted***

Cream 1%

RESTRICTED
For continuation only

Ciclosporin

Eye drops 0.05%, single dose

Eye oint 0.2%

Cap 25 mg

Cap 50 mg

Cap 100 mg

Oral liq 100 mg per ml

Inj 50 mg per ml, 5 ml ampoule

Cidofovir

Inj 75 mg per ml, 5 ml vial - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist, otolaryngologist or oral surgeon

Cilazapril

Tab 0.5 mg

Tab 2.5 mg

Tab 5 mg

Cilazapril with hydrochlorothiazide

Tab 5 mg with hydrochlorothiazide 12.5 mg

Cimetidine

Tab 200 mg

Tab 400 mg

Cinacalcet hydrochloride

Tab 30 mg

Tab 60 mg

Tab 90 mg

Cinchocaine hydrochloride with hydrocortisone

Oint 5 mg with hydrocortisone 5 mg per g

Suppos 5 mg with hydrocortisone 5 mg per g

Ciprofloxacin

Tab 250 mg - ***restricted***

Tab 500 mg - ***restricted***

Tab 750 mg - ***restricted***

Oral liq 50 mg per ml - ***restricted***

Oral liq 100 mg per ml - ***restricted***

Inj 2 mg per ml, 100 ml bag - ***restricted***

Eye drops 0.3%

RESTRICTED – infectious disease physician or clinical microbiologist

Cisapride

Tab 10 mg

Oral liq 1 mg per ml

Cisplatin

Inj 1 mg per ml, 50 ml vial

Inj 1 mg per ml, 100 ml vial

Citalopram hydrobromide

Tab 20 mg

Citric acid

Powder BP

Citric acid with magnesium oxide and sodium picosulfate

Powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet

Note: Picoprep

Citric acid with sodium bicarbonate

Powder 382.2 mg per g with sodium bicarbonate 551.3 mg per g, 4 g sachet

Cladribine

Inj 1 mg per ml, 10 ml vial

Inj 2 mg per ml, 5 ml vial

Clarithromycin

Tab 250 mg - ***restricted***

Tab 500 mg - ***restricted***

Grans for oral liq 25 mg per ml - ***restricted***

Inj 500 mg vial - ***restricted***

RESTRICTED
Tab 250 mg and oral liquid
1 Atypical mycobacterial infection; or
2 Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents.
Tab 500 mg
Helicobacter pylori eradication.
Infusion
1 Atypical mycobacterial infection; or
2 Mycobacterium tuberculosis infection where there is drug resistance or intolerance to standard pharmaceutical agents; or
3 Community-acquired pneumonia (clarithromycin is not to be used as the first-line macrolide).

Clindamycin

Cap 150 mg - ***restricted***

Oral liq 15 mg per ml - ***restricted***

Inj 150 mg per ml, 4 ml ampoule - ***restricted***

Soln 1%

RESTRICTED – infectious disease physician or clinical microbiologist

Clobazam

Tab 10 mg

Clobetasol propionate

Crm 0.05%

Oint 0.05%

Scalp app 0.05%

Clobetasone butyrate

Crm 0.05%

Oint 0.05%

Clofarabine

Inj 1 mg per ml, 20 ml

Clofazamine

Cap 50 mg - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist or dermatologist

Clomiphene citrate

Tab 50 mg

Clomipramine hydrochloride

Tab 10 mg

Tab 25 mg

Clonazepam

Inj 1 mg per ml, 1 ml ampoule

Oral drops 2.5 mg per ml

Tab 500 mcg

Tab 2 mg

Clonidine

Patch 2.5 mg, 100 mcg per day

Patch 5 mg, 200 mcg per day

Patch 7.5 mg, 300 mcg per day

Clonidine hydrochloride

Inj 1.5 mg per ml, 1 ml

Inj 1.5 mg per ml, 2 ml

Inj 1.5 mg per ml, 20 ml

Inj 150 mcg per ml, 1 ml ampoule

Tab 150 mcg

Tab 25 mcg

Clopidogrel

Tab 75 mg

Clostridium botulinum type A toxin

Inj 100 u vial

Inj 500 u vial

Clotrimazole

Crm 1%

Soln 1% - ***restricted***

Vaginal crm 1% with applicator

Vaginal crm 2% with applicator

Vaginal cream 10%

Pessaries 100 mg

Pessaries 500 mg

RESTRICTED
For continuation only

Clove oil

Liq

Clozapine

Tab 25 mg

Tab 50 mg

Tab 100 mg

Tab 200 mg

Oral liq 50 mg per ml

Coal tar

Shampoo 4%

Soln BP

Coal tar with allantoin, menthol, phenol and sulphur

Soln 5% with sulphur 0.5%, menthol 0.75%, phenol 0.5% and allantoin crm 2.5%

Coal tar with salicylic acid and sulphur

Oint 12% with salicylic acid 2% and sulphur 4%

Coal tar with triethanolamine laryl sulphate and fluorescein

Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium

Cocaine hydrochloride

Paste 5%

Soln 4%, 2 ml syringe

Soln 15%, 2 ml syringe

Cocaine hydrochloride with adrenaline

Paste 15% with adrenaline 0.06%

Paste 25% with adrenaline 0.06%

Codeine phosphate

Tab 15 mg

Tab 30 mg

Tab 60 mg

Inj 50 mg per ml, 1 ml

Powder

Colaspase [L-asparaginase]

Inj 10,000 iu vial

Colchicine

Tab 500 mcg

Colestipol hydrochloride

Grans for oral liquid 5 g

Colistin sulphomethate [Colestimethate]

Inj 150 mg per ml, 1 ml vial - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist or respiratory physician

Collodion flexible

Liq

Compound electrolytes

Inj glucose 50 g with 40 mmol sodium, 13 mmol potassium, 1.5 mmol magnesium, 40 mmol chloride and 16 mmol acetate, 1,000 ml {Plasma-Lyte 56 in Glucose}

Ice block 62.5 ml {Hydralyte}

Inj sodium 140 mmol/L with potassium 5 mmol/L, magnesium 1.5 mmol/L, chloride 98 mmol/L, acetate 27 mmol/L and gluconate 23 mmol/l, 500 ml bag

Inj sodium 140 mmol/L with potassium 5 mmol/L, magnesium 1.5 mmol/L, chloride 98 mmol/L, acetate 27 mmol/L and gluconate 23 mmol/l, 1,000 ml bag

Powder for oral soln

Compound electrolytes with glucose

Inj glucose 50 g with 140 mmol/L sodium, 5 mmol/L potassium, 1.5 mmol/L magnesium, 98 mmol/L chloride 27 mmol/L acetate and 23 mmol/L gluconate, 1,000 ml bag

Soln with electrolytes

Compound hydroxybenzoate

Soln

Compound sodium lactate [Hartmann's solution]

Inj sodium 131 mmol/L with potassium 5 mmol/L, calcium 2 mmol/L, bicarbonate 29 mmol/L, chloride 111 mmol/L, 500 ml bag

Inj sodium 131 mmol/L with potassium 5 mmol/L, calcium 2 mmol/L, bicarbonate 29 mmol/L, chloride 111 mmol/L, 1,000 ml bag

Compound sodium lactate with glucose

Inj sodium 131 mmol/L with potassium 5 mmol/L, calcium 2 mmol/L, bicarbonate 29 mmol/L, chloride 111 mmol/L and glucose 5%, 1,000 ml bag

Corticotrorelin (ovine)

Inj 100 mcg vial

Cortisone acetate

Tab 5 mg

Crisantaspase

Inj 10,000 iu {Erwinase}

Crotamiton

Crm 10%

Cyclizine hydrochloride

Tab 50 mg

Cyclizine lactate

Inj 50 mg per ml, 1 ml ampoule

Cyclopenthiazide

Tab 500 mcg

Cyclopentolate hydrochloride

Eye drops 0.5%, single dose

Eye drops 1%

Eye drops 1%, single dose

Cyclophosphamide

Tab 50 mg

Inj 1 g vial

Inj 2 g vial

Cycloserine

Cap 250 mg - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist or respiratory physician

Cyproheptadine hydrochloride

Tab 4 mg

Cyproterone acetate

Tab 50 mg

Tab 100 mg

Inj 100 mg per ml, 3 ml

Cyproterone acetate with ethinyloestradiol

Tab 2 mg with ethinyloestradiol 35 mcg

Cysteamine hydrochloride

Powder

Cytarabine

Inj 20 mg per ml, 5 ml vial

Inj 200 mg per ml, 25 ml vial

Inj 100 mg per ml, 10 ml vial

Inj 100 mg per ml, 20 ml vial

Dabigatran

Cap 75 mg

Cap 110 mg

Cap 150 mg

Dacarbazine

Inj 200 mg vial

Dactinomycin [Actinomycin D]

Inj 0.5 mg vial

Dalteparin

Inj 2,500 iu in 0.2 ml syringe

Inj 5,000 iu in 0.2 ml syringe

Inj 7,500 iu in 0.75 ml syringe

Inj 10,000 iu in 1 ml syringe

Inj 12,500 iu in 0.5 ml syringe

Inj 15,000 iu in 0.6 ml syringe

Inj 18,000 iu in 0.72 ml syringe

Danaparoid

Inj 750 u in 0.6 ml ampoule - ***restricted***

RESTRICTED
For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance

Danazol

Cap 100 mg

Cap 200 mg

Danthron with poloxamer

Oral liq 25 mg with poloxamer 200 mg per 5 ml - ***restricted***

Oral liq 75 mg with poloxamer 1 g per 5 ml - ***restricted***

RESTRICTED
Only for the prevention or treatment of constipation in the terminally ill

Dantrolene

Cap 25 mg

Cap 50 mg

Inj 20 mg vial

Dapsone

Tab 25 mg - ***restricted***

Tab 100 mg - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist or dermatologist

Daptomycin

Inj 350 mg vial - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Darunavir

Tab 400 mg - ***restricted***

Tab 600 mg - ***restricted***

Must meet community Special Authority criteria

Dasatinib

Tab 20 mg - ***restricted***

Tab 50 mg - ***restricted***

Tab 70 mg - ***restricted***

Tab 100 mg - ***restricted***

RESTRICTED
For use in patients with approval from the CML/GIST Co-ordinator

Daunorubicin

Inj 2 mg per ml, 10 ml vial

Daunorubicin citrate, liposomal

Inj 50 mg

Deferasirox

Tab 125 mg

Tab 250 mg

Tab 500 mg

Deferiprone

Tab 500 mg

Oral liq 100 mg per ml

Defibrotide

Inj 80 mg per ml, 2.5 ml ampoule - ***restricted***

RESTRICTED - haematologist
Patient has moderate or severe sinusoidal obstruction syndrome as a result of regimen-related toxicities after allogeneic stem cell transplantation

Demeclocycline hydrochloride

Cap 150 mg

Desferrioxamine mesilate

Inj 500 mg vial

Desflurane

Soln for inhalation 100%, 240 ml bottle

Desmopressin

Tab 200 mg

Nasal spray 150 mcg per dose

Desmopressin acetate

Tab 100 mcg

Inj 4 mcg per ml, 1 ml ampoule

Inj 15 mcg per ml, 1 ml ampoule

Nasal drops 100 mcg per ml

Nasal spray 10 mcg per dose

Desogestrel

Tab 75 mcg

Dexamethasone

Tab 1 mg

Tab 4 mg

Oral liq 1 mg per ml

Eye drops 0.1%

Eye oint 0.1%

Dexamethasone phosphate

Inj 4 mg per ml, 1 ml ampoule

Inj 4 mg per ml, 2 ml vial

Dexamethasone with framycetin and gramicidin

Ear/eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml

Dexamethasone with neomycin sulphate and polymyxin B sulphate

Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per g

Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per g

Dexamethasone with tobramycin

Eye drops 0.1% with tobramycin 0.3%

Dexamphetamine sulphate

Tab 5 mg - ***restricted***

Must meet community Special Authority criteria

Dexmedetomidine hydrochloride

Inj 100 mcg per ml, 2 ml vial

Dextran 40 in glucose

Inf 10% with glucose 5%, 500 ml

Dextran 40 in sodium chloride

Inf 10% with sodium chloride 0.9%, 500 ml

Dextran 70 in glucose

Inf 6% with glucose 5%, 500 ml

Dextran 70 in sodium chloride

Inf 6% with sodium chloride 0.9%, 50 ml

Dextrochlorpheniramine maleate

Tab 2 mg

Tab long-acting 6 mg

Oral liq 2 mg per 5 ml

Dextromethorphan

Oral liq 15 mg per 5 ml

Dextrose with sodium citrate and citric acid [Acid Citrate Dextrose A]

Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml, 100 ml bag

Diatrizoate meglumine with diatrizoate sodium

Oral liq 660 mg per ml with diatrizoate sodium 100 mg per ml, 100 ml

Inj 146 mg with sodium amidotrizoate 40 mg per ml, 250 ml bottle

Inj 370 mg with sodium amidotrizoate 100 mg per, 50 ml bottle

Diatrizoate sodium

Oral liq 370 mg per ml, 10 ml

Diazepam

Rectal tubes 5 mg

Rectal tubes 10 mg

Inj 5 mg per ml, 2 ml ampoule

Tab 2 mg

Tab 5 mg

Oral liq 10 mg per 10 ml

Diazoxide

Inj 15 mg per ml, 20 ml ampoule

Cap 25 mg - ***restricted***

Cap 100 mg - ***restricted***

Cap 50 mg

RESTRICTED
For patients with confirmed hypoglycaemia caused by hyperinsulinism

Dichlorobenzyl alcohol with amylmetacresol

Lozenge 1.2 mg with amylmetacresol 0.6 mg

Note: Strepsils

Dichlorobenzyl alcohol with amylmetacresol and lignocaine

Lozenge 1.2 mg with amylmetacresol 0.6 mg and lignocaine hydrochloride 10 mg

Note: Strepsils Plus

Diclofenac

Gel 1%

Diclofenac potassium

Tab 12.5 mg

Tab 25 mg

Diclofenac sodium

Inj 25 mg per ml, 3 ml ampoule

Suppos 100 mg

Suppos 12.5 mg

Suppos 25 mg

Suppos 50 mg

Tab 50 mg dispersible

Tab EC 25 mg

Tab EC 50 mg

Tab long-acting 100 mg

Tab long-acting 75 mg

Eye drops 0.1%

Eye drops 0.1%, single dose

Dicobalt edetate

Inj 15 mg per ml, 20 ml ampoule

Didanosine [DDI]

Cap 125 mg - ***restricted***

Cap 200 mg - ***restricted***

Cap 250 mg - ***restricted***

Cap 400 mg - ***restricted***

Must meet community Special Authority criteria

Diethyl ether

Liquid

Diflucortolone valerate

Crm 0.1% - ***restricted***

Fatty oint 0.1% - ***restricted***

RESTRICTED
For continuation only

Digoxin

Inj 250 mcg per ml, 2 ml vial

Oral liq 50 mcg per ml

Tab 250 mg

Tab 62.5 mg

Digoxin immune Fab

Inj 38 mg vial

Inj 40 mg vial

Dihydrocodeine tartrate

Tab long-acting 60 mg

Dihydroergotamine mesylate

Inj 1 mg per ml, 1 ml ampoule

Diltiazem hydrochloride

Cap long-acting 120 mg (twice daily)

Cap long-acting 90 mg (twice daily)

Cap long-acting 120 mg

Cap long-acting 180 mg

Cap long-acting 240 mg

Inj 5 mg per ml, 5 ml vial

Tab 30 mg

Tab 60 mg

Dimercaprol

Inj 50 mg per ml, 2 ml ampoule

Dimercaptosuccinic acid

Cap 100 mg

Dimethicone

Crm 5%

Cream 10%

Dimethicone with calamine and retinol palmitate

Crm 10 mg with calamine 100 mg and retinol palmitate 150 µg per g

Dimethicone with cetyl alcohol and glycerol

Crm 15% with cetyl alcohol 5% and glycerol 2%

Dimethyl sulfoxide

Soln 50%

Dinoprost trometamol

Inj 5 mg per ml, 1 ml

Dinoprostone

Pessaries 10 mg

Gel 1 mg in 2.5 ml

Gel 2 mg in 2.5 ml

Diphemanil metilsulfate

Powder 2%

Diphenhydramine hydrochloride

Oral liq 12.5 mg per 5 ml

Diphenoxylate hydrochloride with atropine sulphate

Tab 2.5 mg with atropine sulphate 25 mcg

Diphtheria and tetanus vaccine

Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid in 0.5 ml syringe - ***restricted***

RESTRICTED
Any of the following:
1 For vaccination of patients aged 45 and 65 years old; or
2 For vaccination of previously unimmunised patients; or
3 For revaccination following immunosuppression; or
4 For revaccination for patients with tetanus-prone wounds.

Diphtheria antitoxin

Inj 10,000 iu vial

Diphtheria toxoid with haemophilus B conjugate vaccine, pertussis vaccine; and tetanus toxoid

Injection

Diphtheria, tetanus and pertussis vaccine

Inj 2 IU diphtheria toxoid with 20 IU tetanus toxoid, 8 mcg pertussis toxoid, 8 mcg pertussis filamentous haemagluttinin and 2.5 mcg pertactin in 0.5 ml syringe - ***restricted***

RESTRICTED
Either:
1 For primary vaccination in children aged 7-18 years and older; or
2 For pregnant women between gestational weeks 28 and 38 during epidemics.

Diphtheria, tetanus, pertussis and polio vaccine

Inj 30 IU diphtheria toxoid with 30IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagluttinin, 8 mcg pertactin and 80 D antigen units poliomyelitis virus in 0.5 ml syringe - ***restricted***

RESTRICTED
For primary vaccination in children

Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine

Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagluttinin, 8 mcg pertactin, 80 D-antigen units poliomyelitis virus, 10 mcg hepatitis B surface antigen in 0.5 ml syringe (1) and inj 10 mcg h - ***restricted***

RESTRICTED
Either:
1 For primary vaccination in children; or
2 For revaccination following immunosuppression.

Dipyridamole

Tab 25 mg

Tab long-acting 150 mg

Inj 5 mg per ml, 2 ml ampoule

Disodium edetate

Inj 150 mg per ml, 100 ml vial

Inj 150 mg per ml, 20 ml ampoule

Inj 150 mg per ml, 20 ml vial

Disodium hydrogen phosphate with sodium dihydrogen phosphate

Inj 37.46 mg with sodium dihydrogen phosphate 47.7 mg in 1.5 ml ampoule {Amphotericin Buffer Solution}

Disopyramide phosphate

Cap 100 mg

Cap 150 mg

Disulfiram

Tab 200 mg

Dithranol

Crm 1%

Powder

Dobutamine hydrochloride

Inj 12.5 mg per ml, 20 ml vial

Docetaxel

Inj 10 mg per ml, 2 ml vial

Inj 10 mg per ml, 8 ml vial

Docusate sodium

Cap 50 mg

Cap 120 mg

Ear drops 0.5%

Enema 18%

Docusate sodium with sennosides

Tab 50 mg with sennosides 8 mg

Domperidone

Tab 10 mg

Oral liq 1 mg per ml

Suppos 10 mg

Donepezil hydrochloride

Tab 5 mg

Tab 10 mg

Dopamine hydrochloride

Inj 40 mg per ml, 5 ml ampoule

Doripenem

Inj 500 mg

Dornase alfa

Nebuliser soln 2.5 mg per 2.5 ml ampoule - ***restricted***

RESTRICTED
For use in patients with approval by the Cystic Fibrosis Advisory Panel

Please note that we are still considering the use of dornase alfa for other situations.

Dorzolamide

Eye drops 2%

Dorzolamide with timolol

Eye drops 2% with timolol 0.5%

Dothiepin hydrochloride

Cap 25 mg

Tab 75 mg

Doxapram

Inj 20 mg per ml, 5 ml vial

Doxazosin

Tab 2 mg

Tab 4 mg

Doxepin hydrochloride

Cap 10 mg

Cap 25 mg

Cap 50 mg

Doxorubicin hydrochloride

Inj 2 mg per ml, 5 ml vial

Inj 2 mg per ml, 25 ml vial

Inj 2 mg per ml, 50 ml vial

Inj 2 mg per ml, 100 ml vial

Doxycycline

Tab 50 mg - ***restricted***

Tab 100 mg

Inj 5 mg per ml, 20 ml vial

RESTRICTED
For continuation only

Dronaderone

Tab 400 mg

Droperidol

Inj 2.5 mg per ml, 1 ml ampoule

Inj 5 mg per ml, 2 ml ampoule

Drospirenone with ethinyloestradiol

Tab 3 mg with ethinyloestradiol 20 µg

Tab 3 mg with ethinyloestradiol 30 µg

Droxidopa

Cap 100 mg

Duloxetine

Cap 30 mg

Cap 45 mg

Cap 60 mg

Dydrogesterone

Tab 10 mg

Econazole nitrate

Crm 1% - ***restricted***

Foaming soln 1%

RESTRICTED
For continuation only

Edrophonium chloride

Inj 10 mg per ml, 1 ml ampoule - ***restricted***

RESTRICTED
For the diagnosis of myasthenia gravis

Efavirenz

Tab 50 mg - ***restricted***

Tab 200 mg - ***restricted***

Tab 600 mg - ***restricted***

Oral liq 30 mg per ml - ***restricted***

Must meet community Special Authority criteria

Efavirenz with emtricitabine and tenofovir disoproxil fumarate

Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg - ***restricted***

Must meet community Special Authority criteria

Eformoterol fumarate

Powder for inhalation 6 mcg per dose

Powder for inhalation 12 mcg per dose

Electrolytes

Inj 110 mmol/l sodium, 16 mmol/l potassium, 1.2 mmol/l calcium, 16 mmol/l magnesium and 160 mmol/l chloride, 1000 ml bag

Inj citric acid 0.07973 mg per ml, sodium phosphate 0.06119 mg per ml, potassium chloride 2.181 mg per m sodium chloride 1.788 mg ml, sodium citrate 0.6412 mg per ml and trometamol 5.9 mg per ml, 523 ml bag

Inj aspartic acid 8.481 mg per ml, citric acid 0.8188 mg per ml, glutamic acid 9.375 mg per ml, sodium phosphate 0.6285 mg per ml, potassium chloride 2.5 mg per ml, sodium citrate 6.585 mg per ml, sodium hydroxide 5.133 mg per ml and trometamol 9.097 mg p

Inj aspartic acid 10.43 mg per ml, citric acid 0.22476 mg per ml, glutamic acid 11.53 mg per ml, sodium phosphate 0.1725 mg per ml, potassium chloride 2.15211 mg per ml, sodium citrate 1.80768 mg per ml, sodium hydroxide 6.31 mg per ml and trometamol 11.2

Inj 143 mmol/L sodium, 16 mmol/L potassium, 16 mmol/L magnesium and 1.2 mmol/L calcium, 1000 ml bag

Emtricitabine

Cap 200 mg - ***restricted***

Must meet community Special Authority criteria

Emtricitabine with tenofovir disoproxil fumarate

Tab 200 mg with tenofovir disoproxil fumarate 300 mg - ***restricted***

Must meet community Special Authority criteria

Emulsifying ointment

Oint BP

Enalapril maleate

Tab 10 mg

Tab 20 mg

Tab 5 mg

Enalapril maleate with hydrochlorothiazide

Tab 20 mg with hydrochlorothiazide 12.5 mg - ***restricted***

RESTRICTED
For continuation only

Enfuvirtide

Inj 108 mg vial - ***restricted***

Must meet community Special Authority criteria

Enoxaparin

Inj 20 mg in 0.2 ml syringe

Inj 40 mg in 0.4 ml syringe

Inj 60 mg in 0.6 ml syringe

Inj 80 mg in 0.8 ml syringe

Inj 100 mg in 1 ml syringe

Inj 120 mg in 0.8 ml syringe

Inj 150 mg in 1 ml syringe

Enoxolone with povidone and sodium hyaluronate

Gel 15 ml

Entacapone

Tab 200 mg

Entecavir

Tab 0.5 mg - ***restricted***

Tab 1 mg

Must meet community Special Authority criteria

Enteral feed 1 kcal/ml

Liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per 100 ml, 500 ml bag {Nutrison Multi Fibre} - ***restricted***

Liquid 4 g protein, 12.3 g carbohydrate, 3.9 g fat and 1.5 g fibre per 100 ml, 1000 ml bag {Nutrison Multi Fibre} - ***restricted***

Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, 500 ml bottle {Nutrison RTH / Nutrison Low Sodium} - ***restricted***

Liquid 4 g protein, 12.3 g carbohydrate and 3.9 g fat per 100 ml, 1000 ml bag {Nutrison RTH / Nutrison Low Sodium} - ***restricted***

Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, 250 ml can {Osmolite} - ***restricted***

Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, 500 ml bottle {Osmolite } - ***restricted***

Liquid 4 g protein, 13.6 g carbohydrate and 3.4 g fat per 100 ml, 1000 ml bottle {Osmolite RTH} - ***restricted***

Liquid 4 g protein, 13.6 g carbohydrate and 3.3 g fat per 100 ml, 250 ml can {Isosource Standard} - ***restricted***

Liquid 4 g protein, 13.6 g carbohydrate and 3.3 g fat per 100 ml, 1000 ml bottle {Isosource Standard RTH} - ***restricted***

Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, 237 ml can {Jevity} - ***restricted***

Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, 500 ml bottle {Jevity RTH} - ***restricted***

Liquid 4 g protein, 14.1 g carbohydrate, 3.47 g fat and 1.76 g fibre per 100 ml, 1000 ml bottle {Jevity RTH} - ***restricted***

Liquid 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml {Cubison}

RESTRICTED
Any of the following:
1 For patients with malnutrition, defined as any of the following:
- 1.1 BMI < 18.5; or
- 1.2 Greater than 10% weight loss in the last 3-6 months; or
- 1.3 BMI < 20 with greater than 5% weight loss in the last 3-6 months; or

2 For patients who have, or are expected to, eat little or nothing for 5 days; or
3 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
4 For use pre- and post-surgery; or
5 For patients being tube-fed; or
6 For tube-feeding as a transition from intravenous nutrition; or
7 For any other condition that meets the community Special Authority criteria.

Enteral feed 1.2 kcal/ml

Liquid 5.55 g protein, 15.1 g carbohydrate, 3.93 g fat and 2 g fibre per 100 ml, 1000 ml bag {Jevity Plus RTH} - ***restricted***

RESTRICTED
Any of the following:
1 For patients with malnutrition, defined as any of the following:
- 1.1 BMI < 18.5; or
- 1.2 Greater than 10% weight loss in the last 3-6 months; or
- 1.3 BMI < 20 with greater than 5% weight loss in the last 3-6 months; or

2 For patients who have, or are expected to, eat little or nothing for 5 days; or
3 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
4 For use pre- and post-surgery; or
5 For patients being tube-fed; or
6 For tube-feeding as a transition from intravenous nutrition; or
7 For any other condition that meets the community Special Authority criteria.

Enteral feed 1.5 kcal/ml

Liquid 6 g protein, 18.3 g carbohydrate and 5.8 g fat per 100 ml, 1000 ml bag {Nutrison Energy} - ***restricted***

Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 1.5 g fibre per 100 ml, 1000 ml bag {Nutrison Energy Multi Fibre} - ***restricted***

Liquid 6.25 g protein, 20 g carbohydrate and 5 g fat per 100 ml, 250 ml can {Ensure Plus HN} - ***restricted***

Liquid 6.27 g protein, 20.4 g carbohydrate and 4.9 g fat per 100 ml, 1000 ml bag {Ensure Plus HN RTH} - ***restricted***

Liquid 6.38 g protein, 21.1 g carbohydrate, 4.9 g fat and 1.2 g fibre per 100 ml, 1000 ml bag {Jevity HiCal RTH} - ***restricted***

RESTRICTED

Any of the following:

1 For patients with malnutrition, defined as any of the following:

- 1.1 BMI < 18.5; or
- 1.2 Greater than 10% weight loss in the last 3-6 months; or
- 1.3 BMI < 20 with greater than 5% weight loss in the last 3-6 months; or

2 For patients who have, or are expected to, eat little or nothing for 5 days; or

3 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or

4 For use pre- and post-surgery; or

5 For patients being tube-fed; or

6 For tube-feeding as a transition from intravenous nutrition; or

7 For any other condition that meets the community Special Authority criteria.

Enteral feed 2 kcal/ml

Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 500 ml bag {Nutrison Concentrated} - ***restricted***

Liquid 8.4 g protein, 21.9 g carbohydrate, 9.1 g fat and 0.5 g fibre per 100 ml, 1000 ml bottle {TwoCal HN RTH} - ***restricted***

RESTRICTED

Either:

1 Patient is fluid restricted; or

2 Both:

- 2.1 Any of the following:
  - 2.1.1 Cystic fibrosis; or
  - 2.1.2 Any condition causing malabsorption; or
  - 2.1.3 Faltering growth in an infant/child; or
  - 2.1.4 Increased nutritional requirements; and
- 2.2 Patient has substantially increased metabolic requirements.

Ephedrine

Inj 3 mg per ml, 10 ml syringe

Inj 30 mg per ml, 1 ml ampoule

Epirubicin hydrochloride

Inj 2 mg per ml, 5 ml vial

Inj 2 mg per ml, 25 ml vial

Inj 2 mg per ml, 50 ml vial

Inj 2 mg per ml, 100 ml vial

Eptacog alfa [Recombinant factor VIIa]

Inj 1 mg vial

Inj 2 mg vial

Inj 5 mg vial

Inj 8 mg vial

Eptifibatide

Inj 750 mcg per ml, 100 ml vial - ***restricted***

Inj 2 mg per ml, 10 ml vial - ***restricted***

RESTRICTED
For use in patients with acute coronary syndromes undergoing percutaneous coronary intervention

Ergocalciferol

Tab 1.25 g

Ergometrine maleate

Inj 500 mcg per ml, 1 ml ampoule

Ergotamine tartrate with caffeine

Tab 1 mg with caffeine 100 mg

Erlotinib

Tab 100 mg - ***restricted***

Tab 150 mg - ***restricted***

Must meet community Special Authority criteria

Ertapenem

Inj 1 g vial - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Erythromycin (as ethylsuccinate)

Tab 400 mg

Grans for oral liq 200 mg per 5 ml

Grans for oral liq 400 mg per 5 ml

Erythromycin (as lactobionate)

Inj 1 g vial

Erythromycin (as stearate)

Tab 250 mg - ***restricted***

Tab 500 mg - ***restricted***

RESTRICTED
For continuation only

Erythromycin lactobionate

Inj 300 mg

Erythropoietin alpha

Inj 1,000 iu in 0.5 ml syringe - ***restricted***

Inj 2,000 iu in 0.5 ml syringe - ***restricted***

Inj 3,000 iu in 0.3 ml syringe - ***restricted***

Inj 4,000 iu in 0.4 ml syringe - ***restricted***

Inj 5,000 iu in 0.5 ml syringe - ***restricted***

Inj 6,000 iu in 0.6 ml syringe - ***restricted***

Inj 10,000 iu in 1 ml syringe - ***restricted***

RESTRICTED
Both:
1 Both:
- 1.1 Patient in chronic renal failure; and
- 1.2 Haemoglobin ≤ 100g/L; and

2 Any of the following:
- 2.1 Both:
  - 2.1.1 Patient is not diabetic; and
  - 2.1.2 Glomerular filtration rate ≤ 30ml/min; or
- 2.2 Both:
  - 2.2.1 Patient is diabetic; and
  - 2.2.2 Glomerular filtration rate ≤ 45ml/min; or
- 2.3 Patient is on haemodialysis or peritoneal dialysis.

Erythropoietin beta

Inj 2,000 iu in 0.3 ml syringe - ***restricted***

Inj 3,000 iu in 0.3 ml syringe - ***restricted***

Inj 4,000 iu in 0.3 ml syringe - ***restricted***

Inj 5,000 iu in 0.3 ml syringe - ***restricted***

Inj 6,000 iu in 0.3 ml syringe - ***restricted***

Inj 10,000 iu in 0.6 ml syringe - ***restricted***

RESTRICTED
Both:
1 Both:
- 1.1 Patient in chronic renal failure; and
- 1.2 Haemoglobin ≤ 100g/L; and

2 Any of the following:
- 2.1 Both:
  - 2.1.1 Patient is not diabetic; and
  - 2.1.2 Glomerular filtration rate ≤ 30ml/min; or
- 2.2 Both:
  - 2.2.1 Patient is diabetic; and
  - 2.2.2 Glomerular filtration rate ≤ 45ml/min; or
- 2.3 Patient is on haemodialysis or peritoneal dialysis.

Escitalopram

Tab 10 mg

Tab 20 mg

Esmolol hydrochloride

Inj 250 mg per ml, 10 ml

Inj 10 mg per ml, 10 ml vial

Etanercept

Inj 25 mg vial - ***restricted***

Inj 50 mg autoinjector - ***restricted***

Inj 50 mg syringe - ***restricted***

RESTRICTED

Initiation – juvenile idiopathic arthritis – rheumatologist or named specialist

Re-assessment required after 4 months

All of the following:

1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and

3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and

4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m2 weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and

5 Both:

- 5.1 Either:
  - 5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
  - 5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
- 5.2 Physician's global assessment indicating severe disease.

Continuation – juvenile idiopathic arthritis – rheumatologist or named specialis

Re-assessment required after 6 months

All of the following:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2 Either:

- 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
- 2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Initiation – rheumatoid arthritis – rheumatologist

Re-assessment required after 6 months

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
- 1.2 Either:
  - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
  - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or

2 All of the following:

- 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
- 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
- 2.5 Any of the following:
  - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
  - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or

2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

2.6 Either:

2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or

2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and

2.7 Either:

2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or

2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation – rheumatoid arthritis – rheumatologist

Re-assessment required after 6 months

All of the following:

1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

2 Either:

2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

2.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – ankylosing spondylitis – rheumatologist

Re-assessment required after 6 months

Either:

1 Both:

1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and

1.2 Either:

1.2.1 The patient has experienced intolerable side effects from adalimumab; or

1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or

2 All of the following:

2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and

2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and

2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and

2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal anti-inflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and

2.5 Either:

2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or

2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and

2.6 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of starting treatment.

Average normal chest expansion corrected for age and gender:

18-24 years - Male: 7.0 cm; Female: 5.5 cm

25-34 years - Male: 7.5 cm; Female: 5.5 cm

35-44 years - Male: 6.5 cm; Female: 4.5 cm

45-54 years - Male: 6.0 cm; Female: 5.0 cm

55-64 years - Male: 5.5 cm; Female: 4.0 cm

65-74 years - Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Continuation – ankylosing spondylitis – rheumatologist
Re-assessment required after 6 months
All of the following:
1 Following 12 weeks of etanercept treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and
2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – psoriatic arthritis – rheumatologist
Re-assessment required after 6 months
Either:
1 Both:
- 1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
- 1.2 Either:
  - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
  - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or

2 All of the following:
- 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
- 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
- 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
- 2.4 Either:
  - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
  - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.5 Any of the following:
  - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
  - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
  - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Continuation – psoriatic arthritis – rheumatologist
Re-assessment required after 6 months
All of the following:
1 Either:
- 1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and

2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Initiation – plaque psoriasis, prior TNF use – dermatologist
Re-assessment required after 4 months
Both:
1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
2 Either:
- 2.1 The patient has experienced intolerable side effects from adalimumab; or
- 2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; and

3 Patient must be reassessed for continuation after 3 doses.

Initiation – plaque psoriasis, treatment-naïve – dermatologist
Re-assessment required after 4 months
All of the following:
1 Either:
1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
4 The most recent PASI assessment is no more than 1 month old at the time of initiation.
Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Continuation – plaque psoriasis – dermatologist
Re-assessment required after 6 months
All of the following:
1 Either:
1.1 Both:
1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
1.1.2 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-etanercept treatment baseline value; or
1.2 Both:
1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
1.2.2 Either:
1.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
1.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-etanercept treatment baseline value; and
2 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Ethambutol hydrochloride

Tab 100 mg - ***restricted***

Tab 400 mg - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist or respiratory physician

Ethanol

Liq 96%

Ethanol with glucose

Inj 10% with glucose 5%, 500 ml bottle

Ethanol, dehydrated

Inj 100%, 20 ml

Inj 100%, 5 ml ampoule

Ethanolamine oleate

Inj 5%, 5 ml

Ethinyloestradiol

Tab 10 mcg

Ethinyloestradiol with desogestrel

Tab 20 mcg with desogestrel 150 mcg

Tab 30 mcg with desogestrel 150 mcg

Ethinyloestradiol with gestodene

Tab 30 µg with gestodene 75 µg

Ethinyloestradiol with levonorgestrel

Tab 20 mcg with levonorgestrel 100 mcg

Tab 30 mcg with levonorgestrel 150 mcg

Tab 50 mcg with levonorgestrel 125 mcg

Ethinyloestradiol with norethisterone

Tab 35 mcg with norethisterone 500 mcg

Tab 35 mcg with norethisterone 1 mg

Ethionamide

Tab 250 mg

Ethosuximide

Cap 250 mg

Oral liq 50 mg per ml

Ethyl chloride

Spray 100%

Etidronate disodium

Tab 200 mg

Etomidate

Inj 2 mg per ml, 10 ml ampoule

Etonogestrel

Subdermal implant 68 mg

Etoposide

Cap 50 mg

Cap 100 mg

Inj 20 mg per ml, 5 ml vial

Etoposide (as phosphate)

Inj 100 mg vial

Etoricoxib

Tab 30 mg

Tab 60 mg

Tab 90 mg

Tab 120 mg

Note: Peri-operative use of etoricoxib is still under consideration.

Etravirine

Tab 100 mg - ***restricted***

Tab 200 mg - ***restricted***

Must meet community Special Authority criteria

Eucalyptus oi

Liquid

Exemestane

Tab 25 mg

Extensively hydrolysed formula

Powder 14 g protein, 53.4 g carbohydrate and 27.3 g fat per 100 g, 450 g can {Karicare Aptamil Pepti Junic Gold} - ***restricted***

RESTRICTED
Initiation – new patients
Any of the following:
1 Both:
1.1 Cows' milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
1.2 Either:
1.2.1 Soy milk formula has been trialled without resolution of symptoms; or
1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
2 Severe malabsorption; or
3 Short bowel syndrome; or
4 Intractable diarrhea; or
5 Biliary atresia; or
6 Cholestatic liver diseases causing malsorption; or
7 Cystic fibrosis; or
8 Proven fat malabsorption; or
9 Severe intestinal motility disorders causing significant malabsorption; or
10 Intestinal failure.
Initiation – step down from amino acid formula
Both:
1 The infant is currently receiving funded amino acid formula; and
2 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula.
Continuation
Both:
1 An assessment as to whether the infant can be transitioned to a cows' milk protein or soy infant formula has been undertaken; and
2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula.

Extensively hydrolysed infant formula

Powder {Alfare}

Ezetimibe

Tab 10 mg - ***restricted***

RESTRICTED
All of the following:
1. Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
2. Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
3. Any of the following:
    1. The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 × normal) when treated with one statin; or
    2. The patient is intolerant to both simvastatin and atorvastatin; or
    3. The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Ezetimibe with simvastatin

Tab 10 mg with simvastatin 10 mg - ***restricted***

Tab 10 mg with simvastatin 20 mg - ***restricted***

Tab 10 mg with simvastatin 40 mg - ***restricted***

Tab 10 mg with simvastatin 80 mg - ***restricted***

RESTRICTED
All of the following:
1. Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
2. Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
3. The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Famotidine

Tab 20 mg

Tab 40 mg

Fat-modified feed

Powder 11.4 g protein, 68 g carbohydrate and 11.8 g fat per 100 g, 400 g can {Monogen} - ***restricted***

RESTRICTED
Any of the following:
1 Patient has metabolic disorders of fat metabolism; or
2 Patient has a chyle leak; or
3 Modified as a modular feed for adults.

Felbamate

Oral liq 120 mg per ml

Felodipine

Tab long-acting 10 mg

Tab long-acting 2.5 mg

Tab long-acting 5 mg

Fentanyl

Patch 12.5 mcg per hour
Patch 25 mcg per hour
Patch 50 mcg per hour
Patch 75 mcg per hour
Patch 100 mcg per hour
Inj 10 mcg per ml, 10 ml syringe
Inj 10 mcg per ml, 50 ml bag
Inj 10 mcg per ml, 50 ml syringe
Inj 10 mcg per ml, 100 ml bag
Inj 20 mcg per ml, 50 ml syringe
Inj 20 mcg per ml, 100 ml bag
Inj 50 mcg per ml, 2 ml ampoule
Inj 50 mcg per ml, 10 ml ampoule
Inj 50 mcg per ml, 50 ml syringe

Ferric subsulfate

Soln 500 ml
Gel 25.9%

Ferrous fumarate

Tab 200 mg (65 mg elemental)

Ferrous fumarate with folic acid

Tab 310 mg (100 mg elemental) with folic acid 350 mcg

Ferrous gluconate with ascorbic acid

Tab 170 mg (20 mg elemental) with ascorbic acid 40 mg

Ferrous sulphate

Oral liq 30 mg (6 mg elemental) per ml
Tab long-acting 325 mg (105 mg elemental)

Ferrous sulphate with ascorbic acid

Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 mg

Ferrous sulphate with folic acid

Tab long-acting 325 mg (105 mg elemental) with folic acid 350 mcg

Fexofenadine hydrochloride

Tab 60 mg
Tab 120 mg
Tab 180 mg

Fibre supplement

Powder 3.4 g protein, 13.2 g carbohydrate, 0.3 g fat and 76 g fibre per 100 g {Stimulance}

Filgrastim

Inj 300 mcg in 1 ml vial - ***restricted***

Inj 300 mcg in 0.5 ml syringe - ***restricted***

Inj 480 mcg in 0.5 ml syringe - ***restricted***

RESTRICTED – oncologist or haematologist

Finasteride

Tab 5 mg - ***restricted***

RESTRICTED
Both:
1. Patient has symptomatic benign prostatic hyperplasia; and
2. Either:
    1. The patient is intolerant of non-selective alpha blockers or these are contraindicated; or
    2. Symptoms are not adequately controlled with non-selective alpha blockers.

Flecainide acetate

Cap long-acting 100 mg

Cap long-acting 200 mg

Inj 10 mg per ml, 15 ml ampoule

Tab 100 mg

Tab 50 mg

Flucloxacillin

Cap 250 mg

Cap 500 mg

Grans for oral liq 25 mg per ml

Grans for oral liq 50 mg per ml

Inj 250 mg vial

Inj 500 mg vial

Inj 1 g vial

Fluconazole

Cap 50 mg - ***restricted***

Cap 150 mg - ***restricted***

Cap 200 mg - ***restricted***

Oral liquid 50 mg per 5 ml - ***restricted***

Inj 2 mg per ml, 50 ml vial - ***restricted***

RESTRICTED – consultant

Flucytosine

Cap 500 mg - ***restricted***

Cap 100 mg

Inj 2 mg per ml, 50 ml

Inf 10 mg per ml, 250 ml

Fludarabine phosphate

Tab 10 mg

Inj 50 mg vial

Fludrocortisone acetate

Tab 100 mcg

Flumazenil

Inj 0.1 mg per ml, 5 ml ampoule

Flumetasone pivalate with clioquinol

Ear drops 0.02% with clioquinol 1%

Flunitrazepam

Inj 2 mg

Fluocortolone caproate with fluocortolone pivalate and cinchocaine

Oint 950 mcg with fluocortolone pivalate 920 mcg

Suppos 630 mcg with fluocortolone pivalate

Fluorescein sodium

Eye drops 2%, single dose

Ophthalmic strips 1 mg

Eye drops 1%, single dose

Inj 10%, 5 ml vial

Fluorescein sodium with lignocaine hydrochloride

Eye drops 0.25% with lignocaine hydrochloride 4%, single dose

Fluorometholone

Eye drops 0.1%

Fluorouracil

Inj 25 mg per ml, 100 ml vial

Inj 50 mg per ml, 10 ml vial

Inj 50 mg per ml, 20 ml vial

Inj 50 mg per ml, 50 ml vial

Inj 50 mg per ml, 100 ml vial

Fluorouracil sodium

Crm 5%

Inj 25 mg per ml, 20 ml

Fluoxetine hydrochloride

Cap 20 mg

Tab dispersible 20 mg, scored

Flupenthixol decanoate

Inj 20 mg per ml, 1 ml ampoule

Inj 20 mg per ml, 2 ml ampoule

Inj 100 mg per ml, 1 ml ampoule

Fluphenazine decanoate

Inj 12.5 mg per 0.5 ml ampoule

Inj 25 mg per ml, 1 ml ampoule

Inj 100 mg per ml, 1 ml ampoule

Flurbiprofen

Eye drops 0.03%

Flutamide

Tab 250 mg

Fluticasone

Aerosol inhaler 50 mcg per dose

Aerosol inhaler 125 mcg per dose

Aerosol inhaler 250 mcg per dose

Powder for inhalation 50 mcg per dose

Powder for inhalation 100 mcg per dose

Powder for inhalation 250 mcg per dose

Fluticasone propionate

Nasal spray 50 mcg per dose

Fluticasone with salmeterol

Aerosol inhaler 50 mcg with salmeterol 25 mcg - ***restricted***

Aerosol inhaler 125 mcg with salmeterol 25 mcg - ***restricted***

Powder for inhalation 100 mcg with salmeterol 50 mcg - ***restricted***

Powder for inhalation 250 mcg with salmeterol 50 mcg - ***restricted***

Aerosol inhaler 250 mcg with salmeterol 25 mcg

Powder for inhalation 500 mcg with salmeterol 50 mcg

Must meet community Special Authority criteria

Folic acid

Oral liq 50 mcg per ml

Tab 0.8 mg

Tab 5 mg

Inj 5 mg per ml, 10 ml vial

Follitropin alfa

Inj 150 iu

Inj 75 iu

Follitropin beta

Inj 300 iu

Inj 600 iu

Fondaparinux sodium

Inj 2.5 mg in 0.5 ml syringe - ***restricted***

Inj 7.5 mg in 0.6 ml syringe - ***restricted***

RESTRICTED
For use in heparin-induced thrombocytopaenia, heparin resistance or heparin intolerance

Foscarnet sodium

Inj 24 mg per ml, 250 ml bottle - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Fosfomycin

Grans 3 g

Framycetin sulphate

Ear/eye drops 0.5%

Frucose-based formula

Powder 14.6 g protein, 49.7 g carbohydrate and 30.8 g fat per 100 g, 400 g can {Galactomin 19}

Fuller's earth

Powder

Furosemide (frusemide)

Inj 10 mg per ml, 2 ml ampoule

Inj 10 mg per ml, 25 ml ampoule

Oral liq 10 mg per ml

Tab 40 mg

Tab 500 mg

Fusidate sodium [Fusidic acid]

Crm 2%

Oint 2%

Fusidic acid

Tab 250 mg - ***restricted***

Eye drops 1%

Inj 50 mg per ml, 10 ml

RESTRICTED – infectious disease physician or clinical microbiologist

Gabapentin

Cap 100 mg - ***restricted***

Cap 300 mg - ***restricted***

Cap 400 mg - ***restricted***

Tab 600 mg - ***restricted***

Must meet community Special Authority criteria

Gadobenic acid

Inj 334 mg per ml, 10 ml vial

Inj 334 mg per ml, 20 ml vial

Gadobutrol

Inj 1 mmol per ml, 7.5 ml syringe

Inj 1 mmol per ml, 15 ml vial

Gadodiamide

Inj 287 mg per ml, 5 ml vial

Inj 287 mg per ml, 10 ml vial

Inj 287 mg per ml, 10 ml syringe

Inj 287 mg per ml, 15 ml vial

Inj 287 mg per ml, 15 ml syringe

Inj 287 mg per ml, 20 ml vial

Inj 287 mg per ml, 20 ml syringe

Gadoteric acid

Inj 0.5 mmol per ml, 5 ml bottle

Inj 0.5 mmol per ml, 10 ml bottle

Inj 0.5 mmol per ml, 20 ml bottle

Gadoxetate disodium

Inj 181 mg per ml, 10 ml syringe

Galantamine

Cap 8 mg

Cap 16 mg

Cap 24 mg

Ganciclovir

Inj 500 mg vial - ***restricted***

Cap 250 mg

RESTRICTED – infectious disease physician or clinical microbiologist

Ganirelix

Inj 0.25 mg / 0.5 ml

Gatofloxacin

Tab 400 mg

Inj 10 mg per ml, 40 ml

Gefitinib

Tab 250 mg - ***restricted***

Must meet community Special Authority criteria

Gelatine, succinylated

Inj 4%, 500 ml bag

Gemcitabine

Inj 10 mg per ml, 20 ml vial

Inj 10 mg per ml, 100 ml vial

Inj 200 mg vial

Inj 1 g vial

Gemfibrozil

Tab 600 mg

Gentamicin sulphate

Inj 10 mg per ml, 1 ml ampoule

Inj 40 mg per ml, 2 ml ampoule

Eye drops 0.3%

Gestrinone

Cap 2.5 mg

Glatiramer acetate

Inj 20 mg per ml, 1 ml syringe - ***restricted***

RESTRICTED
Only for use in patients with approval by the Multiple Sclerosis Treatment Assessments Committee

Glibenclamide

Tab 5 mg

Gliclazide

Tab 80 mg

Glipizide

Tab 5 mg

Glucagon hydrochloride

Inj 1 mg syringe kit

Glucarpidase (carboxypeptidase G2)

Inj 1000 u

Glucose

Gel 40%

Tab 1.5 g

Inj 5%, 10 ml

Inj 25%, 1,000 ml

Inj 50%, 50 ml syringe

Tab 3.1 mg

Inj 5%, 50 ml bag

Inj 5%, 100 ml bag

Inj 5%, 250 ml bag

Inj 5%, 500 ml bag

Inj 5%, 1,000 ml bag

Inj 10%, 500 ml bag

Inj 10%, 1,000 ml bag

Inj 50%, 10 ml ampoule

Inj 50%, 90 ml bottle

Inj 50%, 500 ml bag

Inj 70%, 500 ml bag

Inj 70%, 1,000 ml bag

Powder

Glucose with potassium chloride

Inj 5% glucose with 20 mmol/L potassium chloride, 1,000 ml bag

Inj 5% glucose with 30 mmol/L potassium chloride, 1,000 ml bag

Inj 10% glucose with 10 mmol/L potassium chloride, 500 ml bag

Glucose with potassium chloride and sodium chloride

Inj 2.5% with potassium chloride 20 mmol/L and sodium chloride 0.45%, 500 ml

Inj 4% with potassium chloride 20 mmol/L and sodium chloride 0.18%, 500 ml

Inj 2.5% glucose with potassium chloride 20 mmol/L and sodium chloride 0.45%, 3000 ml bag

Inj 4% glucose with potassium chloride 20 mmol/L and sodium chloride 0.18%, 500 ml bag

Inj 4% glucose with potassium chloride 20 mmol/L and sodium chloride 0.18%, 1,000 ml bag

Inj 4% glucose with potassium chloride 30 mmol/L and sodium chloride 0.18%, 1,000 ml bag

Inj 10% glucose with potassium chloride 10 mmol and sodium chloride 15 mmol, 500 ml bag

Glucose with sodium chloride

Inj 4% with sodium chloride 0.18%, 500 ml

Inj 4% with sodium chloride 0.18%, 1,000 ml

Inj 5% with sodium chloride 0.45%, 500 ml

Inj glucose 2.5% with sodium chloride 0.45%, 500 ml bag

Inj glucose 5% with sodium chloride 0.2%, 500 ml bag

Inj glucose 5% with sodium chloride 0.45%, 1000 ml bag

Inj glucose 5% with sodium chloride 0.9%, 1000 ml bag

Glucose with sucrose and fructose

Gel 19.7% with sucrose 35% and fructose 19.7%, 18 g sachet {Hypo-Fit}

Glycerin with sodium saccharin

Suspension

Glycerin with sucrose

Suspension

Glycerol

Suppos 1.27 g

Suppos 2.55 g

Suppos 3.6 g

Liq

Glycerol trierucate

Liquid, 1000 ml bottle - ***restricted***

RESTRICTED
Either:
1 For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria isovaleric acidaemia, propionic acidaemia, methylmalonic acidaemia, tyrosinaemia or urea cycle disorders; or
2 Patient has adrenoleukodystrophy; or
3 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Glycerol trioleate

Liquid, 500 ml bottle - ***restricted***

RESTRICTED
Either:
1 For the dietary management of homocystinuria, maple syrup urine disease, phenylketonuria (PKU), glutaric aciduria isovaleric acidaemia, propionic acidaemia, methylmalonic acidaemia, tyrosinaemia or urea cycle disorders; or
2 Patient has adrenoleukodystrophy; or
3 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Glycerol with paraffin

Crm glycerol 10% with white soft paraffin 5% and liquid paraffin 10%

Glyceryl trinitrate

Inj 1 mg per ml, 5 ml ampoule

Inj 1 mg per ml, 50 ml vial

Inj 5 mg per ml, 10 ml ampoule

Oral spray, 400 mcg per dose

Patch 25 mg, 5 mg per day

Patch 50 mg, 10 mg per day

Tab 600 mcg

Oint 2%

Glycine

Irrigation soln 1.5%, 2000 ml bottle

Irrigation soln 1.5%, 3000 ml bottle

Glycopyrronium bromide

Inj 0.2 mg per ml, 1 ml ampoule

Golimumab

Inj 50 mg

Gonadorelin

Inj 100 mcg vial

Goserelin

Implant 3.6 mg

Implant 10.8 mg

Guaifenesin

Oral liq 100 mg per 5 ml

Oral liq 200 mg per 15 ml

Guaifenesin with bromhexine hydrochloride

Oral liq 100 mg with bromhexine hydrochloride 3 mg per 5 ml

Oral liq 100 mg with bromhexine hydrochloride 4 mg per 5 ml

Guanethidine monosulphate

Tab 10 mg

Inj 10 mg per ml, 1 ml ampoule

Note: use of guanethidine for complex regional pain syndrome is still being considered.

Guar gum

Powder {Guarcol}

Haem arginate

Inj 25 mg per ml, 10 ml ampoule

Haemophilus B conjugate vaccine with hepatitis B vaccine

Injection

Haemophilus influenzae type B vaccine

Inj 10 mcg vial with diluent syringe - ***restricted***

RESTRICTED
Any of the following:
1 For primary vaccination in children; or
2 For revaccination following immunosuppression; or
3 For children aged 0-18 years with functional asplenia; or
4 For patients pre- and post-splenectomy.

Haloperidol

Tab 500 mcg

Tab 1.5 mg

Tab 5 mg

Oral liq 2 mg per ml

Inj 5 mg per ml, 1ml ampoule

Haloperidol decanoate

Inj 50 mg per ml, 1 ml ampoule

Inj 100 mg per ml, 1 ml ampoule

Hamamelis extract

Solution

Heparin sodium

Inj 50 mg per ml, 500 ml

Inj 100 iu per ml, 250 ml bag

Inj 1,000 iu per ml, 1 ml ampoule

Inj 1,000 iu per ml, 5 ml ampoule

Inj 1,000 iu per ml, 35 ml ampoule

Inj 5,000 iu per ml, 1 ml ampoule

Inj 5,000 iu per ml, 5 ml ampoule

Inj 5,000 iu in 0.2 ml ampoule

Heparinised saline

Inj 10 iu per ml, 5 ml ampoule

Inj 100 iu per ml, 2 ml ampoule

Inj 100 iu per ml, 5 ml ampoule

Heparinoid

Crm 0.3%

Hepatic oral feed

Powder 11 g protein, 64 g carbohydrate and 20 g fat per 100 g, 400 g can {Heparon Junior} - ***restricted***

RESTRICTED
For children (up to 18 years) who require a liver transplant

Hepatitis A vaccine

Inj 720 ELISA units in 0.5 ml syringe - ***restricted***

Inj 1440 ELISA units in 1 ml syringe - ***restricted***

RESTRICTED
Any of the following:
1 For use in transplant patients; or
2 For use in children with chronic liver disease; or
3 For close contacts of known hepatitis A carriers.

Hepatitis A vaccine with hepatitis B vaccine

Injection

Hepatitis B vaccine

Inj 5 mcg in 0.5 ml vial - ***restricted***

Inj 10 mcg in 1 ml vial - ***restricted***

RESTRICTED
Any of the following:
1 Household or sexual contacts of known hepatitis B carriers; or
2 Children born to mothers who are hepatitis B surface antigen (HBsAg) positive; or
3 Dialysis patients; or
4 HIV-positive patients; or
5 Hepatitis C positive patients; or
6 For use in transplant patients; or
7 For use following immunosuppression.

Hexamine hippurate

Tab 1 g

High arginine oral feed 1.4 kcal/ml

Liquid 7.6 g protein, 18.9 g carbohydrate, 3.9 g fat and 1.4 g fibre per 100 ml, 237 ml carton {Impact Advanced Recovery} - ***restricted***

RESTRICTED
Three packs per day for 5 to 7 days prior to major gastrointestinal, head or neck surgery

High fat formula

Powder 15.3 g protein, 7.2 g carbohydrate and 67.7 g fat per 100 g, 300 g can {KetoCal 3:1} - ***restricted***

Powder 15.25 g protein, 3 g carbohydrate and 73 g fat per 100 g, 300 g can {KetoCal 4:1} - ***restricted***

RESTRICTED
For patients with intractable epilepsy, pyruvate dehydrogenase deficiency or glucose transported type-1 deficiency and other conditions requiring a ketogenic diet.

High protein enteral feed 1.25 kcal/ml

Liquid 6.3 g protein, 14.2 g carbohydrate and 4.9 g fat per 100 ml, 1000 ml bag {Nutrison Protein Plus} - ***restricted***

Liquid 6.3 g protein, 14.1 g carbohydrate, 4.9 g fat and 1.5 g fibre per 100 ml, 1000 ml bag {Nutrison Protein Plus Multi Fibre} - ***restricted***

RESTRICTED
Both:
1 The patient has a high protein requirement; and
2 Any of the following:
- 2.1 Patient has liver disease; or
- 2.2 Patient is obese (BMI > 30) and is undergoing surgery; or
- 2.3 Patient is fluid restricted; or
- 2.4 Patient does not have increased energy requirements.

High protein oral feed 1 kcal/ml

Liquid 10 g protein, 10.3 g carbohydrate and 2.1 g fat per 100 ml, 200 ml bottle {Fortimel Regular} - ***restricted***

RESTRICTED
Any of the following:
1 Decompensating liver disease without encephalopathy; or
2 Protein losing gastro-enteropathy; or
3 Patient has increased protein requirements without increased energy requirements.

High protein oral feed 1.25 kcal/ml

Liquid 10 g protein, 14.2 g carbohydrate and 3.5 g fat per 100 m {Cubitan}

High protein oral feed 1.6 kcal/ml

Cream 9.5 g protein, 19.3 g carbohydrate and 5 g fat per 100 g {Forticreme}

Liquid 9 g protein, 19.1 g carbohydrate, 5.3 g fat and 2.1 g fibre per 100 ml {Forticare}

Histamine acid phosphate

Nebuliser soln 0.6%, 10 ml vial

Nebuliser soln 2.5%, 10 ml vial

Nebuliser soln 5%, 10 ml vial

Homatropine

Eye drops 2%

Eye drops 2%, single dose

Human papilomavirus (6, 11, 16 and 18) vaccine

Inj 120 mcg in 0.5 ml syringe - ***restricted***

RESTRICTED
Any of the following:
1 Women aged between 9 and 18 years old; or
2 Male patients aged between 9 and 25 years old with confirmed HIV infection; or
3 For use in transplant patients.

Hyaluronidase

Inj 1500 iu ampoule

Hydralazine hydrochloride

Inj 20 mg ampoule

Tab 25 mg - ***restricted***

RESTRICTED
Either:
1. For the treatment of refractory hypertension; or
2. For the treatment of heart failure, in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers.

Hydrochlorothiazide

Tab 25 mg

Hydrocortisone

Tab 5 mg

Tab 20 mg

Inj 100 mg vial

Crm 1%

Cream 0.5%

Powder

Hydrocortisone acetate

Rectal foam 10% (14 applications)

Crm 1%

Hydrocortisone butyrate

Crm 0.1%

Milky emul 0.1%

Oint 0.1%

Scalp lotn 0.1%

Hydrocortisone butyrate with chlorquinaldol

Crm 0.1% with clioquiniol 3%

Hydrocortisone with ciprofloxacin

Ear drops 1% with ciprofloxacin 0.2%

Hydrocortisone with miconazole

Crm 1% with miconazole nitrate 2%

Cream 0.5% with miconazole nitrate 2%

Hydrocortisone with natamycin and neomycin

Crm 1% with natamycin 1% and neomycin sulphate 0.5%

Oint 1% with natamycin 1% and neomycin sulphate 0.5%

Hydrocortisone with paraffin and wool fat

Lotn 1% with paraffin liquid 15.9% and wool fat 0.6%

Hydrogen peroxide

Crm 1%

Soln 10 vol (3%)

Soln 20 vol (6%)

Hydroxocobalamin

Inj 2.5 g vial

Hydroxocobalamin acetate

Inj 1 mg per ml, 1 ml ampoule

Hydroxychloroquine

Tab 200 mg

Hydroxyethyl starch 130/0.4 with magnesium chloride, potassium chloride, sodium acetate and sodium chloride

Inj 6% with magnesium chloride 0.03%, potassium chloride 0.03%, sodium acetate 0.463% and sodium chloride 0.6%, 500 ml bag

Hydroxyethyl starch 130/0.4 with sodium chloride

Inj 6% with sodium chloride 0.9%, 500 ml bag

Hydroxyethyl starch 200/0.5

Inf 6%, 500 ml

Inf 10%, 500 ml

Hydroxyurea

Cap 500 mg

Hyoscine butylbromide

Inj 20 mg, 1 ml ampoule

Tab 10 mg

Hyoscine hydrobromide

Patch 1.5 mg - ***restricted***

Inj 400 mcg per ml, 1 ml ampoule

RESTRICTED (PATCH)
Any of the following:
1 Control of intractable nausea, vomiting, or inability to swallow saliva in the treatment of malignancy or chronic disease where the patient cannot tolerate or does not adequately respond to oral anti-nausea agents; or
2 Control of clozapine-induced hypersalivation where trials of at least two other alternative treatments have proven ineffective; or
3 For treatment of post-operative nausea and vomiting where cyclizine, droperidol and a 5HT3 antagonist have proven ineffective, are not tolerated or are contraindicated.

Hypromellose

Inj 2%, 1 ml syringe

Inj 2%, 2 ml syringe

Eye drops 0.3%

Eye drops 2%

Eye drops 0.5%

Hypromellose sodium

Oral gel 20 mg per ml

Hypromellose with dextran

Eye drops 0.3% with dextran 0.1%

Eye drops 0.3% with dextran 0.1%, single dose

Ibuprofen

Inj 5 mg per ml, 2 ml ampoule

Oral liq 20 mg per ml

Tab 200 mg

Tab 400 mg - ***restricted***

Tab 600 mg - ***restricted***

Tab long-acting 800 mg

RESTRICTED
For continuation only

Ibuprofen lysine

Inj 400 mg per 3 ml

Ibuprofen with codeine phosphate

Tab 200 mg with codeine phosphate 12.8 mg

Ichthammol

Liquid

Idarubicin hydrochloride

Cap 5 mg

Cap 10 mg

Inj 5 mg vial

Inj 10 mg vial

Ifosfamide

Inj 1 g vial

Inj 2 g vial

Iloprost

Inj 50 mcg in 0.5 ml ampoule

Nebuliser soln 10 mcg per ml, 2 ml - ***restricted***

RESTRICTED
Any of the following:
1. For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
2. For diagnostic use in catheter laboratories; or
3. For use following mitral or tricuspid valve surgery; or
4. In-hospital stabilisation in emergency situations.

Imatinib

Tab 100 mg - ***restricted***

RESTRICTED
For use in patients with approval from the CML/GIST Co-ordinator

Imiglucerase

Inj 40 iu per ml, 5 ml vial - ***restricted***

Inj 40 iu per ml, 10 ml vial - ***restricted***

RESTRICTED
Only for use in patients with approval by the Gaucher's Treatment Panel

Imipenem with cilastatin

Inj 500 mg with 500 mg cilastatin vial - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Imipramine hydrochloride

Tab 10 mg

Tab 25 mg

Imiquimod

Crm 5%, 250 mg sachet - ***restricted***

RESTRICTED
Any of the following:
1 The patient has external anogenital warts and podophyllotoxin has been tried and failed (or is contraindicated); or
2 The patient has external anogenital warts and podophyllotoxin is unable to be applied accurately to the site; or
3 The patient has confirmed superficial basal cell carcinoma where other standard treatments, including surgical excision, are contraindicated or inappropriate.
Notes:
Superficial basal cell carcinoma
- Surgical excision remains first-line treatment for superficial basal cell carcinoma as it has a higher cure rate than imiquimod and allows histological assessment of tumour clearance.
- Imiquimod has not been evaluated for the treatment of superficial basal cell carcinoma within 1 cm of the hairline, eyes, nose, mouth or ears.
- Imiquimod is not indicated for recurrent, invasive, infiltrating, or nodular basal cell carcinoma.
- Every effort should be made to biopsy the lesion to confirm that it is a superficial basal cell carcinoma.

External anogenital warts
Imiquimod is only indicated for external genital and perianal warts (condyloma acuminata).

Indapamide

Tab 2.5 mg

Indigo carmine

Inj 4 mg per ml, 5 ml ampoule

Inj 8 mg per ml, 5 ml ampoule

Indinavir

Cap 200 mg - ***restricted***

Cap 400 mg - ***restricted***

Must meet community Special Authority criteria

Indocyanine green

Inj 25 mg vial

Indomethacin

Cap 25 mg

Cap 50 mg

Cap long-acting 75 mg

Inj 1 mg vial

Suppos 100 mg

Infliximab

Inj 100 mg - ***restricted***

Note: Decisions for infliximab have to date been made for use in dermatology, rheumatology, gastroenterology, ophthalmology and respiratory medicine. Use in other areas will be considered at a later time.

RESTRICTED
Initiation – rheumatoid arthritis – rheumatologist
Re-assessment required after 3-4 months
All of the following:
1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for rheumatoid arthritis; and
2 Either:
- 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
- 2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept; and

3 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance.

Continuation – rheumatoid arthritis – rheumatologist
Re-assessment required after 6 months
All of the following:
1 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
2 Either:
- 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and

3 Infliximab to be administered at doses no greater than 3 mg/kg every 8 weeks.

Initiation – ankylosing spondylitis – rheumatologist
Re-assessment required after 3 months
Both:
1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for ankylosing spondylitis; and
2 Either:
- 2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
- 2.2 Following 12 weeks of adalimumab and/or etanercept treatment, the patient did not meet the renewal criteria for adalimumab and/or etanercept for ankylosing spondylitis.

Continuation – ankylosing spondylitis – rheumatologist
Re-assessment required after 6 months
All of the following:
1 Following 12 weeks of infliximab treatment, BASDAI has improved by 4 or more points from pre-infliximab baseline on a 10 point scale, or by 50%, whichever is less; and
2 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and

3 Infliximab to be administered at doses no greater than 5 mg/kg every 6-8 weeks.

Initiation – psoriatic arthritis – rheumatologist
Re-assessment required after 3-4 months
Both:
1 The patient has had an initial Special Authority approval for adalimumab and/or etanercept for psoriatic; and
2 Either:
2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
2.2 Following 3-4 months' initial treatment with adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for psoriatic arthritis.

Continuation – psoriatic arthritis – rheumatologist
Re-assessment required after 6 months
Both:
1 Either:
1.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
1.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior infliximab treatment in the opinion of the treating physician; and
2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Initiation – severe ocular inflammation
Re-assessment required after 3 doses
Both:
1 Patient has severe, vision-threatening ocular inflammation requiring rapid control; and
2 Either:
2.1 Patient has failed to achieve control of severe vision-threatening ocular inflammation following high-dose steroids (intravenous methylprednisolone) followed by high dose oral steroids; or
2.2 Patient developed new inflammatory symptoms while receiving high dose steroids.

Initiation – chronic ocular inflammation
Re-assessment required after 3 doses
Both:
1 Patient has severe uveitis uncontrolled with treatment of steroids and other immunosuppressants with a severe risk of vision loss; and
2 Patient has tried at least two other immunomodulatory agents.

Continuation – ocular inflammation
Both:
1 Patient had a good clinical response to initial treatment; and
2 Either:
2.1 A withdrawal of infliximab has been trialled and patient has relapsed after trial withdrawal; or
2.2 Patient has Behçet's disease.

Pulmonary sarcoidosis
Both:
1 Patient has life-threatening pulmonary sarcoidosis that is refractory to other treatments; and
2 Treatment is to be prescribed by, or has been recommended by, a physician with expertise in the treatment of pulmonary sarcoidosis.

Initiation – Crohn's disease (adults) – gastroenterologist
Re-assessment required after 3 months
All of the following:
1 Patient has severe active Crohn's disease; and
2 Any of the following:
2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further

bowel resection; or

2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and

3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and

4 Surgery (or further surgery) is considered to be clinically inappropriate; and

5 Patient must be reassessed for continuation after 3 months of therapy.

Continuation – Crohn's disease (adults) – gastroenterologist

Re-assessment required after 6 months

All of the following:

1 One of the following:

1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or

1.2 CDAI score is 150 or less; or

1.3 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and

2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and

3 Patient must be reassessed for continuation after further 6 months.

Initiation – Crohn's disease (children) – gastroenterologist

Re-assessment required after 3 months

All of the following:

1 Paediatric patient has severe active Crohn's disease; and

2 Any of the following:

2.1 Patient has a Paediatric Crohn's Disease Activity Index (PCDAI) score of greater than or equal to 30; or

2.2 Patient has extensive small intestine disease; and

3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and

4 Surgery (or further surgery) is considered to be clinically inappropriate; and

5 Patient must be reassessed for continuation after 3 months of therapy.

Continuation - Crohn's disease (Children) - gastroenterologist

Re-assessment required after 6 months

1 One of the following:

1.1 PCDAI score has reduced by 10 points from the CDAI score when the patient was initiated on infliximab; or

1.2 PCDAI score is 15 or less; or

1.3 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and

2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and

3 Patient must be reassessed for continuation after further 6 months.

Initiation – fistulising Crohn's disease – gastroenterologist

All of the following:

1 Patient has confirmed Crohn's disease; and either:

1.1 Patient has one or more complex externally draining enterocutaneous fistula(e); or

1.2 Patient has one or more rectovaginal fistula(e); and

2 Either:

2.1 An adequate trial of conventional treatment has not been successful (defined as at least 4 months therapy with an adequate dose of thiopurine); or

2.2 A trial of immunomodulators is not appropriate due to rapid and severe onset of fistulae; and

3 Patient must be reassessed for continuation after 4 months of therapy.

Continuation – fistulising Crohn's disease – gastroenterologist
All of the following:
1 Either:
1.1 The number of open draining fistulae have decreased from baseline by at least 50%; or
1.2 There has been a marked reduction in drainage of all fistula(e) from baseline (in the case of adult patients, as demonstrated by a reduction in the Fistula Assessment score), together with less induration and patient reported pain; and
2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
3 Patient must be reassessed for continuation after further 6 months.

Initiation – acute severe fulminant ulcerative colitis – gastroenterologist
All of the following:
1 Patient has acute, severe fulminant ulcerative colitis; and
2 Treatment with intravenous or high dose oral corticosteroids has not been successful; and
3 Patient must be reassessed for continuation after 6 weeks of therapy.

Continuation – severe fulminant ulcerative colitis – gastroenterologist
All of the following:
1 Where maintenance treatment is considered appropriate, infliximab should be used in combination with immunomodulators and reassessed every 6 months;
2 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle; and
3 Patient must be reassessed for continuation after further 6 months.

Initiation – plaque psoriasis, prior TNF use – dermatologist
Re-assessment required after 3 doses
Both:
1 The patient has had an initial Special Authority approval for adalimumab or etanercept for severe chronic plaque psoriasis; and
2 Either:
2.1 The patient has experienced intolerable side effects from adalimumab or etanercept; or
2.2 The patient has received insufficient benefit from adalimumab or etanercept to meet the renewal criteria for adalimumab or etanercept for severe chronic plaque psoriasis.

Initiation – severe ulcerative colitis – gastroenterologist
All of the following:
1 Patient has histologically confirmed ulcerative colitis; and
2 The Simple Clinical Colitis Activity Index (SCCAI) is ≥ 4
3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses for an adequate duration (unless contraindicated) and corticosteroids; and
4 Surgery (or further surgery) is considered to be clinically inappropriate; and
5 Patient must be reassessed for continuation after 3 months of therapy.

Continuation – severe ulcerative colitis – gastroenterologist
All of the following:
1 Patient is continuing to maintain remission and the benefit of continuing infliximab outweighs the risks;
2 SCCAI score has reduced by ≥ 2 points from the SCCAI score when the patient was initiated on infliximab; and
3 Infliximab to be administered at doses up to 5 mg/kg every 8 weeks. Up to 10 mg/kg every 8 weeks (or equivalent) can be used for up to 3 doses if required for secondary non-response to treatment for re-induction. Another re-induction may be considered sixteen weeks after completing the last re-induction cycle.

Initiation – plaque psoriasis, treatment-naïve – dermatologist
Re-assessment required after 3 doses
All of the following:
1 Either:
1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
4 The most recent PASI assessment is no more than 1 month old at the time of initiation.
Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Graft vs host disease
Patient has steroid-refractory acute graft vs. host disease of the gut

Continuation – plaque psoriasis – dermatologist
Re-assessment required after 3 doses
All of the following:
1 Either:
1.1 Both:
1.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
1.1.2 Following each prior infliximab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-infliximab treatment baseline value; or
1.2 Both:
1.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
1.2.2 Either:
1.2.2.1 Following each prior infliximab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
1.2.2.2 Following each prior infliximab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-infliximab treatment baseline value; and
2 Infliximab to be administered at doses no greater than 5 mg/kg every 8 weeks.

Influenza vaccine

Inj 45 mcg in 0.5 ml syringe - ***restricted***

RESTRICTED
Any of the following:
1 All people 65 years of age and over; or
2 People under 65 years of age who:
- 2.1 Have any of the following cardiovascular diseases:
  - 2.1.1 Ischaemic heart disease; or
  - 2.1.2 Congestive heart disease; or
  - 2.1.3 Rheumatic heart disease; or
  - 2.1.4 Congenital heart disease; or
  - 2.1.5 Cerebo-vascular disease; or
- 2.2 Have any of the following chronic respiratory diseases:
  - 2.2.1 Asthma, if on a regular preventative therapy; or
  - 2.2.2 Other chronic respiratory disease with impaired lung function; or
- 2.3 Have diabetes;
- 2.4 Have chronic renal disease;
- 2.5 Have any cancer, excluding basal and squamous skin cancers if not invasive;
- 2.6 Have any of the following other conditions:
  - 2.6.1 Autoimmune disease;
  - 2.6.2 Immune suppression;
  - 2.6.3 HIV;
  - 2.6.4 Transplant recipients;
  - 2.6.5 Neuromuscular and CNS diseases;
  - 2.6.6 Haemoglobinopathies;
  - 2.6.7 Are children on long term aspirin; or
- 2.7 Are pregnant, or
- 2.8 Are children aged four and under who have been hospitalised for respiratory illness or have a history of significant respiratory illness; or

3 People under 18 years of age living within the boundaries of the Canterbury District Health Board.
Note: The following conditions are excluded from funding:
- asthma not requiring regular preventative therapy; and
- hypertension and/or dyslipidaemia without evidence of end-organ disease.

Insulin aspart

Inj 100 u per ml, 10 ml vial

Inj 100 u per ml, 3 ml cartridge

Insulin aspart with insulin aspart protamine

Inj insulin aspart 30% with insulin aspart protamine 70%, 100 u per ml, 3 ml prefilled pen

Insulin detemir

Inj 100 u per ml, 3 ml

Insulin glargine

Inj 100 u per ml, 10 ml vial

Inj 100 u per ml, 3 ml cartridge

Inj 100 u per ml, 3 ml disposable pen

Insulin glulisine

Inj 100 u per ml, 10 ml vial

Inj 100 u per ml, 3 ml cartridge

Inj 100 u per ml, 3 ml disposable pen

Insulin isophane

Insulin human 100 u per ml, 10 ml vial

Insulin human 100 u per ml, 3 ml cartridge

Insulin lispro

Inj 100 u per ml, 10 ml vial

Inj 100 u per ml, 3 ml cartridge

Insulin lispro with insulin lispro protamine

Inj insulin lispro 25% with insulin lispro protamine 75%, 100 u per ml, 3 ml cartridge

Inj insulin lispro 50% with insulin lispro protamine 50%, 100 u per ml, 3 ml cartridge

Insulin neutral

Inj human 100 u per ml, 10 ml vial

Inj human 100 u per ml, 3 ml cartridge

Insulin neutral with insulin isophane

Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 10 ml vial

Inj insulin neutral 30% with insulin isophane 70%, 100 u per ml, 3 ml cartridge

Inj insulin neutral 40% with insulin isophane 60%, 100 u per ml, 3 ml cartridge

Inj insulin neutral 50% with insulin isophane 50%, 100 u per ml, 3 ml cartridge

Interferon alpha-2a

Inj 3 m iu prefilled syringe

Inj 6 m iu prefilled syringe

Inj 9 m iu prefilled syringe

Interferon alpha-2b

Inj 18 m iu, 1.2 ml multidose pen

Inj 30 m iu, 1.2 ml multidose pen

Inj 60 m iu, 1.2 ml multidose pen

Interferon beta-1-alpha

Inj 6 million iu vial - ***restricted***

Inj 6 million iu in 0.5 ml pen - ***restricted***

Inj 6 million iu in 0.5 ml syringe - ***restricted***

RESTRICTED
Only for use in patients with approval by the Multiple Sclerosis Treatment Assessments Committee

Interferon beta-1-beta

Inj 8 million iu per ml, 1 ml vial - ***restricted***

RESTRICTED
Only for use in patients with approval by the Multiple Sclerosis Treatment Assessments Committee

Interferon gamma

Inj 100 mcg in 0.5 ml vial - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Iodine

Soln BP 50 mg per ml

Iodine with ethanol

Soln 1% with ethanol 70%

Iodised oil

Inj 480 mg per ml, 10 ml ampoule

Iodixanol

Inj 270 mg per ml, 20 ml vial
Inj 270 mg per ml, 50 ml bottle
Inj 270 mg per ml, 100 ml bottle
Inj 320 mg per ml, 20 ml vial
Inj 320 mg per ml, 50 ml bottle
Inj 320 mg per ml, 100 ml bottle
Inj 320 mg per ml, 150 ml bottle
Inj 320 mg per ml, 200 ml bottle

Iohexol

Inj 240 mg per ml, 50 ml bottle
Inj 300 mg per ml, 20 ml bottle
Inj 300 mg per ml, 50 ml bottle
Inj 300 mg per ml, 100 ml bottle
Inj 300 mg per ml, 500 ml bottle
Inj 350 mg per ml, 20 ml bottle
Inj 350 mg per ml, 50 ml bottle
Inj 350 mg per ml, 75 ml bottle
Inj 350 mg per ml, 100 ml bottle
Inj 350 mg per ml, 200 ml bottle
Inj 350 mg per ml, 500 ml bottle

Iomeprol

Inj 150 mg per ml, 50 ml bottle
Inj 300 mg per ml, 20 ml vial
Inj 300 mg per ml, 50 ml bottle
Inj 300 mg per ml, 100 ml bottle
Inj 350 mg per ml, 20 ml vial
Inj 350 mg per ml, 50 ml bottle
Inj 350 mg per ml, 75 ml bottle
Inj 350 mg per ml, 100 ml bottle
Inj 400 mg per ml, 50 ml bottle

Iopromide

Inj 240 per ml, 50 ml bottle
Inj 300 per ml, 20 ml vial
Inj 300 per ml, 50 ml bottle
Inj 300 per ml, 100 ml bottle
Inj 370 per ml, 30 ml vial
Inj 370 per ml, 50 ml bottle
Inj 370 per ml, 100 ml bottle
Inj 370 per ml, 200 ml bottle

Iotrolan

Inj 240 mg per ml, 10 ml vial

Ipecacuanha

Tincture

Ipratropium bromide

Nasal spray 0.03%
Aerosol inhaler 20 mcg per dose
Nebuliser soln 250 mcg per ml, 1 ml ampoule
Nebuliser soln 250 mcg per ml, 2 ml ampoule

Irbesartan

Tab 300 mg

Irinotecan hydrochloride

Inj 20 mg per ml, 2 ml vial
Inj 20 mg per ml, 5 ml vial

Iron polymaltose

Inj 50 mg per ml, 2 ml ampoule

Iron sucrose

Inj 20 mg per ml, 5 ml ampoule

Isoflurane

Soln for inhalation 100%, 250 ml bottle

Isoniazid

Tab 100 mg - ***restricted***

RESTRICTED – internal medicine physician, clinical microbiologist, dermatologist or public health physician

Isoniazid with rifampicin

Tab 100 mg with rifampicin 150 mg - ***restricted***
Tab 150 mg with rifampicin 300 mg - ***restricted***

RESTRICTED – internal medicine physician, clinical microbiologist, dermatologist or public health physician

Isoprenaline

Inj 200 mcg per ml, 1 ml ampoule

Inj 200 mcg per ml, 5 ml ampoule

Isopropyl alcohol

Liquid

Soln 70%

Isosorbide mononitrate

Tab 20 mg

Tab long-acting 40 mg

Tab long-acting 60 mg

Isotretinoin

Cap 10 mg

Cap 20 mg

Gel 0.05%

Ispaghula (psyllium) husk

Powder for oral soln

Isradipine

Cap long-acting 2.5 mg

Cap long-acting 5 mg

Tab 2.5 mg

Itraconazole

Cap 100 mg - ***restricted***

Oral liquid 10 mg per ml - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist, clinical immunologist or dermatologist

Ivabradine

Tab 5 mg

Tab 7.5 mg

Ivermectin

Tab 3 mg - ***restricted***

Tab 6 mg

RESTRICTED – infectious disease physician or clinical microbiologist

Ketamine

Inj 1 mg per ml, 10 ml syringe

Ketamine hydrochloride

Inj 1 mg per ml, 100 ml bag

Inj 4 mg per ml, 50 ml syringe

Inj 10 mg per ml, 10 ml syringe

Inj 100 mg per ml, 2 ml vial

Ketoconazole

Shampoo 2%

Tab 200 mg - ***restricted***

Cream 2%

Shampoo 1%

RESTRICTED – infectious disease physician, clinical microbiologist, dermatologist, endocrinologist or oncologist

Ketoprofen

Cap long-acting 100 mg

Cap long-acting 200 mg

Ketorolac trometamol

Eye drops 0.5%

Labetalol

Inj 5 mg per ml, 20 ml ampoule

Oral liquid

Tab 100 mg

Tab 200 mg

Tab 400 mg

Tab 50 mg

Lacosamide

Tab 50 mg - ***restricted***

Tab 100 mg - ***restricted***

Tab 150 mg - ***restricted***

Tab 200 mg - ***restricted***

Inj 10 mg per ml, 20 ml vial - ***restricted***

Must meet community Special Authority criteria

Lactose

Powder

Lactose-free formula

Powder 1.5 g protein, 7.2 g carbohydrate and 3.6 g fat per 100 ml, 900 g can {S26 Lactose Free}

Powder 1.7 g protein, 7.5 g carbohydrate and 3.7 g fat per 100 ml, 900 g can {Karicare Aptamil De-Lact}

Lactulose

Oral liq 10 g per 15 ml

Lamivudine

Oral liq 10 mg per ml - ***restricted***

Tab 150 mg - ***restricted***

Oral liq 5 mg per ml - ***restricted***

Tab 100 mg - ***restricted***

Must meet community Special Authority criteria

Lamotrigine

Tab dispersible 2 mg

Tab dispersible 5 mg

Tab dispersible 25 mg

Tab dispersible 50 mg

Tab dispersible 100 mg

Tab dispersible 200 mg

Lansoprazole

Cap 15 mg

Cap 30 mg

Lapatinib

Tab 250 mg - ***restricted***

Must meet community Special Authority criteria

Latanoprost

Eye drops 0.005%

Lavender oil

Liquid

Leflunomide

Tab 10 mg

Tab 100 mg

Tab 20 mg

Lenograstim

Inj 105 mcg

Inj 263 mcg

Lepirudin

Inj 50 mg

Letrozole

Tab 2.5 mg

Leuprorelin

Inj 5 mg per ml, 2.8 ml

Leuprorelin acetate

Inj 3.75 mg syringe
Inj 3.75 mg vial
Inj 7.5 mg syringe
Inj 11.25 mg syringe
Inj 11.25 mg vial
Inj 22.5 mg syringe
Inj 30 mg syringe
Inj 30 mg vial
Inj 45 mg syringe

Levamisole

Tab 50 mg

Levetiracetam

Tab 250 mg
Tab 500 mg
Tab 750 mg
Inj 100 mg per ml, 5 ml vial
Tab 1000 mg
Oral liq 100 mg per ml

Levobunolol hydrochloride

Eye drops 0.25%
Eye drops 0.5%

Levocabastine

Eye drops 0.05%

Levocarnitine

Cap 500 mg - ***restricted***
Inj 200 mg per ml, 5 ml vial - ***restricted***
Oral soln 500 mg per 15 ml - ***restricted***

RESTRICTED – metabolic disorders physician, metabolic disorders dietitian or neurologist

Levodopa with benserazide

Cap 50 mg with benserazide 12.5 mg
Tab dispersible 50 mg with benserazide 12.5 mg
Cap 100 mg with benserazide 25 mg
Cap long-acting 100 mg with benserazide 25 mg
Cap 200 mg with benserazide 50 mg

Levodopa with carbidopa

Tab 100 mg with carbidopa 25 mg
Tab 250 mg with carbidopa 25 mg
Tab long-acting 200 mg with carbidopa 50 mg

Levofloxacin

Tab 500 mg

Levomepromazine maleate

Tab 25 mg

Tab 100 mg

Inj 25 mg per ml, 1 ml ampoule

Levonorgestrel

Tab 1.5 mg

Tab 30 mcg

Implant 75 mg

Intra-uterine system, 20 mcg per day - ***restricted***

RESTRICTED (intrauterine system)
Initiation
All of the following:
1. The patient has a clinical diagnosis of heavy menstrual bleeding; and
2. The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and
3. Either:
    1. Serum ferritin level < 16 mcg/l (within the last 12 months); or
    2. Haemoglobin level < 120 g/l.

Continuation
Either:
1. Patient demonstrated clinical improvement of heavy menstrual bleeding; or
2. Previous insertion was removed or expelled within 3 months of insertion.

Levosimendan

Inj 2.5 mg per ml, 10 ml vial - ***restricted***

Inj 2.5 mg per ml, 5 ml vial - ***restricted***

RESTRICTED
Heart transplant
Either:
1. For use as a bridge to heart transplant, in patients who have been accepted for transplant; or
2. For the treatment of heart failure following heart transplant.

Heart failure – cardiologist or intensivist
For the treatment of severe acute decompensated heart failure that is non-responsive to dobutamine.

Levothyroxine

Tab 25 mcg

Tab 50 mcg

Tab 100 mcg

Injection

Lignocaine hydrochloride

Inj 1%, 5 ml ampoule

Inj 1%, 20 ml ampoule

Inj 2%, 5 ml ampoule

Inj 2%, 20 ml ampoule

Gel 2%, 10 ml urethral syringes

Gel 2%

Oral (viscous) soln 2%

Spray 10%

Soln 4%

Inj 0.5%, 5 ml

Inj 1%, 10 ml syringe

Inj 2%, 5 ml syringe

Inj 2%, 2 ml ampoule

Inj 2%, 2.2 ml dental cartridge

Inj 2%, 50 ml ampoule

Patch 5%

Oint 5%

Lignocaine hydrochloride with adrenaline

Inj 1% with adrenaline 1:100,000, 5 ml ampoule

Inj 1% with adrenaline 1:200,000, 20 ml vial

Inj 2% with adrenaline 1:200,000, 20 ml vial

Inj 2% with adrenaline 1:80,000, 1.7 ml dental cartridge

Lignocaine hydrochloride with adrenaline and tetracaine hydrochloride

Inj 4% with adrenaline 0.1% and tetracaine hydrochloride 0.5%, 5 ml syringe

Lignocaine hydrochloride with chlorhexidine

Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes

Lignocaine hydrochloride with phenylephrine hydrochloride

Nasal spray 5% with phenylephrine hydrochloride 0.5%

Lignocaine with cetrimide

Lozenge 5% with cetrimide 0.15%

Lignocaine with glucose

Inj 0.4% with 5% glucose, 250 ml bag

Inj 0.4% with 5% glucose, 500 ml bag

Inj 0.4% with 5% glucose, 1000 ml bag

Lignocaine with prilocaine

Crm 2.5% with prilocaine 2.5%

Patch 25 mcg with prilocaine 25 mcg

Lincomycin

Inj 300 mg per ml, 2 ml vial - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Lindane [Gamma benzene hexachloride]

Crm 1%

Linezolid

Tab 600 mg - ***restricted***

Oral liq 20 mg per ml - ***restricted***

Inj 2 mg per ml, 300 ml bag - ***restricted***

Tab 250 mg

RESTRICTED – infectious disease physician or clinical microbiologist

Liothyronine

Tab 20 mg

Liothyronine sodium

Inj 20 mcg vial

Lisinopril

Tab 10 mg

Tab 20 mg

Tab 5 mg

Lissamine green

Ophthalmic strips 1.5 mg

Lisuride hydrogen maleate

Tab 200 mcg

Lithium carbonate

Cap 250 mg

Tab 250 mg

Tab 400 mg

Tab long-acting 400 mg

Lodoxamide

Eye drops 0.1%

Lomustine

Cap 10 mg

Cap 40 mg

Long-chain triglyceride supplement

Liquid 50 g fat per 100 ml, 200 ml bottle {Calogen} - ***restricted***

Liquid 50 g fat per 100 ml, 500 ml bottle {Calogen} - ***restricted***

RESTRICTED
Use as an additive
Any of the following:
1 Patient has inborn errors of metabolism; or
2 Faltering growth in an infant/child; or
3 Bronchopulmonary dysplasia; or
4 Fat malabsorption; or
5 Lymphangiectasia; or
6 Short bowel syndrome; or
7 Infants with necrotising enterocolitis; or
8 Biliary atresia; or
9 For use in a ketogenic diet; or
10 Chyle leak; or
11 Ascites; or
12 Patient has increased energy requirements, and for whom dietary measures have not been successful.
Use as a module
For use as a component in a modular formula

Loperamide hydrochloride

Cap 2 mg

Tab 2 mg

Lopinavir with ritonavir

Oral liq 80 mg with ritonavir 20 mg per ml - ***restricted***

Tab 100 mg with ritonavir 25 mg - ***restricted***

Tab 200 mg with ritonavir 50 mg - ***restricted***

Must meet community Special Authority criteria

Loratadine

Oral liq 1 mg per ml

Tab 10 mg

Lorazepam

Inj 2 mg vial

Inj 4 mg per ml, 1 ml vial

Tab 1 mg

Tab 2.5 mg

Lormetazepam

Tab 1 mg - ***restricted***

RESTRICTED
For continuation only

L-ornithine L-aspartate

Grans for oral liquid 3 g

Losartan potassium

Tab 100 mg

Tab 12.5 mg

Tab 25 mg

Tab 50 mg

Losartan potassium with hydrochlorothiazide

Tab 50 mg with hydrochlorothiazide 12.5 mg

Low carbohydrate oral feed 1.5 kcal/ml

Liquid 6.2 g protein, 10.5 g carbohydrate and 9.32 g fat per 100 ml, 237 ml bottle {Pulmocare} - ***restricted***

RESTRICTED
For patients with CORD and hypercapnia, defined as a CO_2 value exceeding 55 mmHg

Low electrolyte enteral feed 2 kcal/ml

Liquid 7 g protein, 20.6 g carbohydrate, 9.6 g fat and 1.56 g fibre per 100 ml, 500 ml bottle {Nepro RTH} - ***restricted***

RESTRICTED
For patients with acute or chronic kidney disease

Low electrolyte oral feed

Powder 7.5 g protein, 59 g carbohydrate and 26.3 g fat per 100 g, 400 g can {Kindergen} - ***restricted***

RESTRICTED
For children (up to 18 years) with acute or chronic kidney disease

Low electrolyte oral feed 2 kcal/ml

Liquid 3 g protein, 25.5 g carbohydrate and 9.6 g fat per 100 ml, 237 ml bottle {Suplena} - ***restricted***

Liquid 7 g protein, 20.6 g carbohydrate, 9.6 g fat and 1.56 g fibre per 100 ml, 200 ml carton {Nepro} - ***restricted***

Liquid 7.4 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 237 ml carton {Novasource Renal} - ***restricted***

Liquid 7.5 g protein, 20 g carbohydrate and 10 g fat per 100 ml, 125 ml carton {Renilon 7.5} - ***restricted***

Liquid {Renilon 4.0}

RESTRICTED
For patients with acute or chronic kidney disease

Low-calcium formula

Powder 14.6 g protein, 53.7 g carbohydrate and 26.1 g fat per 100 g, 400 g can {Locasol}

Low-GI enteral feed 1 kcal/ml

Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 1000 ml bottle {Glucerna Select RTH} - ***restricted***

Liquid 4.3 g protein, 11.3 g carbohydrate and 4.2 g fat per 100 ml, 1000 ml bag {Nutrison Advanced Diason} - ***restricted***

RESTRICTED
Any of the following:
1 For patients with type I or type II diabetes suffering weight loss and malnutrition that requires nutritional support; or
2 For patients with pancreatic insufficiency; or
3 For patients who have, or are expected to, eat little or nothing for 5 days;
4 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
5 For use pre- and post-surgery; or
6 For patients being tube-fed; or
7 For tube-feeding as a transition from intravenous nutrition.

Low-GI oral feed 1 kcal/ml

Liquid 5 g protein, 9.6 g carbohydrate and 5.4 g fat per 100 ml, 250 ml bottle {Glucerna Select} - ***restricted***

Liquid 6.4 g protein, 9.5 g carbohydrate, 4.7 g fat and 1.2 fibre per 100 ml, 237 ml can {Resource Diabetic} ***restricted***

Liquid 4.9 g protein, 11.7 g carbohydrate, 3.8 g fat and 2 g fibre per 100 ml, 200 ml bottle {Diasip} - ***restricted***

RESTRICTED
Any of the following:
1 For patients with type I or type II diabetes suffering weight loss and malnutrition that requires nutritional support; or
2 For patients with pancreatic insufficiency; or
3 For patients who have, or are expected to, eat little or nothing for 5 days;
4 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
5 For use pre- and post-surgery; or
6 For patients being tube-fed; or
7 For tube-feeding as a transition from intravenous nutrition.

Lymecycline

Cap 408 mg

Macrogol 3350 with ascorbic acid, potassium chloride and sodium chloride

Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet

Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 210 g sachet

Note: Glycoprep-C

Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride

Powder for oral soln 6.563 g with potassium chloride 23.3 mg, sodium bicarbonate 89.3 mg and sodium chloride 175.4 mg - ***restricted***

Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg - ***restricted***

RESTRICTED
Either:
1. The patient has problematic constipation requiring intervention with a per rectal preparation despite an adequate trial of other oral pharmacotherapies including lactulose where lactulose is not contraindicated; or
2. For short-term use for faecal disimpaction.

Note: Lax-Sachets and Movicol-Half.

Please note that we expect to consult soon on changes to the community Special Authority criteria and to these hospital restrictions.

Macrogol 3350 with potassium chloride, sodium bicarbonate, sodium chloride and sodium sulphate

Powder for oral soln 59 g with potassium chloride 0.7425 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g and sodium sulphate 5.685 g per sachet

Powder for oral soln 856.92 mg with potassium chloride 112.5 mg, sodium bicarbonate 25.32 mg, sodium chloride 22 mg and sodium sulphate 84.81 mg per g

Note: Klean-Prep (included) and Glycoprep (excluded)

Macrogol 400 with propylene glycol

Eye drops 0.04% with propylene glycol 0.3%

Magnesium carbonate

Powder

Magnesium chloride

Inf 96 mg per ml, 5 ml

Magnesium hydroxide

Tab 5 mg

Tab 311 mg

Paste

Magnesium sulphate

Paste

Inj 0.4 mmol per ml, 250 ml bag

Inj 2 mmol per ml, 5 ml ampoule

Maize starch

Powder {Resource Thicken Up / Nutilis}

Malathion [Maldison]

Lotn 0.5%

Shampoo 1%

Malathion with permethrin

Aerosol spray malathion 0.25% with permethrin 0.5%

Maltodextrin with xanthan gum

Powder {Instant Thick}

Maltodextrin with xanthan gum and ascorbic acid

Powder {Easy Thick}

Mannitol

Inj 10%, 1000 ml bag

Inj 15%, 500 ml bag

Inj 20%, 500 ml bag

Maprotiline hydrochloride

Tab 25 mg

Tab 75 mg

Measles, mumps and rubella vaccine

Inj 1000 TCID50 measles, 12500 TCID50 mumps and 1000 TCID50 rubella vial with diluent - ***restricted***

RESTRICTED
Any of the following:
1 For primary vaccination in children; or
2 For revaccination following immunosuppression; or
3 For any individual susceptible to measles, mumps or rubella.

Mebendazole

Tab 100 mg

Oral liq 100 mg per 5 ml

Chocolate squares, 100 mg

Mebeverine hydrochloride

Tab 135 mg

Meclozine hydrochloride

Tab 12.5 mg

Medium-chain triglyceride supplement

Liquid 95 g fat per 100 ml, 500 ml bottle {MCT Oil} - ***restricted***

Liquid 50 g fat per 100 ml, 250 ml bottle {Liquigen} - ***restricted***

RESTRICTED
Use as an additive
Any of the following:
1 Patient has inborn errors of metabolism; or
2 Faltering growth in an infant/child; or
3 Bronchopulmonary dysplasia; or
4 Fat malabsorption; or
5 Lymphangiectasia; or
6 Short bowel syndrome; or
7 Infants with necrotising enterocolitis; or
8 Biliary atresia; or
9 For use in a ketogenic diet; or
10 Chyle leak; or
11 Ascites; or
12 Patient has increased energy requirements, and for whom dietary measures have not been successful.
Use as a module
For use as a component in a modular formula

Medroxyprogesterone acetate

Inj 150 mg per ml, 1 ml syringe

Tab 2.5 mg

Tab 5 mg

Tab 10 mg

Medroxyprotesterone

Tab 100 mg

Tab 200 mg

Mefenamic acid

Cap 250 mg - ***restricted***

RESTRICTED
For continuation only

Mefloquine hydrochloride

Tab 250 mg - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist, dermatologist or rheumatologist

Megestrol acetate

Tab 160 mg

Meglumine gadopentate

Inj 469 mg per ml, 10 ml vial

Inj 469 mg per ml, 10 ml syringe

Inj 469 mg per ml, 15 ml vial

Inj 469 mg per ml, 20 ml vial

Melaleuca oil

Tanacetum cineriifolium flower 600 mg, adhatoda vasica leaf 100 mg, stemona sessifolia root 80 mg, echinacea purpurea herb flower 40 mg, melaleuca oil 20 mg; with applicator

Melatonin

Tab 1 mg

Tab 2 mg

Cap 2 mg

Tab 3 mg

Cap 3 mg

Meloxicam

Tab 7.5 mg - ***restricted***

RESTRICTED
All of the following:
1. The patient has moderate to severe haemophilia with less than or equal to 5% of normal circulating functional clotting factor; and
2. The patient has haemophilic arthropathy; and
3. Pain and inflammation associated with haemophilic arthropathy is inadequately controlled by alternative funded treatment options, or alternative funded treatment options are contraindicated.

Melphalan

Tab 2 mg

Inj 50 mg vial

Memantine hydrochloride

Tab 10 mg

Menadiol phosphate

Tab 10 mg

Meningococcal (A, C, Y and W-135) conjugate vaccine

Inj 48 mcg in 0.5 ml vial - ***restricted***

RESTRICTED
Any of the following:
1 For patients pre- and post-splenectomy; or
2 For children aged 0-18 years with functional asplenia; or
3 For organisation and community based outbreaks; or
4 For use in transplant patients; or
5 For use following immunosuppression.

Meningococcal (A, C, Y and W-135) polysaccharide vaccine

Inj 200 mcg vial with diluent - ***restricted***

RESTRICTED
Any of the following:
1 For patients pre- and post-splenectomy; or
2 For children aged 0-18 years with functional asplenia; or
3 For organisation and community based outbreaks.

Meningococcal C conjugate vaccine

Inj 10 mcg in 0.5 ml syringe - ***restricted***

RESTRICTED
Any of the following:
1 For patients pre- and post-splenectomy; or
2 For children aged 0-18 years with functional asplenia; or
3 For organisation and community based outbreaks; or
4 For use in transplant patients aged under 2 years; or
5 For use following immunosuppression in patients aged under 2 years.

Menthol

Cap 35.55 mg

Crystals

Mepivacaine hydrochloride

Inj 3%, 1.8 ml dental cartridge

Inj 3%, 2.2 ml dental cartridge

Mercaptopurine

Tab 50 mg

Meropenem

Inj 500 mg vial - ***restricted***

Inj 1 g vial - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Mesalazine

Tab 400 mg

Tab EC 500 mg

Tab long-acting 500 mg

Suppos 500 mg

Suppos 1 g

Enema 1 g per 100 ml

Mesna

Tab 400 mg

Tab 600 mg

Inj 100 mg per ml, 4 ml ampoule

Inj 100 mg per ml, 10 ml ampoule

Metaraminol

Inj 0.5 mg per ml, 20 ml syringe

Inj 1 mg per ml, 1 ml ampoule

Inj 1 mg per ml, 10 ml syringe

Inj 10 mg per ml, 1 ml ampoule

Metformin

Tab immediate-release 500 mg

Tab immediate-release 850 mg

Methadone hydrochloride

Tab 5 mg

Oral liq 2 mg per ml

Oral liq 5 mg per ml

Oral liq 10 mg per ml

Inj 10 mg per ml, 1 ml vial

Powder

Methohexital sodium

Inj 10 mg per ml, 50 ml vial

Methotrexate

Inj 25 mg per ml, 40 ml

Tab 2.5 mg

Tab 10 mg

Inj 2.5 mg per ml, 2 ml vial

Inj 25 mg per ml, 2 ml vial

Inj 25 mg per ml, 20 ml vial

Inj 100 mg per ml, 10 ml vial

Inj 100 mg per ml, 50 ml vial

Methoxsalen [8-methoxypsoralen]

Cap 10 mg

Lotn 1.2%

Methyl aminolevulinate hydrochloride

Crm 16% - ***restricted***

RESTRICTED – dermatologist or plastic surgeon

Methyl hydroxybenzoate

Powder

Methyl salicylate with menthol

Crm 12.74% with menthol 5.88%

Methyl salicylate with menthol and eucalyptus oil

Crm 28.3% with menthol 3.8% and eucalyptus oil 8.8%

Methylcellulose

Powder

Suspension

Methylcellulose with glycerin and sodium saccharin

Suspension

Methylcellulose with glycerin and sucrose

Suspension

Methyldopa

Tab 125 mg

Tab 250 mg

Tab 500 mg

Methylergometrine

Inj 200 µg per ml, 1 ml

Methylphenidate hydrochloride

Tab immediate-release 5 mg - ***restricted***

Tab immediate-release 10 mg - ***restricted***

Tab immediate-release 20 mg - ***restricted***

Tab sustained-release 20 mg - ***restricted***

Tab extended-release 18 mg - ***restricted***

Tab extended-release 27 mg - ***restricted***

Tab extended-release 36 mg - ***restricted***

Tab extended-release 54 mg - ***restricted***

Cap modified-release 10 mg - ***restricted***

Cap modified-release 20 mg - ***restricted***

Cap modified-release 30 mg - ***restricted***

Cap modified-release 40 mg - ***restricted***

Must meet community Special Authority criteria

Methylprednisolone (as sodium succinate)

Tab 4 mg

Tab 100 mg

Inj 40 mg vial

Inj 125 mg vial

Inj 500 mg vial

Inj 1 g vial

Methylprednisolone aceponate

Crm 0.1%

Oint 0.1%

Methylprednisolone acetate

Inj 40 mg per ml, 1 ml vial

Methylprednisolone acetate with lignocaine

Inj 40 mg with lignocaine 10 mg per ml, 1 ml vial

Methylthioninium chloride [Methylene blue]

Inj 10 mg per ml, 5 ml ampoule

Inj 10 mg per ml, 10 ml ampoule

Methysergide maleate

Tab 1 mg

Metoclopramide

Suppos 10 mg

Metoclopramide hydrochloride

Tab 10 mg

Oral liq 5 mg per 5 ml

Inj 5 mg per ml, 2 ml ampoule

Metoclopramide hydrochloride with paracetamol

Tab 5 mg with paracetamol 500 mg

Metolazone

Tab 5 mg - ***restricted***

RESTRICTED
Either:
1. For the treatment of heart failure, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers.
2. For the treatment of heart failure, in patients in whom treatment with ACE inhibitors and/or angiotensin receptor blockers are not tolerated due to renal impairment.

Metoprolol succinate

Tab long-acting 190 mg

Tab long-acting 23.75 mg

Tab long-acting 47.5 mg

Tab long-acting 95 mg

Metoprolol tartrate

Inj 1 mg per ml, 5 ml vial

Tab 100 mg

Tab 50 mg

Tab long-acting 200 mg

Metronidazole

Gel 0.75%

Tab 200 mg

Tab 400 mg

Oral liq benzoate 200 mg per 5 ml

Suppos 500 mg

Inj 5 mg per ml, 100 ml bag

Vaginal gel 0.75%

Topical gel 0.5%

Suppos 1 g

Metyrapone

Cap 250 mg

Mexiletine hydrochloride

Cap 150 mg

Cap 250 mg

Mianserin hydrochloride

Tab 30 mg - ***restricted***

Must meet community Special Authority criteria

Miconazole

Oral gel 20 mg per g

Miconazole nitrate

Crm 2%

Lotn 2% - ***restricted***

Tinc 2%

Vaginal crm 2% with applicator

Dusting powder 2%

Spray powder 2%

RESTRICTED
For continuation only

Miconazole nitrate with zinc

Oint 2.5 mg with zinc oxide 150 mg per g

Midazolam

Tab 7.5 mg

Oral liq 2 mg per ml

Inj 1 mg per ml, 5 ml ampoule

Inj 5 mg per ml, 3 ml ampoule

Midodrine

Tab 2.5 mg - ***restricted***

Tab 5 mg - ***restricted***

RESTRICTED
All of the following:
1. Disabling orthostatic hypotension not due to drugs; and
2. Patient has tried fludrocortisone (unless contra-indicated) with unsatisfactory results; and
3. Patient has tried non pharmacological treatments such as support hose, increased salt intake, exercise, and elevation of head and trunk at night.

Mifepristone

Tab 200 mg

Milrinone

Inj 1 mg per ml, 10 ml ampoule

Minocycline

Tab 50 mg

Cap 100 mg - ***restricted***

RESTRICTED
For continuation only

Minoxidil

Tab 10 mg - ***restricted***

RESTRICTED
For patients with severe refractory hypertension which has failed to respond to extensive multiple therapies.

Mirtazapine

Tab 30 mg - ***restricted***

Tab 45 mg - ***restricted***

Must meet community Special Authority criteria

Misoprostol

Tab 200 mcg

Mitomycin

Inj 5 mg vial

Mitotane

Tab 500 mg

Mitozantrone

Inj 2 mg per ml, 5 ml vial

Inj 2 mg per ml, 10 ml vial

Inj 2 mg per ml, 12.5 ml vial

Mivacurium chloride

Inj 2 mg per ml, 5 ml ampoule

Inj 2 mg per ml, 10 ml ampoule

Moclobemide

Tab 150 mg

Tab 300 mg

Modafinil

Tab 100 mg - ***restricted***

Must meet community Special Authority criteria

Mometasone furoate

Crm 0.1%

Lotn 0.1%

Oint 0.1%

Monosodium glutamate with sodium aspartate

Inj 42.68 mg with sodium aspartate 39.48 mg per ml, 250 ml bottle

Montelukast

Tab 4 mg - ***restricted***

Tab 5 mg - ***restricted***

Tab 10 mg - ***restricted***

RESTRICTED
Pre-school wheeze
All of the following:
1 To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years; and
2 The patient has trialled inhaled corticosteroids at a dose of up to 400 mcg per day beclomethasone or budesonide, or 200 mcg per day fluticasone for at least one month; and
3 The patient continues to have at least three severe exacerbations at least one of which required hospitalisation (defined as in-patient stay or prolonged Emergency Department treatment) in the past 12 months.

Exercise-induced asthma
Both:
1 Patient is being treated with maximal asthma therapy, including inhaled corticosteroids and long-acting beta-adrenoceptor agonists; and
2 Patient continues to experience frequent episodes of exercise-induced bronchoconstriction.

Aspirin desensitisation – clinical immunologist or allergist
All of the following:
1 Patient is undergoing aspirin desensitisation therapy under the supervision of a clinical immunologist or allergist; and
2 Patient has moderate to severe aspirin-exacerbated respiratory disease or Samter's triad; and
3 Nasal polyposis, confirmed radiologically or surgically; and
4 Documented aspirin or NSAID allergy confirmed by aspirin challenge or a clinical history of severe reaction to aspirin or NSAID where challenge would be considered dangerous.

Moroctocog alfa [Recombinant factor VIII]

Inj 250 iu vial
Inj 500 iu vial
Inj 1,000 iu vial
Inj 2,000 iu vial
Inj 3,000 iu vial

Morphine hydrochloride

Oral liq 1 mg per ml
Oral liq 2 mg per ml
Oral liq 5 mg per ml
Oral liq 10 mg per ml

Morphine sulphate

Tab immediate-release 10 mg
Tab immediate-release 20 mg
Tab long-acting 10 mg
Tab long-acting 30 mg
Tab long-acting 60 mg
Tab long-acting 100 mg
Cap long-acting 10 mg
Cap long-acting 30 mg
Cap long-acting 60 mg
Cap long-acting 100 mg
Inj 200 mcg in 0.4 ml syringe
Inj 300 mcg in 0.3 ml syringe
Inj 1 mg per ml, 2 ml syringe
Inj 1 mg per ml, 10 ml syringe
Inj 1 mg per ml, 50 ml syringe
Inj 1 mg per ml, 100 ml bag
Inj 2 mg per ml, 30 ml syringe
Inj 5 mg per ml, 1 ml ampoule
Inj 10 mg per ml, 1 ml ampoule
Inj 10 mg per ml, 100 ml bag
Inj 10 mg per ml, 100 mg cassette
Inj 15 mg per ml, 1 ml ampoule
Inj 30 mg per ml, 1 ml ampoule
Cap long-acting 200 mg
Inj 1 mg per ml, 2 ml syringe
Inj 1 mg per ml, 30 ml syringe

Morphine tartrate

Inj 80 mg per ml, 1.5 ml ampoule
Inj 80 mg per ml, 5 ml ampoule

Moxifloxacin

Tab 400 mg - ***restricted***

Inj 1.6 mg per ml, 250 ml bag - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist
Any of the following:
1 Active tuberculosis, with any of the following:
1.1 Documented resistance to one or more first-line medications; or
1.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or
1.3 Impaired visual acuity (considered to preclude ethambutol use); or
1.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or
1.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or
2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated; or
3 Immunocompromised patient with pneumonia that is unresponsive to first-line treatment; or
4 Pneumococcal pneumonia or other invasive pneumococcal disease highly resistant to other antibiotics.

Please note that we are still considering the use of moxifloxacin within ophthalmic infections.

Multivitamins

Cap vitamin A 2500 u, betacarotene 3 mg, cholecalciferol 11 mcg, alpha tocopherol 150 u, phytomenadione 150 mcg, folic acid 0.2 mg, ascorbic acid 100 mg, thiamine 1.5 mg, pantothenic acid 12 mg, riboflavin 1.7 m niacin 20 mg, pyridoxine hydrochloride 1. - ***restricted***

Tab (BPC cap strength)

Powder vitamin A 4200 mcg with vitamin D155.5 mcg, vitamin E 21.4 mg, vitamin C 400 mg, vitamin K1 166 mcg, thiamine 3.2 mg, riboflavin 4.4 mg, niacin 35 mg, vitamin B6 3.4 mg, folic acid 303 mcg, vitamin B12 8. mcg, biotin 214 mcg, pantothenic acid 17 m - ***restricted***

Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1 and inj ascorbic acid 500 mg with nicotinamide 160 mg, 2 ml ampoule (1) {Pabrinex}

Inj thiamine hydrochloride 250 mg with riboflavin 4 mg and pyridoxine hydrochloride 50 mg, 5 ml ampoule (1 and inj ascorbic acid 500 mg with nicotinamide 160 mg and glucose 1000 mg, 5 ml ampoule (1) {Pabrinex}

Inj thiamine hydrochloride 500 mg with riboflavin 8 mg and pyridoxine hydrochloride 100 mg, 10 ml ampoule (1) and inj ascorbic acid 1000 mg with nicotinamide 320 mg and glucose 2000 mg, 10 ml ampoule (1) {Pabrinex}

RESTRICTED (capsule)
Either:
1. Patient has cystic fibrosis with pancreatic insufficiency; or
2. Patient is an infant or child with liver disease or short gut syndrome.

RESTRICTED (powder)
Patient has inborn errors of metabolism

Mupirocin

Oint 2%

Inj 400 mg

Muromonab-CD3

Inj 1 mg per ml, 5 ml

Mycophenolate mofetil

Cap 250 mg - ***restricted***

Tab 500 mg - ***restricted***

Powder for oral liq 1 g per 5 ml - ***restricted***

Inj 500 mg vial - ***restricted***

RESTRICTED
Either:
1 Transplant recipient; or
2 Both:
Patients with diseases where:
2.1 Steroids and azathioprine have been trialled and discontinued because of unacceptable side effects or inadequate clinical response; and
2.2 Either:
Patients with diseases where:
2.2.1 Cyclophosphamide has been trialled and discontinued because of unacceptable side effects or inadequate clinical response; or
2.2.2 Cyclophosphamide treatment is contraindicated

Nadolol

Tab 40 mg

Tab 80 mg

Naloxone hydrochloride

Inj 400 µg per ml, 2 ml pre-filled syringe

Inj 400 mcg per ml, 1 ml ampoule

Naltrexone hydrochloride

Tab 50 mg - ***restricted***

RESTRICTED
Alcohol dependence
Both:
1 Patient is currently enrolled, or is planned to be enrolled, in a recognised comprehensive treatment programme for alcohol dependence; and
2 Naltrexone is to be prescribed by, or on the recommendation of, a physician working in an Alcohol and Drug Service.
Constipation
For the treatment of opioid-induced constipation

Nandrolone decanoate

Inj 50 mg per ml, 1 ml

Naphazoline hydrochloride

Eye drops 0.1%

Naphazoline hydrochloride with antazoline phosphate

Eye drops 0.05% with antazoline phosphate 0.5%

Naproxen

Tab 250 mg

Tab 500 mg

Tab long-acting 1 g

Tab long-acting 750 mg

Naproxen sodium

Tab 275 mg

Tab 550 mg

Natalizumab

Inf 20 mg per ml, 15 ml vial

Natamycin

Eye drops 5%

Nedocromil

Aerosol inhaler 2 mg per dose

Nefopam hydrochloride

Tab 30 mg

Neomycin

Tab 500 mg

Neostigmine

Inj 2.5 mg per ml, 1 ml ampoule

Neostigmine metilsulfate with glycopyrronium bromide

Inj 2.5 mg with glycopyrrolnium bromide 0.5 mg per ml, 1 ml ampoule

Netilmicin

Inj 100 mg per ml, 1.5 ml

Nevirapine

Oral suspension 10 mg per ml - ***restricted***

Tab 200 mg - ***restricted***

Must meet community Special Authority criteria

Nicardipine

Cap 30 mg

Cap 20 mg

Nicorandil

Tab 10 mg - ***restricted***

Tab 20 mg - ***restricted***

RESTRICTED
Both:
1. Patient has refractory angina; and
2. Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long-acting nitrate.

Nicotine

Gum 2 mg

Gum 4 mg

Lozenge 1 mg

Lozenge 2 mg

Patch 7 mg per 24 hours

Patch 14 mg per 24 hours

Patch 21 mg per 24 hours

Inhaler 10 mg per dose

Nasal spray 10 mg per ml, 10 ml

Patch 5 mg per 16 hours

Patch 10 mg per 16 hours

Patch 15 mg per 16 hours

Sublingual tablet 2 mg

Nicotinic acid

Tab 50 mg

Tab 500 mg

Nifedipine

Cap 5 mg

Tab long-acting 10 mg

Tab long-acting 20 mg

Tab long-acting 30 mg

Tab long-acting 60 mg

Nimodipine

Inj 200 mcg per ml, 50 ml vial

Tab 30 mg

Nitazoxanide

Tab 500 mg - ***restricted***

Oral liq 100 mg per 5 ml - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Nitrazepam

Tab 5 mg

Nitrofurantoin

Tab 50 mg

Tab 100 mg

Nonacog alfa [Recombinant factor IX]

Inj 250 iu vial

Inj 500 iu vial

Inj 1,000 iu vial

Inj 2,000 iu vial

Nonoxynol-9

Jelly 2%

Noradrenaline

Inj 0.06 mg per ml, 100 ml bag

Inj 0.06 mg per ml, 50 ml syringe

Inj 0.1 mg per ml, 100 ml bag

Inj 0.12 mg per ml, 100 ml bag

Inj 0.12 mg per ml, 50 ml syringe

Inj 0.16 mg per ml, 50 ml syringe

Inj 1 mg per ml, 100 ml bag

Inj 1 mg per ml, 2 ml ampoule

Norethisterone

Tab 350 mcg

Tab 5 mg

Norethisterone with mestranol

Tab 1 mg with mestranol 50 mcg

Norfloxacin

Tab 400 mg

Nortriptyline hydrochloride

Tab 10 mg

Tab 25 mg

Nystatin

Oral liquid 100,000 u per ml

Crm 100,000 u per g

Vaginal crm 100,000 u per 5 g with applicator(s)

Cap 500,000 u

Tab 500,000 u

Oral liquid 100,000 u per ml

Octocog alfa [Recombinant factor VIII]

Inj 250 iu vial

Inj 500 iu vial

Inj 1,000 iu vial

Inj 1,500 iu vial

Inj 2,000 iu vial

Inj 3,000 iu vial

Octreotide

Inj 50 mcg per ml, 1 ml ampoule

Inj 100 mcg per ml, 1 ml ampoule

Inj 500 mcg per ml, 1 ml ampoule

Inj 10 mg vial - ***restricted***

Inj 20 mg vial - ***restricted***

Inj 30 mg vial - ***restricted***

Must meet community Special Authority criteria
Note: restriction applies only to the long-acting formulations of octreotide

Oestradiol

Tab 1 mg

Tab 2 mg

Patch 25 mcg per day

Patch 50 mcg per day

Patch 100 mcg per day

Tab 2 mg

Implant 50 mg

Pessaries 25 mcg

Oestradiol valerate

Tab 1 mg

Tab 2 mg

Oestradiol with norethisterone acetate

Tab 1 mg with 0.5 mg norethisterone acetate

Tab 2 mg with 1 mg norethisterone acetate

Tab 2 mg with 1 mg norethisterone acetate (10), and tab 2 mg oestradiol (12) and tab 1 mg oestradiol (6)

Oestriol

Crm 1 mg per g with applicator

Pessaries 500 mcg

Oestrogens (conjugated equine)

Tab 300 mcg

Tab 625 mcg

Oestrogens with medroxyprogesterone acetate

Tab 625 mcg conjugated equine with 2.5 mg medroxyprogesterone acetate

Tab 625 mcg conjugated equine with 5 mg medroxyprogesterone acetate

Oil in water emulsion

Crm

Oily cream

Crm BP

Oily phenol

Inj 5%, 5 ml vial

Ointment base, greasy

Oint

Olanzapine

Tab 2.5 mg

Tab 5 mg

Tab 10 mg

Inj 10 mg vial

Inj 210 mg vial - ***restricted***

Inj 300 mg vial - ***restricted***

Inj 405 mg vial - ***restricted***

Tab orodispersible 5 mg

Tab orodispersible 10 mg

RESTRICTED (DEPOT INJECTION)
Initiation
Re-assessment required after 6 months
1 The patient has schizophrenia; and
2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.
Continuation
Either:
Re-assessment required after 12 months
1 The patient has had less than 12 months' treatment with olanzapine depot injection and there is no clinical reason to discontinue treatment; or
2 The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of olanzapine depot injection.

Olive oil

Liq

Olopatadine

Eye drops 0.1%

Olsalazine

Cap 250 mg

Tab 500 mg

Omalizumab

Inj 150 mg vial

Omeprazole

Cap 10 mg

Cap 20 mg

Cap 40 mg

Tab dispersible 20 mg - ***restricted***

Powder for oral liquid

Inj 40 mg ampoule with diluent

Inj 40 mg ampoule

RESTRICTED
Only for use in tube-fed patients

Omeprazole with amoxycillin and clarithromycin

Omeprazole cap 20 mg × 14, amoxycillin cap 500 mg × 28 and clarithromycin tab 500 mg × 14

Ondansetron

Tab 4 mg

Tab 8 mg

Tab dispersible 4 mg

Tab dispersible 8 mg

Inj 2 mg per ml, 2 ml ampoule

Inj 2 mg per ml, 4 ml ampoule

Opiate squill

Linctus BP

Oral feed

Powder 16 g protein, 59.8 g carbohydrate and 14 g fat per 100 g, 900 g can {Ensure} - ***restricted***

Powder 18.7 g protein, 54.5 g carbohydrate and 18.9 g fat per 100 g, 900 g can {Fortisip} - ***restricted***

Powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g, 900 g can {Sustagen Hospital Formula} - ***restricted***

RESTRICTED

Any of the following:

1 For patients with malnutrition, defined as any of the following:

1.1 BMI < 18.5; or

1.2 Greater than 10% weight loss in the last 3-6 months; or

1.3 BMI < 20 with greater than 5% weight loss in the last 3-6 months; or

2 For patients who have, or are expected to, eat little or nothing for 5 days; or

3 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or

4 For use pre- and post-surgery; or

5 For patients being tube-fed; or

6 For tube-feeding as a transition from intravenous nutrition; or

7 For any other condition that meets the community Special Authority criteria.

Oral feed 0.15 kcal/ml

Powder 4.5 g protein with 4 g carbohydrate per 9.2 g sachet {Resource Arginaid}

Oral feed 0.5 kcal/ml

Liquid 12.6 g carbohydrate per 100 ml {preOp}

Oral feed 1 kcal/ml

Liquid 3.8 g protein, 23 g carbohydrate and 12.7 g fibre per 100 ml, 237 ml carton {Resource Fruit Beverage} - ***restricted***

Powder 16.8 g protein, 40.2 g carbohydrate, 8.3 g fat and 3 g fibre per 74 g {Oral Impact}

Liquid 10.5 g protein with 52 g carbohydrate per 237 ml {Resource Arginaid Extra}

Powder 11 g protein, 62 g carbohydrate, 19 g fat per 100 g {Generaid Plus}

RESTRICTED

Any of the following:

1 For patients with malnutrition, defined as any of the following:

1.1 BMI < 18.5; or

1.2 Greater than 10% weight loss in the last 3-6 months; or

1.3 BMI < 20 with greater than 5% weight loss in the last 3-6 months; or

2 For patients who have, or are expected to, eat little or nothing for 5 days; or

3 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or

4 For use pre- and post-surgery; or

5 For patients being tube-fed; or

6 For tube-feeding as a transition from intravenous nutrition; or

7 For any other condition that meets the community Special Authority criteria.

Oral feed 1.5 kcal/ml

Liquid 4 g protein and 33.5 g carbohydrate per 100 ml, 200 ml bottle {Fortijuce} - ***restricted***

Liquid 5.5 g protein, 21.1 g carbohydrate and 4.81 g fat per 100 ml, 237 ml can {Ensure Plus} - ***restricted***

Liquid 6 g protein, 18.4 g carbohydrate and 5.8 g fat per 100 ml, 200 ml bottle {Fortisip} - ***restricted***

Liquid 6.25 g protein, 20.2 g carbohydrate and 4.92 g fat per 100 ml, 200 ml carton {Ensure Plus} - ***restricted***

Liquid 6 g protein, 18.4 g carbohydrate, 5.8 g fat and 2.3 g fibre per 100 ml, 200 ml bottle {Fortisip Multi Fibre} - ***restricted***

RESTRICTED
Any of the following:
1 For patients with malnutrition, defined as any of the following:
- 1.1 BMI < 18.5; or
- 1.2 Greater than 10% weight loss in the last 3-6 months; or
- 1.3 BMI < 20 with greater than 5% weight loss in the last 3-6 months; or

2 For patients who have, or are expected to, eat little or nothing for 5 days; or
3 For patients who have a poor absorptive capacity and/or high nutrient losses and/or increased nutritional needs from causes such as catabolism; or
4 For use pre- and post-surgery; or
5 For patients being tube-fed; or
6 For tube-feeding as a transition from intravenous nutrition; or
7 For any other condition that meets the community Special Authority criteria.

Oral feed 2 kcal/ml

Liquid 8.4 g protein, 22.4 g carbohydrate, 8.9 g fat and 0.8 g fibre per 100 ml, 237 ml can {TwoCal HN} - ***restricted***

RESTRICTED
Either:
1 Patient is fluid restricted; or
2 Both:
- 2.1 Any of the following:
  - 2.1.1 Cystic fibrosis; or
  - 2.1.2 Any condition causing malabsorption; or
  - 2.1.3 Faltering growth in an infant/child; or
  - 2.1.4 Increased nutritional requirements; and
- 2.2 Patient has substantially increased metabolic requirements.

Oral feed 2.5 kcal/ml

Powder 4.7 g protein, 65 g carbohydrate and 24.7 g fat per 100 g {Scandishake}

Orlistat

Cap 120 mg

Ornidazole

Tab 500 mg

Ornipressin

Inj 5 iu per 1 ml ampoule

Orphenadrine citrate

Inj 30 mg per ml, 2 ml

Tab 100 mg

Orphenadrine hydrochloride

Tab 50 mg

Oseltamivir

Cap 75 mg

Oral liq 12 mg per ml

Oxaliplatin

Inj 50 mg vial

Inj 100 mg vial

Oxandrolone

Tab 2.5 mg

Oxazepam

Tab 10 mg

Tab 15 mg

Oxcarbazepine

Tab 150 mg

Tab 300 mg

Tab 600 mg

Oral liq 60 mg per ml

Oxybuprocaine hydrochloride

Eye drops 0.4%, single dose

Oxybutynin

Tab 5 mg

Oral liq 5 mg per 5 ml

Patch 36 mg

Oxycodone hydrochloride

Cap 5 mg

Cap 10 mg

Cap 20 mg

Oral liq 5 mg per 5 ml

Tab controlled-release 5 mg

Tab controlled-release 10 mg

Tab controlled-release 20 mg

Tab controlled-release 40 mg

Tab controlled-release 80 mg

Inj 1 mg per ml, 100 ml bag

Inj 10 mg per ml, 1 ml ampoule

Inj 10 mg per ml, 2 ml ampoule

Inj 50 mg per ml, 1 ml ampoule

Oxymetazoline hydrochloride

Aqueous nasal spray 0.25 mg per ml

Aqueous nasal spray 0.5 mg per ml

Oxytocin

Inj 5 iu per ml, 1 ml ampoule

Inj 10 iu per ml, 1 ml ampoule

Oxytocin with ergometrine maleate

Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule

Paclitaxel

Inj 6 mg per ml, 5 ml vial

Inj 6 mg per ml, 16.7 ml vial

Inj 6 mg per ml, 25 ml vial

Inj 6 mg per ml, 50 ml vial

Inj 6 mg per ml, 100 ml vial

Paediatric enteral feed 0.76 kcal/ml

Liquid 2.5 g protein, 12.5 g carbohydrate, 3.3 g fat and 0.7 g fibre per 100 ml, 500 ml bag {Nutrini Low Energy Multifibre RTH} - ***restricted***

RESTRICTED
Both:
1 Child is aged one to ten years; and
2 Any of the following:
- 2.1 The child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
- 2.2 Any condition causing malabsorption; or
- 2.3 Faltering growth in an infant/child; or
- 2.4 Increased nutritional requirements; or
- 2.5 The child is being transitioned from TPN or tube feeding to oral feeding.

Paediatric enteral feed 1 kcal/ml

Liquid {Tentrini RTH}

Liquid 2.8 g protein, 11.2 g carbohydrate and 5 g fat per 100 ml, 500 ml bag {Pediasure RTH} - ***restricted***

Liquid 2.8 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bag {Nutrini RTH} - ***restricted***

RESTRICTED
Both:
1 Child is aged one to ten years; and
2 Any of the following:
- 2.1 The child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
- 2.2 Any condition causing malabsorption; or
- 2.3 Faltering growth in an infant/child; or
- 2.4 Increased nutritional requirements; or
- 2.5 The child is being transitioned from TPN or tube feeding to oral feeding.

Paediatric enteral feed 1.5 kcal/ml

Liquid 4.1 g protein, 18.5 g carbohydrate and 6.7 g fat per 100 ml, 500 ml bag {Nutrini Energy RTH} - ***restricted***

Liquid 4.1 g protein, 18.5 g carbohydrate, 6.7 g fat and 0.8 g fibre per 100 ml, 500 ml bag {Nutrini Energy Multi Fibre RTH} - ***restricted***

Liquid {Tentrini Energy RTH, Tentrini Energy Multifibre RTH}

RESTRICTED
Both:
1 Child is aged one to ten years; and
2 Any of the following:
- 2.1 The child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
- 2.2 Any condition causing malabsorption; or
- 2.3 Faltering growth in an infant/child; or
- 2.4 Increased nutritional requirements; or
- 2.5 The child is being transitioned from TPN or tube feeding to oral feeding.

Paediatric oral feed

Powder 14.9 g protein, 54.3 g carbohydrate and 24.7 g fat per 100 g, 900 g can {Pediasure} - ***restricted***

RESTRICTED
Both:
1 Child is aged one to ten years; and
2 Any of the following:
- 2.1 The child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
- 2.2 Any condition causing malabsorption; or
- 2.3 Faltering growth in an infant/child; or
- 2.4 Increased nutritional requirements; or
- 2.5 The child is being transitioned from TPN or tube feeding to oral feeding.

Paediatric oral feed 1 kcal/ml

Liquid 2.6 g protein, 10.3 g carbohydrate, 5.4 g fat and 0.8 g fibre per 100 ml, 100 ml bottle {Infatrini} - ***restricted***

Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, 200 ml carton {Pediasure} - ***restricted***

Liquid 4.2 g protein, 16.7 g carbohydrate and 7.5 g fat per 100 ml, 237 ml can {Pediasure} - ***restricted***

RESTRICTED
Both:
1 Child is aged one to ten years; and
2 Any of the following:
- 2.1 The child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
- 2.2 Any condition causing malabsorption; or
- 2.3 Faltering growth in an infant/child; or
- 2.4 Increased nutritional requirements; or
- 2.5 The child is being transitioned from TPN or tube feeding to oral feeding.

Paediatric oral feed 1.5 kcal/ml

Liquid 3.4 g protein, 18.8 g carbohydrate and 6.8 g fat per 100 ml, 200 ml bottle {Fortini} - ***restricted***

Liquid 4.0 g protein, 18.8 g carbohydrate, 6.8 g fat and 1.5 g fibre per 100 ml, 200 ml bottle {Fortini Multifibre} - ***restricted***

RESTRICTED
Both:
1 Child is aged one to ten years; and
2 Any of the following:
- 2.1 The child is being fed via a tube or a tube is to be inserted for the purposes of feeding; or
- 2.2 Any condition causing malabsorption; or
- 2.3 Faltering growth in an infant/child; or
- 2.4 Increased nutritional requirements; or
- 2.5 The child is being transitioned from TPN or tube feeding to oral feeding.

Paliperidone

Tab 3 mg

Tab 6 mg

Tab 9 mg

Tab 12 mg

Inj 25 mg vial

Inj 50 mg vial

Inj 75 mg vial

Inj 100 mg vial

Inj 150 mg vial

Palivizumab

Inj 100 mg

Pamidronate disodium

Inj 3 mg per ml, 5 ml vial

Inj 3 mg per ml, 10 ml vial

Inj 6 mg per ml, 10 ml vial

Inj 9 mg per ml, 10 ml vial

Pancreatic enzyme

Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease

Cap EC 25,000 BP u lipase, 18,000 BP u amylase and 1,000 BP u protease

Cap EC 25,000 BP u lipase, 22,500 BP u amylase and 1,250 BP u protease

Powder 25,000 u lipase with 30,000 u amylase and 1400 u protease per g

Pancuronium bromide

Inj 2 mg per ml, 2 ml ampoule

Pantoprazole

Tab 20 mg

Tab 40 mg

Inj 40 mg vial

Papaverine hydrochloride

Inj 12 mg per ml, 10 ml ampoule

Inj 30 mg per ml, 1 ml vial

Paper wasp venom

Inj 550 mcg vial with diluent - ***restricted***

RESTRICTED
Both:
1 RAST or skin test positive; and
2 Patient has had severe generalised reaction to the sensitising agent.

Para-aminosalicylic acid

Grans for oral liq 4 g - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist or respiratory physician

Paracetamol

Tab 500 mg

Tab soluble 500 mg

Oral liq 120 mg per 5 ml

Oral liq 250 mg per 5 ml

Suppos 25 mg

Suppos 50 mg

Suppos 125 mg

Suppos 250 mg

Suppos 500 mg

Inj 10 mg per ml, 50 ml vial - ***restricted***

Inj 10 mg per ml, 100 ml vial - ***restricted***

Cap 500 mg

Tab soluble 250 mg

Powder

RESTRICTED
Intravenous paracetamol is only to be used where other routes are unavailable or impractical, or where there is reduced absorption. The need for IV paracetamol must be re-assessed every 24 hours.

Paracetamol with caffeine

Tab 500 mg with caffeine 65 mg

Paracetamol with codeine

Tab paracetamol 500 mg with codeine phosphate 8 mg

Tab 500 mg with codeine 15 mg

Paracetamol with ibuprofen

Tab 500 mg with ibuprofen 150 mg

Paraffin

Enema 133 ml

Oral liquid 1 mg per ml

White soft

Yellow soft

Oint liquid paraffin 50% with white soft paraffin 50%

Cream liquid paraffin 12.6% with white soft paraffin 14.5% and wool fat 1%

Liq

Paraffin liquid with soft white paraffin

Eye oint 42.5% with soft white paraffin 57.3%

Paraffin liquid with wool fat

Eye oint 3% with wool fat 3%

Paraffin with retinol palmitate

Oint yellow soft paraffin with retinol palmitate 600 µg per g

Paraffin with wool fat

Lotn liquid paraffin 15.9% with wool fat 0.6%

Lotn liquid paraffin 91.7% with wool fat 3%

Paraldehyde

Inj 5 mg ampoule

Parecoxib

Inj 40 mg vial

Paromomycin

Cap 250 mg - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Paroxetine hydrochloride

Tab 20 mg

Patent blue V

Inj 2.5%, 2 ml ampoule

Pazopanib

Tab 200 mg - ***restricted***

Tab 400 mg - ***restricted***

Must meet community Special Authority criteria

Pegaspargase

Inj 750 iu per ml, 5 ml vial - ***restricted***

Must meet PCT Special Authority criteria

Pegfilgrastim

Inj 10 mg per ml, 0.6 ml

Pegvisomant

Inj 15 mg

Pegylated doxorubicin hydrochloride, liposomal

Inj 2 mg per ml, 10 mg

Inj 2 mg per ml, 25 mg

Pegylated interferon alpha-2a

Inj 135 mcg prefilled syringe - ***restricted***

Inj 180 mcg prefilled syringe - ***restricted***

Inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (112) - ***restricted***

Inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (112) - ***restricted***

Inj 135 mcg prefilled syringe (4) with ribavirin tab 200 mg (168) - ***restricted***

Inj 180 mcg prefilled syringe (4) with ribavirin tab 200 mg (168) - ***restricted***

Must meet community Special Authority criteria

Penicillamine

Tab 125 mg

Tab 250 mg

Pentagastrin

Inj 250 mcg per ml, 2 ml ampoule

Pentamidine isethionate

Inj 300 mg vial - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Pentostatin [Deoxycoformycin]

Inj 10 mg vial

Pentoxifylline (oxpentifylline)

Tab 400 mg

Peppermint oil

Cap 0.2 ml

Oral liquid

Peptide-based enteral feed 1 kcal/ml

Liquid 2.8 g protein, 13.7 g carbohydrate and 3.9 g fat per 100 ml, 500 ml bag {Nutrini Peptisorb} - ***restricte***

Liquid 4 g protein, 17.6 g carbohydrate and 1.7 g fat per 100 ml, 1000 ml bag {Nutrison Advanced Peptisorb} - ***restricted***

RESTRICTED
Any of the following:
1 Malabsorption; or
2 Short bowel syndrome; or
3 Enterocutaneous fistulas; or
4 Eosinophilic enteritis (including oesophagitis); or
5 Inflammatory bowel disease; or
6 Acute pancreatitis where standard feeds are not tolerated; or
7 Patients with multiple food allergies requiring enteral feeding.

Peptide-based oral feed

Powder 7.4 g protein, 25.5 g carbohydrate and 12 g fat per 51 g sachet {Pepdite Junior} - ***restricted***

Powder 12.5 g protein, 55.4 g carbohydrate and 3.25 g fat per 79 g sachet {Vital HN} - ***restricted***

Powder 13.7 g protein, 62.9 g carbohydrate and 17.5 g fat per 100 g, 400 g can {Peptamen Junior} - ***restricted***

Powder 13.8 g protein, 59 g carbohydrate and 18 g fat per 100 g, 400 g can {MCT Pepdite / MCT Pepdite 1 +} - ***restricted***

Powder 15.8 g protein, 49.5 g carbohydrate and 4.65 g fat per 76 g sachet {Alitraq} - ***restricted***

RESTRICTED
Any of the following:
1 Malabsorption; or
2 Short bowel syndrome; or
3 Enterocutaneous fistulas; or
4 Eosinophilic enteritis (including oesophagitis); or
5 Inflammatory bowel disease; or
6 Acute pancreatitis where standard feeds are not tolerated; or
7 Patients with multiple food allergies requiring enteral feeding.

Peptide-based oral feed 1 kcal/ml

Liquid 5 g protein, 16 g carbohydrate and 1.69 g fat per 100 ml, 237 ml carton {Peptamen OS 1.0} - ***restricted***

RESTRICTED
Any of the following:
1 Malabsorption; or
2 Short bowel syndrome; or
3 Enterocutaneous fistulas; or
4 Eosinophilic enteritis (including oesophagitis); or
5 Inflammatory bowel disease; or
6 Acute pancreatitis where standard feeds are not tolerated; or
7 Patients with multiple food allergies requiring enteral feeding.

Pergolide

Tab 0.25 mg

Tab 1 mg

Tab 0.05 mg

Perhexiline maleate

Tab 100 mg - ***restricted***

RESTRICTED
Both:
1. Patient has refractory angina; and
2. Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long-acting nitrate.

Pericyazine

Tab 2.5 mg

Tab 10 mg

Perindopril

Tab 2 mg - ***restricted***

Tab 4 mg - ***restricted***

RESTRICTED
For continuation only

Permethrin

Crm 5%

Lotn 5%

Pethidine hydrochloride

Tab 50 mg

Tab 100 mg

Inj 5 mg per ml, 10 ml syringe

Inj 5 mg per ml, 100 ml bag

Inj 10 mg per ml, 50 ml syringe

Inj 10 mg per ml, 100 ml bag

Inj 50 mg per ml, 1 ml ampoule

Inj 50 mg per ml, 2 ml ampoule

Inj 50 mg per ml, 1.5 ml ampoule

Phenelzine sulphate

Tab 15 mg

Phenindione

Tab 10 mg

Tab 25 mg

Tab 50 mg

Phenobarbitone

Tab 15 mg

Tab 30 mg

Inj 200 mg per ml, 1 ml ampoule

Inj 20 mg in 0.5 ml

Phenobarbitone sodium

Powder

Phenol

Liq

Inj 6%, 10 ml ampoule

Phenol with ioxaglic acid

Inj 12%, 10 ml ampoule

Phenoxybenzamine hydrochloride

Cap 10 mg

Inj 50 mg per ml, 2 ml ampoule

Phenoxymethylpenicillin [Penicillin V]

Cap 250 mg

Cap 500 mg

Grans for oral liq 25 mg per ml

Grans for oral liq 50 mg per ml

Phentermine

Cap 15 mg

Cap 30 mg

Phentolamine mesylate

Inj 10 mg per ml, 1 ml ampoule

Phenylephrine hydrochloride

Inj 10 mg per ml, 1 ml vial

Eye drops 2.5%, single dose

Eye drops 10%, single dose

Phenylephrine hydrochloride with zinc sulphate

Eye drops 0.12% with zinc sulphate 0.25%

Phenytoin

Tab 50 mg

Phenytoin sodium

Inj 50 mg per ml, 2 ml ampoule

Inj 50 mg per ml, 5 ml ampoule

Cap 30 mg

Cap 100 mg

Oral liq 6 mg per ml

Pholcodine

Oral liq 1 mg per ml

Oral liq 2 mg per ml

Oral liq 3 mg per ml

Phosphorus

Tab eff 500 mg

Phytomenadione

Tab 10 mg

Inj 2 mg in 0.2 ml ampoule

Inj 10 mg per ml, 1 ml ampoule

Picibanil

Inj 100 mg vial

Pilocarpine hydrochloride

Eye drops 1%

Eye drops 2%

Pilocarpine nitrate

Eye drops 2%, single dose

Powder

Pimecrolimus

Crm 1%

Pimozide

Tab 2 mg

Tab 4 mg

Pindolol

Tab 10 mg

Tab 15 mg

Tab 5 mg

Pioglitazone

Tab 15 mg

Tab 30 mg

Tab 45 mg

Piperacillin

Inj 2 g

Inj 4 g

Inj 1 g

Piperacillin with tazobactam

Inj 4 g with tazobactam 0.5 g vial - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist or respiratory physician

Pipothiazine palmitate

Inj 50 mg per ml, 1 ml ampoule

Inj 50 mg per ml, 2 ml ampoule

Piracetam

Tab 800 mg

Piroxicam

Tab dispersible 10 mg

Tab dispersible 20 mg

Pivmecillinam

Tab 200 mg

Pizotifen

Tab 500 mcg

Plerixafor

Inj 20 mg per ml, 1.2 ml vial

Pneumococcal (PCV10) conjugate vaccine

Inj 16 mcg in 0.5 ml syringe - ***restricted***

RESTRICTED
For primary vaccination in children

Pneumococcal (PCV13) conjugate vaccine

Inj 30.8 mcg in 0.5 ml syringe - ***restricted***

RESTRICTED
Any of the following:
1 For high risk children under the age of 5; or
2 For patients aged less than 18 years pre- or post-splenectomy or with functional asplenia; or
3 For revaccination following immunosuppression.

Pneumococcal (PPV23) polysaccharide vaccine

Inj 575 mcg in 0.5 ml vial - ***restricted***

RESTRICTED
Any of the following:
1 For patients pre- and post-splenectomy or
2 children aged 0-18 years with functional asplenia
3 For revaccination following immunosuppression.

Podophyllotoxin

Soln 0.5%

Podophyllum resin with salicylic acid

Oint 20% with salicylic acid 25%

Polidocanol

Inj 0.5%, 30 ml vial

Inj 3%, 2 ml

Poliomyelitis vaccine

Inj 80 D-antigen units in 0.5 ml syringe - ***restricted***

RESTRICTED
Either:
1 For previously unvaccinated individuals; or
2 For revaccination following immunosuppression.

Poloxamer

Oral drops 10%

Polygeline

Inf 3.5%, 500 ml

Polyhexamethylene biguanide

Liq

Polyvinyl alcohol

Eye drops 1.4%

Eye drops 3%

Polyvinyl alcohol with povidone

Eye drops 1.4% with povidone 0.6%, single dose

Poractant alfa

Soln 120 mg per 1.5 ml vial

Soln 240 mg per 3 ml vial

Posaconazole

Oral liq 40 mg per ml - ***restricted***

RESTRICTED – infectious disease physician or haematologist
Initiation
Re-assessment required after 6 weeks
Both:
1 Either:
1.1 Patient has acute myeloid leukaemia; or
1.2 Patient is planned to receive a stem cell transplant and is at high risk for aspergillus infection; and
2 Patient is to be treated with high dose remission induction therapy or re-induction therapy
Continuation
Re-assessment required after 6 weeks
Both:
1 Patient has previously received posaconazole prophylaxis during remission induction therapy; and
2 Any of the following:
2.1 Patient is to be treated with high dose remission re-induction therapy; or
2.2 Patient is to be treated with high dose consolidation therapy; or
2.3 Patient is receiving a high risk stem cell transplant.

Potassium acetate

Inj 0.49 g per ml, 5 ml

Inj 4 mmol per ml, 20 ml

Potassium bromide

Powder

Potassium chloride

Inj 150 mg (2 mmol) per ml, 10 ml

Inj 75 mg (1 mmol) per ml, 10 ml ampoule

Inj 225 mg (3 mmol) per ml, 20 ml ampoule

Tab eff 548 mg (14 mmol) with chloride 285 mg (8 mmol)

Tab long-acting 600 mg (8 mmol)

Oral liq 2 mmol per ml

Potassium chloride with sodium chloride

Inj 10 mmol/L potassium chloride with 0.29% sodium chloride, 100 ml bag

Inj 20 mmol/L potassium chloride with 0.9% sodium chloride, 1,000 ml bag

Inj 30 mmol/L potassium chloride with 0.9% sodium chloride, 1,000 ml bag

Inj 40 mmol/L potassium chloride with 0.9% sodium chloride, 100 ml bag

Inj 40 mmol/L potassium chloride with 0.9% sodium chloride, 1,000 ml bag

Potassium citrate

Oral liq 3 mmol per ml - ***restricted***

Tab 540 mg

RESTRICTED
Both:
1. The patient has recurrent calcium oxalate urolithiasis; and
2. The patient has had more than two renal calculi in the two years prior to the application.

Potassium dihydrogen phosphate

Inj 1 mmol per ml, 10 ml ampoule

Potassium iodate

Tab 256 mcg (150 mcg elemental)

Potassium iodate with iodine

Oral liq 10% with iodine 5%

Potassium perchlorate

Cap 200 mg

Potassium permanganate

Tab 400 mg

Povidone K30

Powder

Povidone-iodine

Soln 5%

Soln 7,5%

Soln 10%

Oint 10%

Pad 10%

Swab set 10%

Povidone-iodine with ethanol

Soln 10% with ethanol 30%

Soln 10% with ethanol 70%

Pralidoxime iodide

Inj 25 mg per ml, 20 ml ampoule

Pramipexole hydrochloride

Tab 0.125 mg

Tab 0.25 mg

Tab 0.5 mg

Tab 1 mg

Prasugrel

Tab 5 mg

Tab 10 mg - ***restricted***

RESTRICTED
Bare metal stents
Limited to 6 months' treatment
Patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergic.
Drug-eluting stents
Limited to 12 months' treatment
Patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic.
Stent thrombosis
Patient has experienced cardiac stent thrombosis whilst on clopidogrel.
Myocardial infarction
Limited to 7 days' treatment
For short term use while in hospital following ST-elevated myocardial infarction.

Note: Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.

Pravastatin

Tab 10 mg

Tab 20 mg

Tab 40 mg

Praziquantel

Tab 600 mg

Tab 500 mg

Prazosin

Tab 1 mg

Tab 2 mg

Tab 5 mg

Prednisolone

Oral liq 5 mg per ml

Enema 200 mcg per ml, 100 ml

Tab 5 mg

Prednisolone acetate

Eye drops 0.12%

Eye drops 1%

Prednisolone sodium phosphate

Eye drops 0.5%, single dose

Prednisone

Tab 1 mg

Tab 2.5 mg

Tab 5 mg

Tab 20 mg

Pregabalin

Cap 75 mg

Cap 150 mg

Cap 300 mg

Preterm formula

Liquid 2.2 g protein, 8.4 g carbohydrate and 4.4 g fat per 100 ml, 100 ml bottle {S26 LBW Gold RTF} - ***restricted***

Liquid 2.3 g protein, 8.6 g carbohydrate and 4.2 g fat per 100 ml, 90 ml bottle {Pre Nan Gold RTF} - ***restricted***

Liquid 2.5 g protein, 7.6 g carbohydrate and 4.4 g fat per 100 ml, 60 ml bottle {Karicare Aptamil Preterm Gold+} - ***restricted***

Powder 1.9 g protein, 7.5 g carbohydrate and 3.9 g fat per 14 g, 400 g can {S-26 Gold Premgro}

RESTRICTED
For infants born before 33 weeks' gestation or weighing less than 1.5 kg at birth

Prilocaine hydrochloride

Inj 0.5%, 50 ml vial

Inj 2%, 5 ml ampoule

Prilocaine hydrochloride with felypressin

Inj 3% with felypressin 0.03 iu per ml, 1.8 ml dental cartridge

Inj 3% with felypressin 0.03 iu per ml, 2.2 ml dental cartridge

Primaquine phosphate

Tab 7.5 mg - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Primidone

Tab 250 mg

Probenecid

Tab 500 mg

Procaine hydrochloride

Inj 20 mg per ml, 2 ml ampoule

Procaine hydrochloride with adrenaline and atropine sulphate

Inj 10 mg with adrenaline 1:1000 and atropine 1.67 mg per 0.5 ml ampoule

Procaine penicillin

Inj 1.5 g in 3.4 ml syringe

Procarbazine hydrochloride

Cap 50 mg

Prochlorperazine

Tab 3 mg buccal

Tab 5 mg

Inj 12.5 mg per ml, 1 ml ampoule

Suppos 25 mg

Suppos 5 mg

Procyclidine hydrochloride

Tab 5 mg

Progesterone

Cap 100 mg - ***restricted***

Inj 100 mg in 2 ml

RESTRICTED
Only for use in women with previous preterm delivery (less than 28 weeks) and/or a short cervix (< 25 mm).

Promethazine hydrochloride

Inj 25 mg per ml, 2 ml ampoule

Oral liq 1 mg per ml

Tab 10 mg

Tab 25 mg

Promethazine theoclate

Tab 25 mg - ***restricted***

RESTRICTED
For continuation only

Propafenone hydrochloride

Tab 150 mg

Propamidine isethionate

Eye drops 0.1%

Propantheline bromide

Tab 15 mg

Propofol

Inj 10 mg per ml, 20 ml vial

Inj 10 mg per ml, 20 ml ampoule

Inj 10 mg per ml, 50 ml vial

Inj 10 mg per ml, 50 ml syringe

Inj 10 mg per ml, 100 ml vial

Inj 20 mg per ml, 50 ml syringe

Inj 20 mg per ml, 50 ml vial/ampoule

Propranolol

Cap long-acting 160 mg

Inj 1 mg per ml, 1 ml ampoule

Oral liq 4 mg per ml

Tab 10 mg

Tab 40 mg

Propylene glycol

Liq

Propylthiouracil

Tab 50 mg - ***restricted***

RESTRICTED
Both:
1. The patient has hyperthyroidism; and
2. The patient is intolerant of carbimazole or carbimazole is contraindicated.

Protamine sulphate

Inj 10 mg per ml, 5 ml ampoule

Protein and fat supplement

Liquid 50 g fat (long-chain triglycerides) per 100 ml {Calogen Extra}

Protein supplement

Powder 5 g protein, 0.67 g carbohydrate and 0.6 g fat per 6.6 g, 275 g can {Promod} - ***restricted***

Powder 6 g protein per 7 g, 227 g can {Resource Beneprotein} - ***restricted***

Powder 89 g protein, 0.5 g carbohydrate and 2 g fat per 100 g, 225 g can {Protifar} - ***restricted***

Protionamide

Tab 250 mg - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist or respiratory physician

Protirelin

Inj 100 mcg per ml, 2 ml ampoule

Proxymetacaine

Eye drops 0.5%

Pseudoephedrine hydrochloride

Tab 60 mg

Pyrantel embonate

Oral liq 50 mg per ml

Chocolate squares, 100 mg

Pyrazinamide

Tab 500 mg - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist or respiratory physician

Pyridostigmine bromide

Tab 60 mg

Pyridoxine

Inj 50 mg

Pyridoxine hydrochloride

Tab 25 mg

Tab 50 mg

Inj 100 mg per ml, 1 ml ampoule

Pyrimethamine

Tab 25 mg - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist or maternal-foetal medicine specialist

Quetiapine

Tab 25 mg

Tab 100 mg

Tab 200 mg

Tab 300 mg

Quinapril

Tab 10 mg

Tab 20 mg

Tab 5 mg

Quinapril with hydrochlorothiazide

Tab 10 mg with hydrochlorothiazide 12.5 mg

Tab 20 mg with hydrochlorothiazide 12.5 mg

Quinine dihydrochloride

Inj 60 mg per ml, 10 ml ampoule - ***restricted***

Inj 300 mg per ml, 2 ml vial - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Quinine sulphate

Tab 300 mg

Quinupristin with dalfopristin

Inj 150 mg with dalfopristin 350 mg

Rabies vaccine

Inj 2.5 IU vial with diluent

Raloxifene

Tab 60 mg - ***restricted***

Must meet community Special Authority criteria

Raltegravir potassium

Tab 400 mg - ***restricted***

Must meet community Special Authority criteria

Ranibizumab

Inj 10 mg per ml, 0.23 ml vial - ***restricted***

Inj 10 mg per ml, 0.3 ml vial - ***restricted***

RESTRICTED
Initiation
Re-assessment required after 3 doses
Both:
1. Either
    1. Age-related macular degeneration; or
    2. Chorodial neovascular membrane; and
2. Any of the following:
    1. The patient has had a severe ophthalmic inflammatory response following bevacizumab; or
    2. The patient has had a myocardial infarction or stroke within the last three months; or
    3. The patient has failed to respond to bevacizumab following three intraocular injections; or
    4. The patient is of child-bearing potential and has not completed a family.

Continuation
Both:
1. Documented benefit after three doses must be demonstrated to continue; and
2. In the case of but previous non-response to bevacizumab, a retrial of bevacizumab is required to confirm non-response before continuing with ranibizumab.

Ranitidine

Tab 150 mg

Tab 300 mg

Oral liq 150 mg per 10 ml

Inj 25 mg per ml, 2 ml ampoule

Rasburicase

Inj 1.5 mg vial - ***restricted***

RESTRICTED – haematologist

Reboxetine mesylate

Tab 4 mg

Red back spider antivenom

Inj 500 u vial

Remifentanil hydrochloride

Inj 1 mg vial

Inj 2 mg vial

Inj 5 mg vial

Reteplase

Inj 10 u

Retigabine

Cap 100 mg

Cap 200 mg

Tab 200 mg

Retinol

Cap 9,000 iu

Tab 10,000 iu

Cap 25,000 iu

Oral liq 150,000 iu per ml

Retinol palmitate

Oint 2000 iu per g

Rifabutin

Cap 150 mg - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist, respiratory physician or gastroenterologist

Rifampicin

Cap 150 mg - ***restricted***

Cap 300 mg - ***restricted***

Tab 600 mg - ***restricted***

Oral liq 100 mg per 5 ml - ***restricted***

Inj 600 mg vial - ***restricted***

RESTRICTED – internal medicine physician, clinical microbiologist, dermatologist, paediatrician or public health physician

Rifaximin

Tab 200 mg

Ringer's solution

Inj sodium 147 mmol/L with potassium 4 mmol/L, calcium 2.2 mmol/L, chloride 156 mmol/L, 1,000 ml bag

Risperidone

Tab 0.5 mg

Tab 1 mg

Tab 2 mg

Tab 3 mg

Tab 4 mg

Oral liq 1 mg per ml

Inj 25 mg vial - ***restricted***

Inj 37.5 mg vial - ***restricted***

Inj 50 mg vial - ***restricted***

Tab orodispersible 0.5 mg - ***restricted***

Tab orodispersible 1 mg - ***restricted***

Tab orodispersible 2 mg - ***restricted***

RESTRICTED (DEPOT INJECTION)
Re-assessment required after 6 months
1 The patient has schizophrenia; and
2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.
Continuation
Either:
Re-assessment required after 12 months
1 The patient has had less than 12 months' treatment with risperidone depot injection and there is no clinical reason to discontinue treatment; or
2 The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone depot injection.

RESTRICTED (ORODISPERSIBLE TABS)
Acute situations
Both:
1 For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid; and
2 The patient is under direct supervision for administration of medicine.
Chronic situations
1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
2 The patient is under direct supervision for administration of medicine.

Ritonavir

Tab 100 mg - ***restricted***

Oral liq 80 mg per ml - ***restricted***

Must meet community Special Authority criteria

Rituximab

Inj 10 mg per ml, 10 ml vial - ***restricted***

Inj 10 mg per ml, 50 ml vial - ***restricted***

Note: Decisions for rituximab have to date been made only for use in rheumatology. Use in other areas will be considered at a later time.

RESTRICTED

Initiation – rheumatoid arthritis - prior TNF inhibitor use – rheumatologist
Re-assessment required after 2 doses
All of the following:
1 Both:
1.1 The patient has had an initial community Special Authority approval for at least one of etanercept and/or adalimumab for rheumatoid arthritis; and
1.2 Either:
1.2.1 The patient has experienced intolerable side effects from a reasonable trial of adalimumab and/or etanercept; or
1.2.2 Following at least a four month trial of adalimumab and/or etanercept, the patient did not meet the renewal criteria for adalimumab and/or etanercept for rheumatoid arthritis; and
2 Either:
2.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
2.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
3 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initiation – rheumatoid arthritis - TNF inhibitors contraindicated – rheumatologist
Re-assessment required after 2 doses
All of the following:
1 Treatment with a Tumour Necrosis Factor alpha inhibitor is contraindicated; and
2 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
5 Any of the following:
5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
6 Either:
6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
7 Either:
7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months; and
8 Either:
8.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
8.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
9 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation – rheumatoid arthritis - re-treatment in 'partial responders' to rituximab – rheumatologist
Re-assessment required after 2 doses
All of the following:
1 Either:
1.1 At 4 months following the initial course of rituximab infusions the patient had between a 30% and 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
1.2 At 4 months following the second course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
1.3 At 4 months following the third and subsequent courses of rituximab infusions, the patient

demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
3 Either:
3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Continuation – rheumatoid arthritis - re-treatment in 'responders' to rituximab – rheumatologist
Re-assessment required after 2 doses
All of the following:
1 Either:
1.1 At 4 months following the initial course of rituximab infusions the patient had at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
1.2 At 4 months following the second and subsequent courses of rituximab infusions, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
2 Rituximab re-treatment not to be given within 6 months of the previous course of treatment; and
3 Either:
3.1 Rituximab to be used as an adjunct to methotrexate or leflunomide therapy; or
3.2 Patient is contraindicated to both methotrexate and leflunomide, requiring rituximab monotherapy to be used; and
4 Maximum of two 1,000 mg infusions of rituximab given two weeks apart.

Initiation – haemophilia with inhibitors – haematologist
Any of the following:
1 Patient has mild congenital haemophilia complicated by inhibitors; or
2 Patient has severe congenital haemophilia complicated by inhibitors and has failed immune tolerance therapy; or
3 Patient has acquired haemophilia.
Continuation – haemophilia with inhibitors – haematologist
All of the following:
1 Patient was previously treated with rituximab for haemophilia with inhibitors; and
2 An initial response lasting at least 12 months was demonstrated; and
3 Patient now requires repeat treatment.

Initiation – post-transplant
Both:
1 The patient has B-cell post-transplant lymphoproliferative disorder*; and
2 To be used for a maximum of 8 treatment cycles.
Note: Indications marked with * are Unapproved Indications.

Continuation – post-transplant
All of the following:
1 The patient has had a rituximab treatment-free interval of 12 months or more; and
2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
3 To be used for no more than 6 treatment cycles.
Note: Indications marked with * are Unapproved Indications.

Initiation – indolent, low-grade lymphomas
Either:
1 Both:
1.1 The patient has indolent low grade NHL with relapsed disease following prior chemotherapy; and
1.2 To be used for a maximum of 6 treatment cycles; or
2 Both:
2.1 The patient has indolent, low grade lymphoma requiring first-line systemic chemotherapy; and
2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Continuation – indolent, low-grade lymphomas

All of the following:

1 The patient has had a rituximab treatment-free interval of 12 months or more; and

2 The patient has indolent, low-grade NHL with relapsed disease following prior chemotherapy; and

3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Initiation – aggressive CD20 positive NHL

Either:

1 All of the following:

- 1.1 The patient has treatment naive aggressive CD20 positive NHL; and
- 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 1.3 To be used for a maximum of 8 treatment cycles; or

2 Both:

- 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
- 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

Continuation – aggressive CD20 positive NHL

1 The patient has had a rituximab treatment-free interval of 12 months or more; and

2 The patient has relapsed refractory/aggressive CD20 positive NHL; and

3 To be used with a multi-agent chemotherapy regimen given with curative intent; and

4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia.

Chronic lymphocytic leukaemia

All of the following:

1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and

2 The patient is rituximab treatment naive; and

3 Either:

- 3.1 The patient is chemotherapy treatment naive; or
- 3.2 Both:
  - 3.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
  - 3.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; and

4 The patient has good performance status; and

5 The patient has good renal function (creatinine clearance ≥ 30 ml/min); and

6 The patient does not have chromosome 17p deletion CLL; and

7 Rituximab to be administered in combination with fludarabine and cyclophosphamide for a maximum of 6 treatment cycles; and

8 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration).

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to <2.

Rivaroxaban

Tab 10 mg - ***restricted***

RESTRICTED
Limited to five weeks' treatment
Either:
1 For the prophylaxis of venous thromboembolism following a total hip replacement; or
2 For the prophylaxis of venous thromboembolism following a total knee replacement.

Rivastigmine

Cap 1.5 mg

Cap 3 mg

Cap 4.5 mg

Cap 6 mg

Patch 4.6 mg / 24 h

Patch 9.5 mg / 24 h

Patch 13.3 mg / 24 h

Patch 17.4 mg / 24 h

Rizatriptan benzoate

Tab orodispersible 10 mg

Rocuronium bromide

Inj 10 mg per ml, 5 ml vial

Inj 10 mg per ml, 10 ml vial

Ropinirole

Tab 0.25 mg (42), 0.5 mg (42), 1 mg (21)

Tab 0.5 mg (42), 1 mg (21), 2 mg (63)

Ropinirole hydrochloride

Tab 0.25 mg

Tab 1 mg

Tab 2 mg

Tab 5 mg

Ropivacaine hydrochloride

Inj 2 mg per ml, 10 ml ampoule

Inj 2 mg per ml, 20 ml ampoule

Inj 2 mg per ml, 100 ml bag

Inj 2 mg per ml, 200 ml bag

Inj 7.5 mg per ml, 10 ml ampoule

Inj 7.5 mg per ml, 20 ml ampoule

Inj 10 mg per ml, 10 ml ampoule

Inj 10 mg per ml, 20 ml ampoule

Ropivacaine hydrochloride with fentanyl

Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag

Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag

Rose bengal sodium

Ophthalmic strips 1%

Eye drops 1%, single dose

Rosuvastatin

Tab 5 mg

Tab 10 mg

Tab 20 mg

Tab 40 mg

Rotavirus vaccine

Oral liq

Roxithromycin

Tab 150 mg

Tab 300 mg

Salbutamol

Aerosol inhaler, 100 mcg per dose

Inj 1 mg per ml, 5 ml ampoule

Inj 500 mcg per ml, 1 ml ampoule

Nebuliser soln 1 mg per ml, 2.5 ml ampoule

Nebuliser soln 2 mg per ml, 2.5 ml ampoule

Oral liq 0.4 mg per ml

Salbutamol with ipratropium bromide

Aerosol inhaler 100 mcg with ipratropium bromide 20 mcg per dose

Nebuliser soln 2.5 mg with ipratropium bromide 0.5 mg per 2.5 ml ampoule

Salicylic acid

Gel 27%

Powder

Salicylic acid with lactic acid

Liq 16.7% with lactic acid 16.7%

Salmeterol

Aerosol inhaler 25 mcg per dose

Powder for inhalation 50 mcg per dose

Salmonella typhi vaccine

Inj 25 mcg in 0.5 ml syringe - ***restricted***

RESTRICTED
For use during typhoid fever outbreaks

Sargramostim

Inj 250 mcg

Inj 500 mcg

Secretin pentahydrochloride

Inj 100 u ampoule

Inj 100 u ampoule

Selegiline hydrochloride

Tab 5 mg

Sennosides

Tab 7.5 mg

Sertraline

Tab 50 mg

Tab 100 mg

Sevelamer hydrochloride

Tab 800 mg

Sevoflurane

Soln for inhalation 100%, 250 ml bottle

Sildenafil

Tab 100 mg - ***restricted***

Tab 20 mg

Tab 25 mg - ***restricted***

Tab 50 mg - ***restricted***

RESTRICTED
Any of the following:
1. For use in patients with approval by the Pulmonary Arterial Hypertension Panel; or
2. For use in neonatal units for persistent pulmonary hypertension of the newborn (PPHN);
3. For use in weaning patients from inhaled nitric oxide;
4. For perioperative use in cardiac surgery patients;
5. For use in intensive care as an alternative to nitric oxide;
6. In-hospital stabilisation in emergency situations; or
7. All of the following:
    7.1. Patient has Raynaud's phenomenon; and
    7.2. Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and
    7.3. Patient is following lifestyle management (proper body insulation, avoidance of cold exposure, smoking cessation support, avoidance of sympathomimetic drugs); and
    7.4. Patient has persisting severe symptoms despite treatment with calcium channel blockers and nitrates (unless contraindicated or not tolerated).

Silver nitrate

Sticks with applicator

Crystals

Simeticone

Oral drops 100 mg per ml

Cap 100 mg

Simvastatin

Tab 10 mg

Tab 20 mg

Tab 40 mg

Tab 80 mg

Sincalide

Inj 5 mcg

Sirolimus

Tab 1 mg - ***restricted***

Tab 2 mg - ***restricted***

Oral liq 1 mg per ml - ***restricted***

RESTRICTED
For rescue therapy for an organ transplant recipient
Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR<30 ml/min; or
- Rapidly progressive transplant vasculopathy; or
- Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- Leukoencepthalopathy; or
- Significant malignant disease

Sitagliptin

Tab 25 mg

Tab 50 mg

Tab 100 mg

Snake antivenom

Inj 50 ml vial

Sodium acetate

Inj 4 mmol per ml, 20 ml ampoule

Sodium alginate with magnesium alginate

Powder for oral soln 225 mg with magnesium alginate 87.5 mg

Note: Gaviscon Infant

Sodium alginate with sodium bicarbonate and calcium carbonate

Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml

Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg

Tab 250 mg with sodium bicarbonate 133.5 mg and calcium carbonate 80 mg tablets

Note: brands include Acidex and Gaviscon

Sodium aurothiomalate

Inj 10 mg in 0.5 ml ampoule

Inj 20 mg in 0.5 ml ampoule

Inj 50 mg in 0.5 ml ampoule

Sodium benzoate

Cap 500 mg

Inj 20%, 10 ml ampoule

Powder

Soln 100 mg per ml

Sodium bicarbonate

Inj 5%, 500 ml

Inj 8.4%, 50 ml syringe

Inj 8.4%, 10 ml vial

Inj 8.4%, 50 ml vial

Inj 8.4%, 100 ml vial

Cap 840 mg

Powder BP

Sodium calcium edetate

Inj 200 mg per ml, 2.5 ml ampoule

Inj 200 mg per ml, 5 ml ampoule

Sodium carboxymethylcellulose with pectin and gelatine

Paste

Powder

Note: brands include Orabase and Stomahesive

Sodium chloride

Aqueous nasal spray 6.5 mg per ml

Nebuliser soln 7%, 90 ml bottle

Aqueous nasal spray 7.4 mg per ml

Inj 0.45%, 500 ml bag

Inj 0.9%, 5 ml ampoule

Inj 0.9%, 10 ml ampoule

Inj 0.9%, 20 ml ampoule

Inj 0.9%, 50 ml bag

Inj 0.9%, 100 ml bag

Inj 0.9%, 250 ml bag

Inj 0.9%, 500 ml bag

Inj 0.9%, 1,000 ml bag

Inj 1.8%, 500 ml bottle

Inj 3%, 1,000 ml bag

Inj 23.4% (4 mmol/ml), 20 ml

Tab 600 mg

Oral liq 2 mmol/ml

Irrigation soln 0.9%, 30 ml ampoule

Irrigation soln 0.9%, 100 ml bottle

Irrigation soln 0.9%, 500 ml bottle

Irrigation soln 0.9%, 1000 ml bottle

Irrigation soln 0.9%, 2,000 ml bottle

Irrigation soln 0.9%, 3,000 ml bottle

Sodium chloride with sodium bicarbonate

Soln for nasal irrigation

Sodium citrate

Oral liq 8.8% (300 mmol/L)

Powder

Sodium citrate with sodium chloride and potassium chloride

Inj 4.2 mg with sodium chloride 5.7 mg and potassium chloride 74.6 mcg per ml, 5000 ml bag

Sodium citrate with sodium lauryl sulphoacetate

Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml

Sodium citro-tartrate

Grans eff 4 g sachets

Sodium cromoglicate

Aerosol inhaler 5 mg per dose

Powder for inhalation 20 mcg per dose

Sodium cromoglycate

Cap 100 mg

Nasal spray 4%

Eye drops 2%

Sodium dihydrogen phosphate [Sodium acid phosphate]

Inj 1 mmol per ml, 20 ml ampoule

Sodium fluoride

Tab 1.1 mg (0.5 mg elemental)

Sodium hyaluronate

Inj 10 mg per ml, 0.85 ml syringe

Inj 14 mg per ml, 0.55 ml syringe

Inj 23 mg per ml, 0.6 ml syringe

Inj 16 mg per ml, 0.25 ml

Inj 16 mg per ml, 0.5 ml

Inj 16 mg per ml, 0.8 ml

Inj 20 mg per ml, 1 ml syringe - ***restricted***

RESTRICTED – otolaryngologists

Sodium hyaluronate with chondroitin sulphate

Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.35 ml syringe and inj 10 mg sodium hyaluronate per ml, 0.4 ml syringe

Inj 30 mg per ml with chondroitin sulphate 40 mg per ml, 0.5 ml syringe and inj 10 mg sodium hyaluronate p ml, 0.4 ml syringe

Inj 30 mg with chondroitin sulphate 40 mg per ml, 0.75 ml syringe

Sodium hydrogen phosphate

Inj 3 mmol per ml, 1 ml

Inj 3 mmol per ml, 5 m

Sodium hypochlorite

Soln

Sodium metabisulfite

Powder

Sodium nitrite

Inj 30 mg per ml, 10 ml ampoule

Sodium nitroprusside

Inj 50 mg vial

Sodium phenylbutyrate

Inj 200 mg per ml, 10 ml ampoule

Oral liq 250 mg per ml

Tab 500 mg

Sodium phosphate with phosphoric acid

Oral liq 16.4% with phosphoric acid 25.14%

Enema 10% with phosphoric acid 6.58%

Note: Fleet Phosphate Enema and Fleet Phospha-Soda Buffered Saline Mixture

Sodium polystyrene sulphonate

Powder

Sodium stibogluconate

Inj 100 mg per ml, 1 ml vial - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Sodium tetradecyl sulphate

Inj 0.5%, 2 ml

Inj 1%, 2 ml

Inj 3%, 2 ml ampoule

Sodium thiosulfate

Inj 250 mg per ml, 10 ml vial

Inj 500 mg per ml, 10 ml vial

Sodium valproate

Tab 100 mg

Tab 200 mg

Tab 500 mg

Oral liq 40 mg per ml

Inj 100 mg per ml, 4 ml vial

Sodium with potassium

Inj 29 mEq/L with potassium 125 mEq/L, 1000 ml bag

Solifenacin succinate

Tab 5 mg - ***restricted***

Tab 10 mg - ***restricted***

RESTRICTED
Patient has overactive bladder and a documented intolerance of oxybutynin.

Somatropin

Inj 16 iu (5.3 mg) vial - ***restricted***

Inj 36 iu (12 mg) vial - ***restricted***

RESTRICTED
Only for use in patients with approval by the New Zealand Growth Hormone Committee or the Adult Growth Hormone Panel

Sotalol

Inj 10 mg per ml, 4 ml ampoule

Tab 160 mg

Tab 80 mg

Soya oil

Inj 20%, 500 ml bag

Inj 20%, 500 ml bottle

Spiramycin

Tab 500 mg - ***restricted***

RESTRICTED – maternal-foetal medicine specialist

Spironalactone

Oral liq 5 mg per ml

Tab 100 mg

Tab 25 mg

Starch

Powder

Stavudine

Cap 30 mg - ***restricted***

Cap 40 mg - ***restricted***

Powder for oral soln 1 mg per ml - ***restricted***

Cap 20 mg

Must meet community Special Authority criteria

Sterculia

Powder for oral soln

Sterculia with frangula

Powder for oral soln - ***restricted***

RESTRICTED
For continuation only

Stiripentol

Cap 250 mg - ***restricted***

Powder for oral liq 250 mg sachet - ***restricted***

RESTRICTED – paediatric neurologist
Initiation
Re-assessment required after 6 months
Both:
1 Patient has confirmed diagnosis of Dravet syndrome; and
2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.
Continuation
Patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.

Streptokinase

Inj 250,000 iu vial

Inj 1,500,000 iu vial

Streptomycin sulphate

Inj 400 mg per ml, 2.5 ml ampoule - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist or respiratory physician

Strontium ranelate

Gran 2 g

Sucralfate

Tab 1 g

Sucrose

Oral liq 25%

Sulindac

Tab 100 mg - ***restricted***

Tab 200 mg - ***restricted***

RESTRICTED
For continuation only

Sulphacetamide sodium

Eye drops 10%

Sulphadiazine

Tab 500 mg - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist or maternal-foetal medicine specialist

Sulphadiazine silver

Crm 1%

Sulphasalazine

Tab 500 mg

Tab EC 500 mg

Sulphur

Precipitated

Sublimed

Sumatriptan

Tab 50 mg

Tab 100 mg

Inj 12 mg per ml, 0.5 ml cartridge

Sunitinib

Cap 12.5 mg - ***restricted***

Cap 25 mg - ***restricted***

Cap 50 mg - ***restricted***

Must meet community Special Authority criteria

Sunscreen, proprietary

Crm

Lotn

Suxamethonium chloride

Inj 50 mg per ml, 2 ml ampoule

Syrup

Liq (pharmaceutical grade)

Tacrolimus

Cap 0.5 mg - ***restricted***

Cap 1 mg - ***restricted***

Cap 5 mg - ***restricted***

Inj 5 mg per ml, 1 ml ampoule - ***restricted***

RESTRICTED
For use in organ transplant recipients

Tadalafil

Tab 5 mg

Tab 10 mg

Tab 20 mg

Talc

Powder

Soln (slurry) 100 mg per ml, 50 ml

Tamoxifen citrate

Tab 10 mg

Tab 20 mg

Tamsulosin

Cap 400 mcg - ***restricted***

Tab long-acting 400 mcg

RESTRICTED
Both:
1. Patient has symptomatic benign prostatic hyperplasia; and
2. The patient is intolerant of non-selective alpha blockers or these are contraindicated.

Tar with coal tar and cade oil

Liq 0.1% with coal tar 0.3% and cade oil 0.3%

Teicoplanin

Inj 400 mg vial - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Temazepam

Tab 10 mg

Temocillin

Inj 1 g vial

Temozolomide

Cap 5 mg - ***restricted***
Cap 20 mg - ***restricted***
Cap 100 mg - ***restricted***
Cap 250 mg - ***restricted***

Must meet community Special Authority criteria

Tenecteplase

Inj 50 mg vial

Teniposide

Inj 10 mg per ml, 5 ml

Tenofovir disoproxil fumarate

Tab 300 mg - ***restricted***

Must meet community Special Authority criteria

Tenoxicam

Inj 20 mg vial
Tab 20 mg

Terazosin

Tab 1 mg
Tab 2 mg
Tab 5 mg

Terbinafine

Tab 250 mg
Cream 1%
Gel 1%

Terbutaline

Inj 500 mcg ampoule - ***restricted***

RESTRICTED (injection) – obstetrician

Terbutaline sulphate

Powder for inhalation 250 mcg per dose

Inj 0.5 mg per ml, 1 ml ampoule

Teriparatide

Inj 250 mcg per ml, 2.4 ml cartridge - ***restricted***

Must meet community Special Authority criteria

Terlipressin

Inj 1 mg vial

Testosterone

Patch 2.5 mg per day

Gel 50 mg per 5 g sachet

Implant 200 mg

Testosterone cypionate

Inj 100 mg per ml, 10 ml vial

Testosterone esters

Inj testosterone decanoate 100 mg, testosterone isocarproate 60 mg, testosterone phenylpropionate 60 mg and testosterone propionate 30 mg per ml, 1 ml ampoule

Testosterone undecanoate

Cap 40 mg

Inj 250 mg per ml, 4 ml ampoule

Tetanus toxoid

Injection

Tetrabenazine

Tab 25 mg

Tetracaine (amethocaine) hydrochloride

Eye drops 0.5%, single dose

Eye drops 1%, single dose

Gel 4%

Tetracosactide [tetracosactrin]

Inj 250 mcg per ml, 1 ml ampoule

Inj 1 mg per ml, 1 ml ampoule

Tetracycline

Tab 250 mg

Thalidomide

Cap 50 mg - ***restricted***

Cap 100 mg - ***restricted***

RESTRICTED
Initiation
Either:
1 The patient has multiple myeloma; or
2 The patient has systemic AL amyloidosis*; or
3 The patient has erythema nodosum leprosum.
Continuation
Patient has obtained a response from treatment during the initial approval period.

Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.
Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.
Indication marked with * is an Unapproved Indication

Theophylline

Oral liq 80 mg per 15 ml

Tab long-acting 250 mg

Thiamine

Cap 100 mg

Thiamine hydrochloride

Tab 50 mg

Tab 100 mg

Inj 100 mg per ml, 2 ml vial

Thickened formula

Powder 1.8 g protein, 8.1 g carbohydrate and 3.3 g fat per 100 ml, 900 g can {Karicare Aptamil Thickened AR}

Thioguanine

Tab 40 mg

Thiopental (thiopentone) sodium

Inj 500 mg ampoule

Thiotepa

Inj 15 mg vial

Thrombin

Powder

Thymol glycerin

Compound, BPC

Thyrotropin alfa

Inj 900 mcg vial

Tiaprofenic acid

Tab 300 mg

Ticarcillin with clavulanic acid

Inj 3 g with clavulanic acid 0.1 mg vial - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist or respiratory physician

Ticlopidine

Tab 250 mg

Tigecycline

Inj 50 mg vial - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Timolol

Eye drops 0.25%

Eye drops 0.25%, gel forming

Eye drops 0.5%

Eye drops 0.5%, gel forming

Timolol maleate

Tab 10 mg

Tinidazole

Tab 500 mg

Tinzaparin

Inj 40,000 iu / 2 ml

Tiotropium bromide

Powder for inhalation 18 mcg per dose - ***restricted***

Must meet community Special Authority criteria

Tirofiban

Inf 12.5 mg / 50 ml

Tobramycin

Inj 40 mg per ml, 2 ml vial - ***restricted***

Inj 100 mg per ml, 5 ml vial - ***restricted***

Eye drops 0.3%

Eye oint 0.3%

Nebuliser soln, 60 mg per ml, 5 ml ampoule

RESTRICTED – infectious disease physician, clinical microbiologist or respiratory physician

Tocilizumab

Inj 20 mg per ml, 4 ml

Inj 20 mg per ml, 10 ml

Tolcapone

Tab 100 mg

Tolterodine tartrate

Tab 1 mg - ***restricted***

Tab 2 mg - ***restricted***

RESTRICTED
Patient has overactive bladder and a documented intolerance of oxybutynin.

Topiramate

Tab 25 mg

Tab 50 mg

Tab 100 mg

Tab 200 mg

Cap sprinkle 15 mg

Cap sprinkle 25 mg

Sprinkle cap 50 mg

Topotecan

Inj 1 mg

Inj 4 mg

Tramadol

Tab sustained-release 50 mg

Tramadol hydrochloride

Cap 50 mg

Tab sustained-release 100 mg

Tab sustained-release 150 mg

Tab sustained-release 200 mg

Oral drops 100 mg per ml

Inj 10 mg per ml, 100 ml bag

Inj 50 mg per ml, 1 ml ampoule

Inj 50 mg per ml, 2 ml ampoule

Trandolapril

Cap 1 mg - ***restricted***

Cap 2 mg - ***restricted***

RESTRICTED
For continuation only

Tranexamic acid

Tab 500 mg

Inj 100 mg per ml, 5 ml ampoule

Tranylcypromine sulphate

Tab 10 mg

Trastuzumab

Inj 150 mg vial - ***restricted***

Inj 440 mg vial - ***restricted***

Must meet PCT Special Authority criteria

Travoprost

Eye drops 0.004%

Travoprost with timolol

Eye drops 0.004% with timolol 0.5%

Tretinoin

Crm 0.05%

Cap 10 mg

Triamcinolone acetonide

Paste 0.1%

Crm 0.02%

Oint 0.02%

Inj 10 mg per ml, 1 ml ampoule

Inj 40 mg per ml, 1 ml ampoule

Triamcinolone acetonide with gramicidin, neomycin and nystatin

Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g

Oint 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g

Triamcinolone acetonide with neomycin sulphate, gramicidin and nystatin

Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g

Triamcinolone hexacetonide

Inj 20 mg per ml, 1 ml vial

Inj 20 mg per ml, 5 ml

Triamterene with hydrochlorothiazide

Tab 50 mg with hydrochlorothiazide 25 mg

Triazolam

Tab 125 mcg - ***restricted***

Tab 250 mcg - ***restricted***

RESTRICTED
For continuation only

Trichloracetic acid

Grans

Trichloroethane

Soln

Trientine dihydrochoride

Cap 300 mg

Trifluoperazine hydrochloride

Tab 1 mg

Tab 2 mg

Tab 5 mg

Oral liq 1 mg per ml

Trimeprazine tartrate

Oral liq 6 mg per ml

Trimethoprim

Tab 100 mg

Tab 300 mg

Trimethoprim with sulphamethoxazole [Co-trimoxazole]

Tab 80 mg with sulphamethoxazole 400 mg

Oral liq 8 mg with sulphamethoxazole 40 mg per ml

Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml ampoule

Trimipramine maleate

Cap 25 mg

Tab 25 mg

Cap 50 mg

Trisodium citrate

Inj 4%, 5 ml ampoule

Inj 46.7%, 5 ml ampoule

Tri-sodium citrate

Crystals

Trometamol

Inj 36 mg per ml, 500 ml bottle

Tropicamide

Eye drops 0.5%

Eye drops 0.5%, single dose

Eye drops 1%

Eye drops 1%, single dose

Tropisetron

Cap 5 mg

Inj 1 mg per ml, 2 ml ampoule

Inj 1 mg per ml, 5 ml ampoule

Tuberculin, purified protein derivative

Inj 10 TIU per 0.1 ml, 1 ml vial

Urea

Crm 10%

Oint 25%

Powder BP

Urea with lactic acid

Crm 10% with lactic acid 5%

Urokinase

Inj 10,000 iu vial

Inj 50,000 iu vial

Inj 100,000 iu vial

Inj 500,000 iu vial

Ursodeoxycholic acid

Cap 250 mg - ***restricted***

Cap 300 mg

Oral liq 50 mg per ml

RESTRICTED
Pregnancy/Cirrhosis
Either:
1. Patient diagnosed with cholestasis of pregnancy; or
2. Both:
    2.1. Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and
    2.2. Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis).

Note: Liver biopsy is not usually required for diagnosis but is helpful to stage the disease.
Haematological Transplant
Both:
1. Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
2. Treatment for up to 13 weeks.

Please note that we are still considering the use of ursodeoxycholic acid for several other indications.

Ustekinumab

Inj 45 mg

Inj 90 mg

Valaciclovir

Tab 500 mg - ***restricted***

Must meet community Special Authority criteria

Valganciclovir

Tab 450 mg - ***restricted***

Must meet community Special Authority criteria

Vancomycin

Inj 500 mg vial - ***restricted***

RESTRICTED – infectious disease physician or clinical microbiologist

Vardenafil

Tab 10 mg

Varenicline

Tab 0.5 mg x 11 and 1 mg x 14 - ***restricted***

Tab 1 mg - ***restricted***

RESTRICTED
All of the following:
1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
3 Either:
- 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
- 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and

4 The patient has not used funded varenicline in the last 12 months; and
5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
6 The patient is not pregnant; and
7 The patient will not be prescribed more than 3 months' funded varenicline in a 12 month period.

Varicella zoster vaccine

Inj 1350 PFU vial with diluent - ***restricted***

Inj 2000 PFU vial with diluent - ***restricted***

RESTRICTED
Any of the following:
1 For use in transplant patients; or
2 For use following immunosuppression; or
3 For household contacts of children undergoing immunosuppression with no previous history or disease (clinical history of disease or negative serology) or vaccination.

Vecuronium bromide

Inj 4 mg ampoule

Inj 10 mg vial

Venlafaxine

Cap modified release 37.5 mg - ***restricted***

Cap modified release 75 mg - ***restricted***

Cap modified release 150 mg - ***restricted***

Tab modified release 37.5 mg - ***restricted***

Tab modified release 75 mg - ***restricted***

Tab modified release 150 mg - ***restricted***

Tab modified release 225 mg - ***restricted***

Tab 75 mg

Must meet community Special Authority criteria

Verapamil hydrochloride

Inj 2.5 mg per ml, 2 ml ampoule

Tab 40 mg

Tab 80 mg

Tab long-acting 120 mg

Tab long-acting 240 mg

Vernakalant hydrochloride

Inj 20 mg per ml, 30 ml

Verteporfin

Inf 15 mg in 15 ml vial

Vigabatrin

Tab 500 mg - ***restricted***

Must meet community Special Authority criteria

Vinblastine sulphate

Inj 1 mg per ml, 10 ml vial

Vincristine sulphate

Inj 1 mg per ml, 1 ml vial

Inj 1 mg per ml, 2 ml vial

Vindesine

Inj 5 mg

Vinorelbine

Inj 10 mg per ml, 1 ml vial

Inj 10 mg per ml, 5 ml vial

Vitamin A with vitamins D and C

Soln 1000 u with vitamin D 400 u and ascorbic acid 30 mg per 10 drops

Vitamin B complex

Tab, strong, BPC

Vitamin E

Cream

Voriconazole

Tab 50 mg - ***restricted***

Tab 200 mg - ***restricted***

Oral liq 40 mg per ml - ***restricted***

Inj 200 mg vial - ***restricted***

RESTRICTED – infectious disease physician, clinical microbiologist or haematologist
Proven or probable aspergillus infection
Both:
1 Patient is immunocompromised; and
2 Patient has proven or probable invasive aspergillus infection.
Possible aspergillus infection
All of the following:
1 Patient is immunocompromised; and
2 Patient has possible invasive aspergillus infection; and
3 A multidisciplinary team (including an Infectious Disease Physician) considers the treatment to be appropriate.
Resistant candidiasis infections and other moulds
All of the following:
1 Patient is immunocompromised, and
2 Either:
- 2.1 Patient has fluconazole resistant candidiasis; or
- 2.2 Patient has mould strain such as Fusarium spp. and Scedosporium spp; and
- 2.3 A multidisciplinary team (including an Infectious Disease Physician or Clinical Microbiologist) considers the treatment to be appropriate.

Walnut oil

Liq - ***restricted***

RESTRICTED
Use as an additive
Any of the following:
1 Patient has inborn errors of metabolism; or
2 Faltering growth in an infant/child; or
3 Bronchopulmonary dysplasia; or
4 Fat malabsorption; or
5 Lymphangiectasia; or
6 Short bowel syndrome; or
7 Infants with necrotising enterocolitis; or
8 Biliary atresia; or
9 For use in a ketogenic diet; or
10 Chyle leak; or
11 Ascites; or
12 Patient has increased energy requirements, and for whom dietary measures have not been successful.
Use as a module
For use as a component in a modular formula

Warfarin sodium

Tab 1 mg

Tab 2 mg

Tab 3 mg

Tab 5 mg

Water

Inj 100 ml

Inj 100 ml

Inj 5 ml ampoule

Inj 10 ml ampoule

Inj 20 ml ampoule

Inj 250 ml bag

Inj 500 ml bag

Inj 1,000 ml bag

Irrigation soln, 100 ml bottle

Irrigation soln, 500 ml bottle

Irrigation soln, 1000 ml bottle

Irrigation soln, 2000 ml bottle

Irrigation soln, 3000 ml bottle

Wool fat

Crm

Oint, anhydrous

Xanthan

Gum 1% {Diluent A}

Xylometazoline hydrochloride

Aqueous nasal spray 0.05%

Aqueous nasal spray 0.1%

Nasal drops 0.05%

Nasal drops 0.1%

Yellow jacket wasp venom

Inj 550 mcg vial with diluent - ***restricted***

RESTRICTED
Both:
1 RAST or skin test positive; and
2 Patient has had severe generalised reaction to the sensitising agent.

Zanamavir

Powder for inhalation 5 mg

Zidovudine [AZT]

Cap 100 mg - ***restricted***

Oral liq 10 mg per ml - ***restricted***

Inj 10 mg per ml, 20 ml vial - ***restricted***

Must meet community Special Authority criteria

Zidovudine [AZT] with lamivudine

Tab 300 mg with lamivudine 150 mg - ***restricted***

Must meet community Special Authority criteria

Zinc

Crm

Oint

Paste

Oral liq 5 mg per drop

Zinc and castor oil

Crm

Oint, BP

Zinc chloride

Inj 5.3 mg per ml, 2 ml ampoule

Zinc oxide

Powder

Zinc oxide with glycerol

Oint

Zinc oxide with peru balsam

Ointment

Suppository

Zinc sulphate

Cap 137.4 mg (50 mg elemental)

Zinc with wool fat

Crm zinc 15.25% with wool fat 4%

Ziprasidone

Cap 20 mg - ***restricted***

Cap 40 mg - ***restricted***

Cap 60 mg - ***restricted***

Cap 80 mg - ***restricted***

Inj 20 mg

Inj 100 mg

RESTRICTED (CAPSULES)

1 Patient is suffering from schizophrenia or related psychoses; and

2 Either:

2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or

2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.

Zoledronic acid

Inj 0.8 mg per ml, 5 ml vial - ***restricted***

Inj 0.05 mg per ml, 100 ml vial - ***restricted***

RESTRICTED
0.8 MG PER ML, 5 ML
For hypercalcaemia of malignancy
0.05 MG PER ML, 100 ML
Must meet community Special Authority criteria

Zopiclone

Tab 7.5 mg

Zuclopenthixol acetate

Inj 50 mg per ml, 1 ml ampoule

Inj 50 mg per ml, 2 ml ampoule

Zuclopenthixol decanoate

Inj 200 mg per ml, 1 ml ampoule

Inj 500 mg per ml, 1 ml ampoule

Zuclopenthixol hydrochloride

Tab 10 mg

Tab 25 mg